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Abstract  
 
Nitric oxide (NO) is a reactive free radical with a short lifetime and area of effect. NO 
behaves as a cellular signalling molecule involved in vasodilation, cell death and 
neurotransmission. Diseases resulting from a deficiency of NO can be treated with 
stable NO donor molecules, however current clinical NO donors are non-specific and 
have issues with toxicity and tolerance.  
Our research was focussed on the NO donor furoxan, which releases NO in presence 
of thiols. Furoxan molecules have been shown to isomerize under irradiation from 
inactive to active NO donors. Previous research into these photoswitchable furoxan 
NO donors was limited by the furoxan absorption being within the UV range which is 
damaging to organic tissue.  
The core of this research investigated visible light absorbing photoswitchable NO 
donors. We hypothesized that a visible light absorbing sensitizer could transfer energy 
to the furoxan moiety and induce isomerization and subsequent NO release.  
Following screening experiments, we selected anthraquinone as a sensitizer to conjoin 
with fluorofuroxan. Initial synthetic routes included ethylene glycol linker chains and 
connection via carbon-carbon bonds formed by palladium catalysed cross coupling. 
However, we encountered regioselectivity and solubility issues. Consolidating on 
these approaches we utilized an organocatalysed [4 + 2] reaction to furnish the 
insoluble anthraquinone core and carbon bridge to furoxan in a single step. We 
demonstrated in vitro photoswitchable NO release under a high degree of control. The 
hybrid molecule also displayed the ability to release NO in the absence of thiol, a rare 
phenomenon for furoxans, but we could not observe whether the molecule was taken 
into cells during testing.  
To address the cellular uptake issue, we designed and synthesised hybrid furoxan-
sensitizer molecules which displayed theranostic properties (the ability to fluoresce 
and sensitize). In our first design we synthesised a fluorescent alkoxyfuroxan-
aminofluorenone hybrid which induced sensitized isomerization in organic solvent but 
not in aqueous solution. A second theranostic sensitizer-furoxan design made use of 
naphthalenediimide (NDI) sensitizer cores. The NDI-furoxan displayed in vitro 
x 
 
fluorescent photoswitchable NO release and enabled us to observe cellular uptake of 
the molecule. Unfortunately, NO was not released from within a cell culture system 
due to biothiols, which possibly quenched the excited state of the sensitizer.  
Finally, we suggest an improved design of NDI-furoxans which would hopefully release 
NO under spatiotemporal control from within a cell culture system.  
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Ⅰ: Introduction       
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1.1 An introduction to nitric oxide  
 
Nitric oxide (NO) is a gaseous reactive radical species which mediates a variety of 
cellular functions, the most notable of which are vasodilation,1,2 platelet aggregation,3 
neuromodulation,4,5,6 wound repair7 and immune response8 (Figure 1). These cellular 
effects were originally attributed to endothelium-derived relaxing factor which was 
later found to be NO,9 much to the surprise of chemists at the time since NO was 
regarded as an environmental pollutant.10  
The importance of NO as a cellular signalling molecule was highlighted in 1992 when 
it was awarded ‘molecule of the year’,11 and once again in 1998 when the Nobel Prize 
was awarded for the discovery of its role as a cardiovascular signalling molecule.9  
 
 
Figure 1: Effects of NO in the cardiovascular system. Figure is reproduced from Miller 
et al,.12 
 
NO can passively diffuse throughout cells and cross intracellular distances with ease, 
the radical nature renders the molecule highly reactive towards other radical species 
and leads to short lifetimes limited within a small area of effect (approximately 100 
μM).12  
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NO is biosynthesised from L-arginine which is transformed into cytrulline and NO by 
nitric oxide synthases enzymes.13 There are three types of NO synthases, neuronal 
nNOS, inducible iNOS and endothelial eNOS.14 NO activates soluble guanylate cyclase 
(sGC) leading to the dephosphorylation of guanylate triphosphate (GTP) to cyclic 
gaunylate monophosphate (c-GMP).15 c-GMP acts through a variety of pathways such 
as protein kinase activation to produce the effects observed in the cardiovascular, 
central nervous and peripheral nervous systems (Figure 2).16 
 
Figure 2: Biosynthesis of NO and action upon sCG. Figure is reproduced from Gasco et 
al.16 
 
High concentrations (μM) of NO produced by macrophages under oxidative stress can 
lead to cytotoxic effects through the formation of reactive nitrogen species (RNS) such 
as peroxynitrite, a product of superoxide and NO radicals.17 These reactive radicals 
can inhibit cellular respiration and lead to cell apoptosis in inflammatory cells. 18 
NO availability is implicated in the development of diseases and disorders such as 
arthritis,19 cardiovascular diseases,20 male impotence21 and neurodegeneration such 
as in Alzheimer’s disease.22  
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1.2 Nitric oxide donors 
 
Delivery of exogenous NO is a therapeutic option for the treatment and prevention of 
diseases which are characterised by both reduced availability and overproduction of 
NO. Duel functionalities are possessed by NO, at endogenous concentrations 
beneficial effects are observed but at superphysiological concentrations NO is 
detrimental.23 Small quantities of exogenous NO have demonstrated inhibition of 
iNOS expression via feedback mechanisms to abrogate upregulation of NO 
biosynthesis.24 
Given that NO and its synthesis is almost ubiquitous and the biological effects of NO 
are concentration dependent, it is clear that NO therapeutics can affect and treat a 
broad range of disorders. The administration of NO as a gas is possible, however 
impractical due to instability, requirement for oxygen exclusion and nonspecific 
nature of gaseous NO.12   
 
1.2.1 Clinical nitric oxide donors 
 
Since NO has a short lifetime and area of effect the use of prodrugs has been 
developed to stabilise NO until its desired release. Currently there are few NO donors 
in clinical use, the most notable of which are sodium nitroprusside (SNP), a nitrosyl 
metal complex and glycerine trinitrate (GTN), an organic nitrate (Figure 3). Both of 
these compounds amongst others are known as ‘accidental NO donors’ since they 
were used before their effects involving NO were understood.16 
 
Figure 3: Clinical NO donors  
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GTN is mainly used for pain relief, one use is in the treatment of angina and it can also 
be used topically to treat anal fissures.12 The main limitation of GTN and other organic 
nitrate donors is the build-up of tolerance with prolonged use.25,26  
SNP is used on site in hospitals for rapid lowering of blood pressure during 
hypertensive crisis.27 The caveat of long term use of SNP is the risk of developing 
cyanosis due to release of cyanide groups,28 although reports of cyanide build up are 
rare, several other inconveniences such as intravenous administration and sensitivity 
to light highlights precedent for the development of alternative donors. 
 
1.2.2   Non-clinical nitric oxide donors 
 
Although not used clinically there are many promising NO donors under investigation, 
the most notable of which are the diazeniumdiolates (NONOates) and the S-nitroso 
thiols. 
The NONOates feature a diolate group from which up to two molar equivalents of NO 
are released. The NONOates decompose spontaneously in physiological pH solutions 
and can be tailored to have specific half-lives from seconds to hours depending on the 
structure.29 Often a requirement of NO donors is the presence of thiols to induce NO 
release, one admirable feature of NONOates is the release of NO independent of thiol 
cofactors.30 Notable examples of NONOates include PROLI/NO, DEA/NO, SPER/NO and 
DETA/NO to name a few (Figure 4) 
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Figure 4: Examples of NONOates and the half-lives of NO release in physiological 
solutions. SPER/NO exhibits a tuneable concentration dependant NO release range as 
a less reactive dimer forms at higher concentrations.29 
The second prominent group of NO donors is the S-nitrosothiols which contain a single 
bond between a sulphydryl and NO moiety. S-Nitrosothiols are not only synthesized 
and administered exogenously but also found endogenously.31 S-Nitrosothiols 
decompose under a variety of conditions such as UV-light, heat and enzymic release 
triggers12,32 and they are particularly susceptible to copper catalysed decomposition.32 
S-Nitrosothiols can also undergo transnitrosation in which NO+ is transferred from S-
nitrosothiol to other cellular thiols.33 The transnitrosation protects the NO under 
conditions of oxidative stress.12 S-Nitrosothiols have an advantage over other NO 
donors, such as the organic nitrates, in that they do not induce a build-up of tolerance 
with prolonged use.34 Notable examples of synthetic S-nitrosothiols include GSNO and 
SNAP (Figure 5).  
 
Figure 5: Notable S-nitrosothiols SNAP and GSNO 
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1.2.3   Hybrid nitric oxide donors 
 
NO donors have been attached to established drugs and are known as NO hybrid drugs. 
The established drug retains its pharmacological properties whilst also showcasing the 
biological activity of the NO donor. Often the NO donating ability of the hybrid drug 
can offset the negative side effects associated with the parent non-hybrid drug. A wide 
variety of hybrid drugs have been developed which include NO donor moieties such 
as NONOates, s-nitrosothiols, nitrates and furoxans and are projected to be used in 
the treatments of inflammatory, cardiovascular and neurodegenerative diseases as 
well as showing antibacterial, antiparasitic and anti-cancer properties.35 Perhaps the 
most renown examples of NO-donor hybrids are the nitric oxide-releasing 
nonsteroidal anti-inflammatory drugs (NO-NSAIDs) of aspirin ‘nitroaspirins’, NicOx 
compounds 9 and 10 were the first aspirin NO-NSAIDs to be produced commercially 
(Figure 6). 
 
 
Figure 6: NO-donor hybrid drugs combining aspirin with an organonitrate. 
 
Aspirin has several uses from pain relief to the treatment of arthritis, however 
prolonged use can lead to gastrointestinal damage and ulcer formation.36 Combining 
the aspirin with a NO donor helps alleviate the negative effects on the gastric tract by 
increasing the production of gastric mucus, increasing blood flow towards gastric 
mucosa, promoting repair and removal of toxins amongst other benefits.12 
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1.3 Furoxan as a nitric oxide donor 
 
Furoxan (1,2,5-oxazadiazole 2-oxide) is a heterocyclic NO prodrug that is susceptible 
to attack from thiols leading to the release of NO, although in some rare cases NO can 
be released in the absence of thiol (Figure 7).37,38 The quantity and rate of NO release 
from each furoxan is related to the substituents on the 3- and 4- positions of the 
ring,39,40 for example one furoxan regioisomer may be stable to NO release but the 
other regioisomer may be highly reactive. In general, electron withdrawing groups 
help induce nucleophilic attack at the electron deficient positions of the furoxan ring 
leading to enhanced quantities of NO release.41 
 
 
Figure 7: A general structure of 1,2,5-oxazadiazole 2-oxide complete with numbering 
convention. 
 
Furoxans have exhibited a wide range of biological activities such as anti-parasitic, 
anti-microbial, immunosuppressive and anticancer effects.42 Furoxan being an NO 
prodrug also shows anti-aggregating and vasorelaxant activity with one derivative, 
CAS 1609, reaching animal testing in which it featured no build-up of tolerance with 
prolonged use.43 Unfortunately, clinical studies with CAS 1609 have been hindered 
due to mutagenic effects.16 
 
1.3.1 Thiol mediated nitric oxide release from furoxan 
 
The mechanism of thiol mediated release under physiological conditions is thought to 
occur by initial attack of a thiolate anion to the furoxan ring which leads to ring 
opening to a tetrahedral intermediate (Scheme 1).38 Depending on whether the 3- or 
4- position is attacked governs the mechanism on release. Attack at the 4-position via 
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14 leads to posterior loss of a nitroxyl anion from the tetrahedral intermediate 15 
which is subsequently oxidised in situ. Thiolate attack at the electron rich 3- position 
leads to release of a nitoxyl anion but may also form S-nitrothiols directly via 
intermediates 17 and 18 interacting with thiol. Only one equivalent of NO is released 
despite there being potential for two. It is suggested that thiol attack on the furoxan 
ring can also lead to ring opening and dioxime formation 13.38 It should be noted that 
thiol mediated NO release mechanisms are speculative at the time of writing and are 
probably substrate specific.  
 
 
 
 
 
 
 
 
Scheme 1: Proposed NO release mechanism of furoxan under physiological conditions. 
Scheme is modified from Gasco et al.16  
 
1.3.2 Furoxans as NO donor hybrids  
 
As mentioned previously, furoxan motifs have appeared in a wide variety of natural 
product and synthetic NO donor hybrids demonstrating  anticancer, antiparasitic, 
antimicrobial, antimalarial and gastroprotective activities.44,45 One example of 
particular interest is the hybrid of natural product brusatol containing 
phenylsulphonyl furoxans (Figure 8).23 Brusatol in its natural form exhibits an 
assortment of pharmacological activities and it has generated particular interest due 
to its anti-inflammatory effects, however it was found to be too toxic for application. 
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Connection of phenysulphonyl furoxans enhanced the pharmacological profile of 
brusatol. The NO release from 20 inhibited iNOS expression in macrophages via 
feedback mechanisms whilst simultaneously reducing toxicity by 100-fold relative to 
brusatol.  The hybrid demonstrated in vivo anti-inflammatory activity and was used in 
the treatment of chronic obstructive pulmonary disease-like lung inflammation in 
mice presenting a promising lead compound.23 
 
 
Figure 8: Brusatol-furoxan hybrid molecule  
 
1.3.3 Furoxan synthesis 
 
Furoxans can be synthesized by a variety of methods (Figure 9),46 one such method is 
the dimerization of benzonitrile N-oxides to form symmetrically substituted 
furoxans,47 although this approach is limited in diversity as both N-oxides are indistinct. 
Asymmetric synthetic methods include the dehydration of glyoximes to afford 
substituted furoxans,48 reaction of dinitroolefins with NaN349 and acid catalysed 
cyclization of α-nitro-oximes.50 These methods often require the tedious preparation 
of pre-functionalized intermediates prior to the formation of the furoxan ring. Perhaps 
the most convenient preparation of furoxan is the treatment of styrene with NaNO2 
under acidic conditions to form nitrofuroxans via dinitrogen trioxide, nitrofuroxan 
products can then be further functionalized via aromatic nucleophilic substitution and 
thermal isomerization.51,52,53 Aside from simplicity, the advantage of using the styrene 
and acidic NaNO2 method lies with the wide range of commercially available, readily 
synthesized and cheap styrene starting materials.54 Recently attempts have been 
made to increase the diversity and utility of furoxan synthesis, especially in the 
11 
 
Matsubara research group where the treatment of styrenes with NOBF4 enabled the 
synthesis of acid sensitive derivatives under basic conditions.54  
 
 
Figure 9: Established furoxan synthetic methods  
 
1.3.4 Furoxan ring modification 
 
Furoxan chemistry is largely underdeveloped due to difficult synthesis and limited 
synthetic utility. Aside from furoxan ring synthesis under basic conditions recent work 
in the Matsubara lab has led to the facile introduction of multiple functional groups 
directly onto the furoxan ring, including carbon-carbon bonds enhancing the 
accessibility of furoxan chemistry. Synthetic methods introducing carbon substituents 
on the furoxan ring prior to this work were rare and non-trivial with only two examples 
using Grignard reagents available and no further evolution of scope.55 Introduction of 
alkynyl groups under mild conditions via alkyl lithiums led to an expansion of carbon-
based substituents in high yields (Scheme 2a).56 The alkynyl furoxans also showed 
photoswitchable character granting access to the 3-isomers. A second contribution to 
carbon-carbon bond forming reactions onto the furoxan ring featured the cyanation 
of nitrofuroxans, once again photoisomerization granted access to the regioisomer 
12 
 
(Scheme 2b).40 The cyano and alkynyl functionalities can be easily modified further to 
grant libraries of biologically active compounds.  
 
 
Scheme 2: SNAr reaction of (a) alkyl lithiums and (b) sodium cyanide on nitrofuroxan 
and subsequent photoisomerization.  
 
1.3.5 Photoswitchable furoxan nitric oxide release  
 
Many options exist when selecting an appropriate NO donor but in the so far discussed 
examples all suffer from a lack of site specific selectivity and general instability. The 
molecules are not activated with a significant element of control. Spatiotemporal 
control over NO release is important since the concentration and location of NO 
release can determine the kind of biological response, whether it is simple 
vasodilation or signalling cell apoptosis.8 This kind of selectivity can be achieved 
through external stimuli and perhaps the most promising of stimuli is light. Light can 
be used to induce reactivity without remaining in the system afterwards, furthermore 
light is highly characterizable and at longer wavelengths is non-invasive. Irradiating 
the intended sight of release for a specific period of time could ideally trigger a specific 
quantity of NO to be released. These kinds of molecules are known as photoinduced 
NO donors (PINODs). 
 
Reports of furoxan PINODS prior to work in the Matsubara group are rare and 
speculative. For example, it has been suggested that diarylfuroxans form 
diaryacetylenes under UV irradiation and generate low yields of NO via azo-N,N'-
13 
 
dioxides (Scheme 3).57 It is of note that Hwang et al. similarly reported UV photolysis 
of 3,4-bis-2'-chlorophenylfuroxan with implied release of NO.58 NO has also been 
released, albeit unquantified, from self-assembled monolayers of furoxans under UV 
irradiation.59 
 
 
Scheme 3: Proposed mechanism of NO liberation from diarylfuroxan under UV 
irradiation. 
 
Recently efforts have been made towards the realisation of furoxan PINODs (Scheme 
4).41,60 Fluorofuroxans displayed a high isomeric ratio at the photostationary state (PS) 
under UV irradiation (approximately 10 : 90 of the 4- : 3- regioisomers respectively). 
The 4-fluoro regioisomer was stable to thiol cofactor but once isomerized to the 3-
regioisomer underwent thiol mediated NO release in up to 40%.41 The fluorofuroxans 
presented the first quantitative photoswitchable NO release under physiological 
conditions. Shortly after, alkoxy furoxans displayed photoswitchable NO release in 
moderate yields under UV irradiation albeit lower total isomeric ratio at the PS. 
Despite the negligible isomeric ratios, the alkoxy furoxans underwent rapid NO release 
with the reactive 3-regioisomer being replenished upon consumption enabling further 
discharge of NO.60  
 
 
Scheme 4: Photoswitchable NO release from fluoro- and alkoxyfuroxans.  
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The limitations of furoxan PINODs were clear; the necessity of UV irradiation 
prevented PINOD furoxans from finding biological application since the high energy 
light required was cytotoxic and poorly penetrating.  
 
1.4 Non-furoxan photoswitchable nitric oxide donors  
 
At the time of writing to the best of our knowledge, other than methoxy and 
fluorofuroxans developed by Matsubara et al.  there are no other furoxan PINODs. 
However, other PINOD systems with diverse structures and release mechanisms have 
been developed and switchable NO release has been achieved using photoirradiation 
ranging from UV to near infra-red (NIR) wavelengths.10,61–68 In this section such PINODs 
will be briefly discussed.  
NO has been ‘uncaged’ from o-nitrobenzyl69 and N,N′-dinitroso-p-phenylenediamine 
substrates in a switchable manner under UV irradaiton.61 S-Nitosothiols became 
thermally stable once adsorbed onto gold surfaces and generated NO under UV 
irradiation.62  
UV light has been utilized to release NO from sterically hindered 2,6-
dimethylnitrobenzene (2,6-DNB) derivatives, which when irradiated demonstrated 
anti-cancer activity in a cell culture system under spatiotemporal control (Scheme 5).10 
The irradiation wavelength required to induce NO release from 2,6-DNB has recently 
been increased to within the visible range (400–430 nm) by conjugation with a 
coumarin moiety.70  
 
 
Scheme 5: Proposed mechanism of photoinduced rearrangement of the twisted nitro 
group and subsequent NO release following isomerization from 2,6-dimethyl-
nitrobenzene derivatives. Scheme is modified from Kitamura et al.70 
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Visible light has been used to decage NO from bycyclic N-pyramidal nitrosoamines.64 
The strained bridged nitroso moiety features attenuated p-orbital overlap expressed 
as greater antibonding character compared to monocyclic nitrosoamines. This lowers 
the HOMO–LUMO energy gap of the n–π* transition, thus extending the decaging 
wavelength into the visible region (Figure 10).  
 
 
Figure 10: Orbital interactions within the nitrosoamino functionality and HOMO–
LUMO transition; (a) monocyclic and (b) bicyclic nitrosoamines. Figure is reproduced 
from Karaki et al.64 
 
Recently NO release from N‑ nitrosated napthalimides via UV or near-red two photon 
irradiation was accompanied by fluorescence turn-on and enabled quantitation 
release analysis (Scheme 6).67 
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Scheme 6: Pathway of NO release and fluorophore generation upon photolysis of 
nitrosoamine.67 
 
Early metal nitrosyl compounds released NO under irradiation but suffered from short 
UV wavelength requirements and poor stability in biological media, it is of note that 
the clinically relevant SNP  is considered amongst them.68 Efforts have been made to 
increase both the stability and irradiation wavelength of ruthenium nitrosyl 
compounds via ligand modification and the attachment of light harvesting dyes, of 
particular merit is a resorufin coordinated Ru-NO ‘1-Resf’ (Figure 11).63 Resorufin 
improves the light harvesting ability of the complex and assists in the sensitization of 
the nitrosyl. Uptake by cancer cells was indicated via trackable red fluorescence 
(which was quenched upon NO release) and following a brief period of irradiation with 
visible light cell apoptosis occurred.63 
 
 
Figure 11: Resorufin coordinated ruthenium nitrosyl complex ‘1-Resf’. 
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An unusual yet effective approach to PINODs is the synthesis of zeolite porous 
coordination polymers from self-assembled nitroimidazole frameworks ‘NOFs’ (Figure 
12).65 Nitroimidazoles tend to undergo photoexcited deactivation, however 
immobilization as the porous frameworks of the NOF complex prevented quenching 
of the ligand reactive excited state. NO flux could be tuned by irradiation intensity and 
quantity of irradiated material and it was demonstrated the NOFs showed 
spatiotemporal release from within a cell culture system under NIR two-photon laser 
absorption.  
 
 
 
Figure 12: Self assembled nitrosoimidazole zeolite complex from 2nlm. Figure 
reproduced from Diring et al.65 
 
Perhaps the most remarkable PINOD recently reported is the NIR uncaging of NO from 
fluorescent hollow gold nanoparticles (HGN) (Scheme 7).66 NIR irradiation induces 
thermochemical release of NO from thiol functionalized cupferron (TCF) absorbed 
onto HGN. Thiolated polyethylene glycol (TPEG) absorbed onto the HGN improved 
water solubility, targeting peptides were also absorbed which induced internalization 
and switchable NO release within cancer cells.  
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Scheme 7: Thiol functionalozed cupferron absorbed onto Hollow gold nanoparticles 
and subsequent NIR NO release. Figure is reproduced from Levy et al.66 
 
1.5 Summary of considerations  
 
The exogenous delivery of NO via stable NO prodrugs is necessary for studying the 
biological effects of NO and for the treatment of cancer, cardiovascular and 
neurological diseases. Current clinical donors are hindered by their toxicity and 
induction of tolerance, whereas non-clinical donors such as S-nitro thiols and 
NONOates appear promising, like their clinical predecessors they still struggle with 
lack of controlled site-specific NO release. To counter the inadequacies of NO-donors 
PINODs have been developed ranging from the impractical UV absorbing caged 
nitrosyls to the fantastical NIR photothermochemical HGN. Despite recent progress, 
the diversity of PINODs and their release mechanisms are sparse and the development 
of new PINODs with novel release mechanisms are required in pursuit of controllable 
discharge of NO under biologically inert conditions.  
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1.6  Hypothesis: visible light furoxan photoswitchable nitric oxide donors 
 
As mentioned previously, visible light is preferable to UV since visible light can 
penetrate further into tissues and is biologically benign whereas UV is toxic. Ideally 
NIR light should be used which can penetrate deeper than surface tissues and into 
organs, although this can often be difficult to achieve without extended conjugation, 
nanoparticles or two photon absorption techniques.  
The recent research into fluoro- and alkoxyfuroxan isomerization were the first steps 
towards spatiotemporal controlled NO release from furoxans. The initial results were 
promising but since the furoxan absorption tends not to extend beyond 320 nm they 
are hindered by the necessity of UV light. Visible to NIR light induced NO release is 
necessary for PINOD furoxans to have any tangible biological application.  
The requirement for visible light furoxan PINODs led us to contemplate how the NO 
release could be induced from the UV absorbing furoxan. We hypothesized that a light 
harvesting moiety could absorb light in the visible range and then transfer the energy 
to the furoxan whereupon it would isomerize to the reactive 3-isomer and become 
vulnerable to thiol attack and release NO (Scheme 8). 
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Scheme 8: Envisioned mechanism of furoxan isomerization and NO release mediated 
by visible light absorbing moieties.   
 
Compared with established NO donors such as S-nitroso thiols and NONOates the 
choice of furoxan NO donor may seem questionable, however since furoxan chemistry 
is underdeveloped there is huge potential for furoxans to equal or even surpass the 
current ‘in vogue’ donors and lead to further application in biology and neuroscience. 
Furoxans are small molecules with low molecular weight making them drug like, 
furthermore furoxans can easily exhibit high solubilities in aqueous solutions with 
simple modifications. Furoxans are also highly stable and have potential for acutely 
controlled NO release with suitable functionalisation.  
 
1.6.1 Research aim 
 
The aim of the research is to synthesize a water soluble furoxan PINOD that releases 
NO under spatiotemporal control from within a cell (Scheme 9). Following NO release, 
the immediate biological response could then be analysed. Once a simple prototype 
visible light harvesting moiety 
excited state light harvesting moiety 
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has been synthesized the molecular complexity could be increased to include 
fluorescent markers to show the region of cellular uptake and recognition moieties to 
target specific cell types or sites within the cell. 
 
 
 
 
 
 
 
 
 
Scheme 9: Model application of visible light switchable furoxan PINOD.  
 
Herein we report on the development of visible light-triggered NO donors based on 
the photosensitization of furoxans. 
 
 
 
 
 
 
 
 
visible light harvesting moiety 
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Ⅱ: Studies towards anthraquinone-fluorofuroxan  
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2.1 The photosensitization of fluorofuroxan  
 
In our hypothesis we suggested that a light harvesting moiety could absorb irradiation 
and transfer the energy to the furoxan inducing NO release (Scheme 8). One family of 
light harvesting moieties are the photosensitizers, which can transfer energy via the 
triplet excited state.71 
In order for energy transfer to occur, the furoxan would also need to be active in the 
triplet state. An indication of triplet activity within a compound is if the molecule 
displays phosphorescence emission. 
 
2.1.1 Phosphorescence of compound 35 
 
The triplet energy level of 3-tolyl-4-fluorofuroxan 35 was investigated by detecting the 
phosphorescence emission. The spectrum was measured in glassy frozen 2-
methyltetrahydrofuran (2-MeTHF) at 77 K. To our delight excitation at 280 nm 
produced a well resolved emission peak with λmax at 420 nm (Figure 13). The emission 
was broad and ranged between 370–570 nm suggesting that light with wavelength 
longer than 400 nm could be used in conjunction with a suitable triplet sensitizer to 
induce isomerization.  
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Figure 13: Phosphorescence spectra of 35 in 2-MeTHF at 77 K with excitation 
wavelength of 280 nm.  
 
2.1.2 Photosensitizer screening of compound 35 
 
Potential photosensitizers were selected based on their photophysical properties as 
recorded in ‘The Handbook of Photochemistry’.72 The selected sensitizers were 
screened by irradiating a 5 mM 1:1 ratio of 35 and sensitizer in deaerated C6D6 and 
measuring the isomerization ratio relative to a dodecane internal standard (Table 1 
and Figure 14) . Samples were irradiated with 400–500 nm light and isomerization 
ratio measured at 15-minute intervals by 1H NMR up to 90 minutes.  
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Table 1: Photosensitized furoxan isomerization under 400–500 nm irradiation. 
Sensitizer (2.4 µmol) and furoxan (2.4 µmol) 1 : 1 eq. in deaerated C6D6 (0.5 mL). 
aDetermined by 1H NMR analysis using dodecane as an internal standard. 
bPhenothiazine decomposed and byproduct started to form after 1 h of irradiation. 
cDDQ reacted with furoxan. dPS was not reached after 1.5 h of irradiation. 
 
 
  Yield of 36 (%)a 
Entry Sensitizer 15 min 30 min PS 
1 anthraquinone 59 75 76 
2 1,2-benzanthraquinone 96 96 96 
3 benzil 79 92 94 
4 phenothiazineb 8 14 - 
5 DDQc 0 0 - 
6 benzophenoned 1 2 >6 
7 none 0 0 0 
 
 
Figure 14: Photosensitized furoxan isomerization under 400–500 nm irradiation. 
Sensitizer (2.4 µmol) and furoxan (2.4 µmol) 1 : 1 eq. in deaerated C6D6 (0.5 mL). 
aDetermined by 1H NMR analysis using dodecane as an internal standard. 
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The quinone sensitizers showed exceptional sensitizing ability. 1,2-
Benzanthraquinone and benzil had the fastest rates of isomerization and the highest 
yields at the PS (Table 1, Entry 2 and 3 respectively). Benzil reached the PS at around 
30 minutes of irradiation and 1,2-benzanthraquinone reached PS in 15 minutes. 
Following 30 minutes of irradiation anthraquinone produced a good yield of 76% at 
the PS (Table 1, Entry 1). Phenothiazine induced a slow rate of isomerization in the 
furoxan but after 30 minutes decomposition of both sensitizer and furoxan were 
observed (Table 1, Entry 4). Benzophenone was ineffective at sensitizing the furoxan 
with a sluggish rate of isomerization which did not reach the PS after 90 minutes of 
irradiation (Table 1, Entry 5). 3-Dichloro-5,6-dicyano-p-benzoquinone (DDQ) did not 
cause isomerization but instead reacted with the furoxan under irradiation (Table 1, 
Entry 6). In the absence of a sensitizer no isomerization was observed due to the 
furoxan not absorbing within the irradiation window (Table 1, Entry 7). 
 
Due to their admirable sensitizing properties the quinones 1,2-benzanthraquinone, 
benzil and anthraquinone were considered for a suitable fluorofuroxan-sensitizer 
conjoined molecule. The ratio of isomerization at the PS was not a significant factor in 
selecting the sensitizer, previous research into furoxan PINODs had shown successful 
NO release from molecules which displayed negligible isomerization at the PS.60 This 
is due to rapid replenishment of isomerized furoxan to maintain said PS. Benzil would 
have provided a challenging synthesis due to the biacetyl nature, furthermore we 
were concerned about stability in biological applications. Possible synthetic routes 
towards 1,2-benzanthraquinone were investigated and found to be non-trivial, 
furthermore the unsymmetrical nature of the molecule would lead to regioisomeric 
complexities during synthesis rendering the sensitizer as unattractive in this instance. 
The symmetry and synthetic utility of the anthraquinone were a positive factor in 
selecting it for synthetic application, although the photophysical properties were not 
as good as other screened quinones the anthraquinone presented a greater chance of 
successful synthesis.  
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2.2 Nucleophilic aromatic substitution towards compound 50 
 
Our first synthetic stratagem was the direct linking between anthraquinone and 
fluorofuroxan via a glycol linker. 
The anthraquinone photosensitizer core is known for its poor solubility and the 
fluorofuroxan is only marginally soluble in phosphate buffer, therefore aqueous 
solubilizing moieties would need to be installed in the molecule for successful 
application. Ethylene glycol and longer chain glycols are known to have a solubilizing 
effect due to the polar ether linkages and terminal alcohol groups. We suspected that 
water solubility may be granted by a suitably long linker between the furoxan and 
anthraquinone. Water solubility has previously been endowed to anthraquinone 
molecules using glycol chains to synthesize antifungal agents for use in catfish ponds.73  
 
2.2.1 Synthesis towards compound 50  
 
With solubility in mind our first synthetic plan utilizing hexaethylene glycol is shown 
in scheme 10.   
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Scheme 10: Proposed synthesis of glycol tethered anthraquinone-furoxan 50. 
 
The glycol-tethered anthraquinone furoxan 50 can be synthesized by benzylic 
substitution of fluorofuroxan 52 with anthraquinone-tethered alcohol 51. 
Anthraquinone 51 is synthesized using commercially available 3-chloroanthraquinone 
and hexaethylene glycol.73 Furoxan 52 is synthesized by bromination of fluorofuroxan 
36 which in turn is synthesized by nucleophilic aromatic substitution of the 
corresponding nitrofuroxan. The Weiland procedure grants nitrofuroxan 55 from 
styrene 56.52  
Stirring 3-chloroanthraquinone in hexaethylene glycol at 130 °C granted 51 in 34% 
yield (Scheme 11) 
 
 
 
Scheme 11: Nucleophilic aromatic substitution reaction to form 51. 
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The furoxan partner 52 was prepared firstly by fluorination of nitrofuroxan and 
subsequent bromination of the benzylic position (Scheme 12). 
 
 
 
Scheme 12: Synthesis of brominated fluorofuroxan 52. 
 
With both reaction partners in hand we attempted to join the furoxan to 
anthraquinone via alkoxy linker (Scheme 13).  
 
 
 
Scheme 13: Attempted conjoining of 51 and 52 firstly under mild conditions and then 
hard conditions. 
 
After 5 hours of stirring the reagents in the presence of weak base no reaction was 
observed by TLC. NaH was added to deprotonate the alcohol and induce reaction. 
After a further 2 hours consumption of furoxan was observed, however crude analysis 
suggested a complex mixture had formed. Purification attempts with both silica 
chromatography and PTLC were unsuccessful and only unreacted anthraquinone 
starting material was successfully recovered. It was clear that optimisation studies 
were required.  
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2.2.2 Synthesis of compound 58 
 
Rather than risk expensive hexaethylene glycol-anthraquinone starting material we 
decided to use a cheaper ethylene glycol model compound 58 for use in screening 
experiments.  
 
 
Scheme 14: Synthesis of model compound 58. 
 
Ethylene glycol was not as solubilizing as hexaethylene glycol and so had to be used in 
excess to adequately dissolve anthraquinone. The product was obtained in moderate 
yield after stirring at 140 °C for 8 hours (Scheme 14). 
 
 2.2.3 Screening experiments towards compound 59 
 
With starting materials in hand, we conducted screening experiments between 58 and 
52 (Table 2). 
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Table 2: Screened conditions for the benzylic nucleophilic substitution of 52. 
 
 
 
 
 
For the nucleophilic substitution reaction high polarity solvents were selected along 
with catalytic KI and Et3N base to enhance SN2 reactivity. Solubility was an issue and 
solvents other than DMF and DMSO struggled to dissolve the anthraquinone. 
In all cases the desired compound was not observed (Table 2). This is due to significant 
and exclusive decomposition of the furoxan starting material, we also observed 
unreacted anthraquinone. Acetonitrile did not adequately solubilise the mixture and 
after 18 hours furoxan had undergone significant decomposition (Table 2, Entry 3). 
Omission of the KI salt did not lead to desired reactivity which led us to suspect that 
the probable cause of decomposition was due to the nature of the base. Changing the 
base to pyridine (Table 2, Entry 7) resulted in the same furoxan decomposition, 
however when more sterically hindered amine bases were used different 
Entry Solvent (x) Base  Additive  Time (h) Yield (%)  
1 DMSO (0.5 M) Et3N  KI  15  0 
2 DMF (0.5 M) Et3N  KI  15  0 
3 MeCN (0.5 M) Et3N  KI   18 0 
4 DMSO (0.5 M) Et3N   -     18  0 
5 MeCN (0.2 M) Et3N   -     18  0 
6 DMF (0.4 M) Et3N   -     18  0 
7 DMSO (0.4 M) Pyridine   -     19  0 
8 DMSO (0.4 M) N,N-Diisopropylethylamine  -     19  0 
9 DMSO (0.4 M) HTMP   -     19  0 
10 DMSO (0.4 M) Na2CO3   -     19  0 
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decomposition products became observable by TLC and 1H NMR (Table 2, Entries 8 
and 9). Using a non-amine base (Table 2, Entry 10) also lead to decomposition of the 
furoxan. The variety of decomposition products suggested that careful choice of base 
was required in future experiments with fluorofuroxan.  
In summary, due to the reactivity of furoxan in the presence of selected bases we were 
unable to connect furoxan 52 and anthraquinone 58 using mild SN2 conditions.  
 
Finally, attempted hard nucleophilic conditions by deprotonating the alcohol with 
sodium hydride (Scheme 15). 
 
 
Scheme 15: Reaction between 58 and 52 using NaH as a base.  
 
Slow addition of the deprotonated 58 into a solution of 52 in THF at -78 °C resulted in 
incorrect regioselectivity and granted 60. Reaction occurred directly at the furoxan 
ring rather than the benzylic position, the byproduct was obtained and the structure 
was assigned based on the absence of a fluorine peak in 31F NMR.  
 
2.2.4 Conclusions 
 
During the synthesis towards compound 50 we encountered stability and 
regioselectivity issues due to the reactive nature of the fluoro- substituted furoxan 4-
position. Interestingly, byproduct 60 may have been a competent alkoxy 
photoswitchable NO donor in its own right, further solubility could have been granted 
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by substitution at the benzylic position with pendant solubilising groups.  
Unfortunately, we were limited to investigating only the anthraquinone and 
fluorofuroxan moiety at this point in the project due to competing research into alkoxy 
furoxan PINODs within the group, so regrettably this route was not further 
investigated. Incorrect regioselectivity aside, the length of the hexaethylene glycol 
chain could have been detrimental to a successfully synthesized anthraquinone-
fluorofuroxan molecule as it places the two partners relatively far apart so excited 
state energy transfer via electron exchange may have been slow if occurring at all.  
We decided to take an alternative approach towards a water soluble anthraquinone 
tethered fluorofuroxan molecule. 
 
2.3 Palladium catalysis towards compound 61 
 
 2.3.1 Heck reaction  
 In order to avoid regioselectivity issues and also to shorten the linker between 
sensitizer and furoxan we decided to investigate the Heck reaction as linker formation 
method 
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 2.3.1.1 Synthesis towards compound 64 
 
The retrosynthetic analysis of compound 64 is shown in Scheme 16.  
 
 
Scheme 16: Retrosynthetic analysis of Heck catalysed formation of 61. 
 
Bearing two bridge alcohol groups we hypothesized that the water solubility of the 
connected molecule 61 would be adequate for NO release testing. The completed 
molecule can be accessed by dihdroxylation of 62, which would in turn be furnished 
by Heck reaction between commercially available 2-vinylanthraquinone and 
fluorofuroxan coupling partner 64. The furoxan 64 would be synthesized by 
fluorination of nitrofuroxan 65 which would be constructed by Wieland conditions 
applied to commercially available 4-bromostyrene 66.  
The synthesis of 64 began with formation of 65 upon treatment of 4-bromostyrene 
with NaNO2 under acidic conditions (Scheme 17). Fluorination of the nitrofuroxan 65 
yielded coupling partner 64 in moderate yield.  
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Scheme 17: Preparation of fluorofuroxan 64.  
 
 2.3.1.2 Screening experiments towards compound 62 
 
After obtaining the furoxan starting material, the Heck reaction conditions were 
investigated (Table 3). 
 
Table 3: Screened Heck reaction conditions 
 
 
Entry Solvent  Base  Catalyst/Ligand (x) 
Temp. 
(°C) 
Time 
(h) 
Yield 
(%)  
1 DMF (0.35 M) NaOAc  Pd(OAc)2 (0.01 eq.)          
P(o-tol)3 (0.02 eq.) 
90  
6 
0 
2 DMF (0.35 M) - Pd(OAc)2 (0.01 eq.)          
P(o-tol)3 (0.02 eq.) 
90  
6 
0 
3 Dioxane (0.35 M) KOAc  Pd(OAc)2 (0.05 eq.)          
P(o-tol)3 (0.1 eq.) 
60  
95 
0 
4 Dioxane (0.8 M) Cy2NMe Pd2(dba)3 (0.05 eq.)   
P(tBu)3HBF4 (0.1 eq.) 
r.t.           
60         
120 
40 
8 
14 
0 
5 DMSO (0.8 M) Cy2NMe Pd2(dba)3 (0.005 
eq.)   P(tBu)3HBF4 
(0.01 eq.) 
r.t          
60  
120 
40 
8 
14 
0 
 
 
We were unable to form the desired product using the Heck conditions in table 3. In 
each case the main observable byproduct was 4-bromobenzontrile. The 2-
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vinylanthraquinone remained unreacted but the furoxan was sensitive to the reaction 
conditions and decomposed to 4-bromobenzonitrile. The omission of base resulted in 
decomposition of both anthraquinone and furoxan starting materials into a complex 
mixture (Table 3, Entry 2). The use of less polar dioxane (Table 3, Entry 3) led to longer 
reaction time and after consumption of furoxan starting material, the product was not 
isolated. In an effort to prevent furoxan decomposition we next employed conditions 
developed for room temperature Heck reaction (Table 3, entry 3).74 Gratifyingly the 
furoxan did not decompose at room temperature after 40 hours, in fact neither the 
anthraquinone nor the furoxan reacted. Warming the reaction mixture to 60 °C for 6 
hours also did not invoke reaction, however when heating to 120 °C we observed full 
decomposition after 14 hours with both dioxane (Table 3, Entry 4) and DMSO (Table 
3, Entry 5) solvents.  
Our current hypothesis is that the furoxan is attacked by base in the presence of a 
Lewis acid chelated palladium species. This is supported by the longer lifetime of the 
furoxan when using sterically hindered base species Cy2NMe, which required higher 
temperatures to decompose the furoxan.  
We concluded that the instability of the furoxan under investigated conditions so far 
was due to the presence of base and decided to try milder palladium catalysed 
conditions which did not require it.  
 
 2.3.2 Stille coupling 
 
Based on the encountered difficulties with furoxan instability in the presence of base 
and palladium catalyst, we hypothesized that the Stille reaction may provide the mild 
conditions necessary for cross coupling between anthraquinone and furoxan partners.  
 
2.3.2.1 Synthesis towards compound 67 
 
With compound 64 already synthesized we designed a synthesis for vinylstannane 
anthraquinone 67 (Scheme 18).  
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Scheme 18: Retrosynthetic analysis of vinyl stannane anthraquinone 67. 
 
Compound 67 is accessed by hydrostannylation of alkyne 68 which in turn in 
synthesized by desilylation of 69 with base. The silyl alkyne 69 is synthesized by 
Sonogashira coupling of 70 with trimethylsilaneacetylene. Compound 70 is granted by 
Sandmeyer reaction on commercially available 2-aminoanthraquinone. 
Our synthesis began by employing modified Sandmeyer conditions which granted 70 
in moderate yield (Scheme 19).75 The Sonogashira coupling of 70 with 
trimethylsilaneacetylene formed the intermediate 69 which upon treatment with 
base, desilylated to 2-alkenylanthraquinone 68 in 71% yield over two steps.76 
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Scheme 19: Synthesis towards 68. aCrude yield. bTwo steps from 70. 
 
Hydrostannylation of 68 produced a moderate yielding mixture of isomers that were 
inseparable by column chromatography.77 based upon coupling constants in the 1H 
NMR, we deduced that the desired E stereoisomer 67 was unexpectantly obtained as 
the minor isomer and the Z isomer 72 was present as the major (26 : 74 respectively) 
(Scheme 20) 
 
 
 
Scheme 20: Hydrostannylation of 68.  
 
 2.3.2.2 Reaction between compound 67 and 72 with compound 64 
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Although we had obtained the undesired isomer of the vinly stannylanthraquinone we 
decided to test if the Stille reaction could work with this substrate (Scheme 21). 
 
 
Scheme 21:  Attempted Stille cross coupling between a mixture of 67 and 72 with 64.  
 
Following purification of the crude mixture the desired product 62 was not isolated, 
instead 36% of furoxan starting material was recovered along with destannylated 2-
vinylanthraquinone 63 as the major component within a complex mixture.  
This reaction showed that although vinylstannanes 67 and 72 are susceptible to 
destannylation, under these conditions the furoxan 64 is not fully decomposed and 
suggested that fluorofuroxans may be suitable for Stille coupling under optimised 
conditions. 
 
2.3.2.3 Synthesis of compounds 73 and 77 
 
To address the incompatibility of 67 as a substrate in the Stille reaction we decided to 
swap the coupling partner roles in the reaction. Stannyl furoxan 73 would need to be 
synthesised, scheme 22 shows the retrosynthetic analysis.  
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Scheme 22: Retrosynthetic analysis of Stannyl furoxan 73. 
 
Compound 72 could be synthesised by fluorination of nitrofuroxan 74, which in turn 
could be constructed by using the standard Wieland procedure on 75. The synthesis 
of 75 had been reported from 4-bromostyrene in an unusual fashion by sonicating the 
styrene in THF with magnesium turnings for two hours.78 The stannylation of 66 is 
reportedly low yielding with standard Grignard type preparation due to 
polymerisation of the starting material. 
Following the sonication procedure, using silica chromatography we were unable to 
cleanly isolate the stannylated styrene due to the highly unpolar nature of the product 
and byproducts. We were concerned that distillation would decompose the product 
or induce polymerisation of the styrene so we decided to carry the material forward 
with minor impurities. To our delight the nitrofuroxan was formed in good yield after 
chromatographic purification and fluorination proceeded smoothly to give us the 
desired coupling partner 73 in 26% yield over 3 steps (Scheme 23).  
 
 
Scheme 23: Synthesis of stannyl furoxan 73. aDue to inseparable byproducts after 
silica chromatography, approximately 76% yield. bDue to impure starting material 
approximately 42% yield.cYield is calculated over 3 steps, 85% from 74. 
 
Due to the difficulty in handling and purifying the anthraquinones we decided to use 
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β-iodostyrene as a model in the Stille reactions. This was synthesised according to 
literature procedure and was isolated in 49% yield (Scheme 24).79 
 
 
Scheme 24: Synthesis of model coupling partner for Stille reaction. 
 
 2.3.2.4 Screening experiments towards compound 78 
 
With the coupling partners in hand we began screening conditions and reagents for 
reaction optimization. The conditions were derived from a comprehensive review on 
Stille coupling by Farina et. al80 
 
We began by screening different palladium catalysts with 10% CuI in DMF at 45 °C 
(Table 4). 
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Table 4: Catalysts screened in the Stille coupling between 77 and 73. aIsolated yield by 
silica PTLC after crude filtration through 10% w/w K2CO3 silica plug. b Reaction length 
for convenience. c Impure product. 
 
Entry Catalyst (y mol%) Ligand Additive  Time (h) Yielda (%) 
1 Pd(PPh3)4 (5%) - CsF  2  9 
2 Pd2(dba)3 (2.5%) - CsF  1  9 
3 Pd(PPh3)Cl2 (5%) - - 5  4 
4 Pd(CNCH3)2Cl2 (5%) - - 23  10 
5 Pd(OAc)2 (5%) P(o-tol)3 - 22  14c 
6 Pd2(dba)3 (2.5%) - - b69  14 
7 Pd(PPh3)4 (5%) - - 6.5  5 
 
 
The screening reactions suggested that the best catalyst was Pd2(dba)3 (Table 4, Entry 
6). The yield was equally high using Pd(OAc)2 (Table 4, Entry 5) but in this case the 
product was not isolated cleanly. The addition of CsF proved to be detrimental to the 
reaction with the use of Pd2(dba)3, CsF supposedly can help by precipitating tin 
residues from the reaction solution (Table 4, Entry 2).81 It is possible that in this case 
it reacted as a fluoride nucleophile and decomposed some of the furoxan. 
Having selected Pd2(dba)3 as the catalyst of choice for the Stille coupling we next 
moved on to investigating the solvent.  
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Table 5: Solvents screened in the Stille coupling between 77 and 73. aIsolated yield by 
silica PTLC after crude filtration through 10% w/w K2CO3 silica plug. bReaction length 
for convenience. cReaction did not reach completion. dImpure product. 
 
 
Entry Solvent Time (h) Yielda (%) 
- DMF b69  14 
1 Toluene 65  13c 
2 THF 65  30c 
3 NMP 24  15d 
4 HMPA 6  34 
 
 
Analysis of the screened solvents shows that DMF (Table 4, Entry 6), NMP (Table 5, 
Entry 3) and toluene (Table 5, Entry 1) provided low yields, whereas THF (Table 5, Entry 
2) and HMPA (Table 5, Entry 4) provided moderate yields. For convenience HMPA was 
selected because the reaction time was considerably shorter and yield slightly higher. 
It would also be easier to investigate temperature later in the screening due to the 
lower volatility and higher boiling point of HMPA relative to THF.  
With a suitable solvent selected we moved on to the investigation of ligand screening 
(Table 6). 
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Table 6: Ligands screened in the Stille coupling between 77 and 77. aIsolated yield by 
silica PTLC after crude filtration through 10% w/w K2CO3 silica plug. bReaction 
incomplete after 8 h, reaction length for convenience.  
 
 
Entry Ligand Time (h) Yielda (%) 
- - 6  34 
1 Ph3As 48 16b 
2 XPhos 48  30b 
 
 
The addition of ligands retarded the reaction rate. Ph3As is supposed to dissociate 
from the metal centre more readily than other ligands creating an active site and 
promoting reactivity, however under the investigated conditions the yield was 
diminished (Table 6, Entry 1). Bulky ligands are also supposed to enhance the Stille 
coupling however XPhos did not provide a significant improvement (Table 6, Entry 2). 
Further ligand screening was not conducted due to the slow reaction rate and poor 
performance of archetypical Stille coupling ligands.  
The effect of temperature on the Stille coupling was investigated next (Table 7).  
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Table 7: Reaction temperature screened in the Stille coupling between 77 and 73. 
aIsolated yield by silica PTLC after crude filtration through 10% w/w K2CO3 silica plug.  
 
 
Entry Temperature (°C) Time (h) Yielda (%) 
- 45 6  34 
1 70 1  35 
2 100 1  31 
 
 
The temperature effect was not significant with respect to the yield; however, the 
reaction rate was increased at higher temperatures. Following this data, we decided 
to conduct the reaction at 70 °C (Table 7, Entry 1).  
We next investigated the effect of additives (Table 8). 
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Table 8: Additives screened in the Stille coupling between 77 and 73. aIsolated yield 
by silica PTLC after crude filtration through 10% w/w K2CO3 silica plug. 
 
 
 
Entry Additive Time (h) Yielda (%) 
- - 1  35 
1 LiCl 1  57 
2 CsF 1.5  21 
 
 
Both LiCl and CuI are common additives used to enhance the Stille coupling, the CuI 
assists with transmetallation of the stannane in polar solvents and the LiCl is reported 
to have an effect on the oxidative addition.80 CsF is suspected to have an accelerating 
effect on the transmetallation and also removes the tin residues in situ by forming 
insoluble polymeric compounds to drive the equilibrium forward.81 
Similar to the results in table 1, entry 2 we found that CsF depreciates the yield (Table 
8, Entry 2). LiCl has a significant effect increasing the yield by 22% (Table 8, Entry 1). 
This suggests that the oxidative addition step may be rate limiting or the palladium 
complex may be less stable without the presence of chloride ions.  
Finally reversing the reagent ratios granted the product in good yield (Table 9). 
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Table 9: The effect of reagent ratio on the Stille coupling reaction between 77 and 73. 
aIsolated yield by silica PTLC after crude filtration through 10% w/w K2CO3 silica plug. 
bIsolated by silica column chromatography. 
 
 
Entry Reagent Eq. (X:Y) Yield (%) 
1 1 : 1.1 57a 
2 1.14 : 1 67b 
 
 
The yield was improved by using a slight excess of β-iodostyrene relative to stannyl 
furoxan. With an optimised yield of 67% we decided to move onto the dihydroxylation 
reaction to break the conjugation and complete the model synthesis.  
 
2.3.2.5 Synthesis of compound 79 
 
We applied standard conditions of the Upjohn Dihydroxylation in two different 
solvents (Table 10). Using THF instead of acetone gave a slightly higher yield and less 
residual osmium contamination (Table 10, Entry 2). 
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Table 10: Dihydroxylation of 78. aOsmium contamination. bMinor osmium 
contamination 
 
 
Entry Solvent Yielda (%) 
1 Acetone : Water 
9 : 1 
86a 
2 THF : Water 
2 : 1 
91b 
 
 
 2.3.2.6 Synthesis of compound 81 
 
We were successfully able to synthesise the model compound 79 and decided to apply 
the developed synthetic route to coupling anthraquinone and stannlyfuroxan.  
 
Firstly, we needed to synthesize the β-iodo-vinylanthraquinone, our initial attempt 
made use of the metathesis reaction used in the synthesis of 77 (Scheme 25).79 Despite 
using the same conditions as the iodination of styrene there was no reaction even 
after 3 days. This is most likely due to the electron deficient nature of the 
anthraquinone conjugated alkene. Instead the vinylanthraquinone starting material 
was recovered.  
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Scheme 25: Attempted synthesis of β-iodo-vinylanthraquinone. 
 
A new method needed to be devised for the synthesis of 81, the retrosynthetic route 
is shown in scheme 26.  
 
 
Scheme 26: Retrosynthetic analysis of β-iodo-vinylanthraquinone 
 
The iodostyrene is granted by halodesilylation of 80 which in turn is accessed by Heck 
reaction from 2-iodoanthraquinone. Sandmeyer reaction with 71 completes the 
retrosynthetic analysis.  
2-Iodoanthraquinone was synthesised using Sandmeyer type conditions and was 
obtained in good yield (Scheme 27).82  
 
 
Scheme 27: Sandmeyer type reaction to form 82. 
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The 2-iodoanthraquinone was then coupled to trimethylvinylsilane via Heck reaction 
to afford 80 in 89% yield (Scheme 28).83 
 
 
Scheme 28: Palladium catalysed Heck reaction of 82 with vinylsilane.  
 
Halodesilylation using iodinemonochloride granted the desired coupling partner 81 
(Scheme 29). 
 
 
Scheme 29: Halodesilylation of 80 with ICl.  
 
 2.3.2.7  Synthesis of compound 61 
 
Next, we attempted the Stille coupling between furoxan 73 and anthraquinone 81 
(Table 11).  
Our first attempt at the Stille coupling (Table 11, Entry 1) utilised our optimised 
conditions for the Stille coupling between 77 and 73 (Table 9, Entry 2). 
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Table 11: Stille coupling between 81 and 73. aIsolated yield by silica PTLC after crude 
filtration through 10% w/w K2CO3 silica plug. bProduct observed by 1H NMR but not 
successfully isolated. 
 
 
Entry Solvent Conc. (M) Time (h) Yield (%)a 
1 HMPA 0.4 1 0 
2 HMPA 0.1 1.5 12 
3 DMSO 0.1 3 0b 
4 DMI 0.1 1 0b 
5 DMPU 0.1 1 0b 
 
 
The solubility of the anthraquinone coupling partner was so poor that in HMPA at 0.4 
M a thick paste formed preventing stirring and efficient reaction, this resulted in a 
complex mixture (Table 11, Entry 1).  
When the concentration was reduced to 0.1 M the reaction proceeded but in low yield 
providing 62, however we encountered significant purification issues and we were not 
able to cleanly isolate the product (Table 11, Entry 2). The reaction conditions did not 
seem suitable since 49% of 81 starting material was recovered and furoxan 
homocoupled byproducts were detected showing that the anthraquinone was not 
particularly reactive.    
We next changed the solvent of the reaction in the hopes that the reaction yield could 
be improved (Table 11, Entries 3-5). Unfortunately, despite observing some product 
formation by 1H NMR we were unable to cleanly isolate the product. 
52 
 
The difficulty with purification raised concerns and we concluded that in future 
reactions it may be preferable to use 62 as a crude mixture in the hopes that the 
dihydroxylated product could be isolated more easily.    
The dihydroxylation step was designed to break the conjugation in the molecule but 
also to improve the solubility of the product.  
The same conditions used in the dihydroxylation of the model molecule 78 were not 
applicable since 62 had significant solubility issues in THF and so the reaction mixture 
was diluted to a 9:1 THF to water mixture (Scheme 30).  Unfortunately, after 48 hours 
TLC and 1H NMR suggested that no reaction had occurred. 
 
 
 
Scheme 30: Attempted dihydroxylation of 62. 
  
Changing the solvent mixture to more polar tBuOH, DCM and H2O lead to the 
formation of a small amount of probable product after 36 hours (Scheme 31). Most of 
the starting material remained unreacted. The product was isolated as part of a 
mixture by PTLC as a white solid (only 1.9 mg) using a highly polar solvent mixture (1% 
Et3N, 5% MeOH and 94% CHCl3). By heating the sample in deuterated methanol, a 
small quantity dissolved so we were able to obtain a proton and fluorine NMR.  
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Scheme 31: Dihydroxylation of precursor 62. 
 
The 1H NMR suggested that the product was obtained as a mixture of isomers. The 19F 
NMR chart supported this with two peaks, these peaks were in agreement with the 
spectra of the two regioisomers of fluorofuroxan, 35 and 36. The integration of the 
peaks suggested that approximately 80% of the sample was the 4-fluorofuroxan 
isomer 35 and the remaining 20% was the isomerized 3-fluorofuroxan 36.  
We irradiated the sample with 400–600 nm of light for 15 minutes to see if the sample 
would isomerize further, perhaps favouring the formation of one regioisomer. 
Following irradiation, inspection of the 1H NMR suggested decomposition had 
occurred. 
 
2.3.3 Conclusions 
 
After encountering regioselectivity issues with ethyleneglycol functionalized 
anthraquinones and fluorofuroxans we attempted palladium catalysed coupling 
reactions to ensure stereospecificity. Our attempts with the Heck reaction were 
limited by the poor stability of furoxan under the conditions. Changing our synthetic 
stratagem to utilize the milder Stille coupling enabled us to connect stannyl furoxan 
with β-iodovinyl functionalized moieties, leading to a coupled anthraquinone-
fluorofuroxan hybrid. Although the synthesis of 83 could be optimised and larger 
quantities obtained, the problem of low solubility and tedious purification remained. 
54 
 
We decided that the practical application of the design was limited, even if further 
functionalisation of the dihydroxy linker was a possibility. We concluded that a new 
design was required, one in which solubility could be guaranteed via a salt 
functionality.  
It is of note that the Stille coupling between 77 and 73 presented an unprecedented 
new range of Stille coupling mediated functionalisation available to furoxan chemistry 
and may find application in future research. 
 
2.4 Organocatalysed [4 + 2] reaction towards compounds 104, 122 and 126 
 and evaluation of NO releasing abilities 
 
It was noted during the previous synthetic routes that the handling, purification and 
characterisation of anthraquinone was difficult and time consuming due to poor 
solubility, so we wanted to synthesise the anthraquinone ring as one of the final steps. 
We also required a modular design that could be easily modified and retrofitted as 
needed. The final requirement was the presence of a salt group to assist with aqueous 
solubility.  
 
 2.4.1 Synthesis towards compound 84 
 
We designed a molecule which exhibited all of the above features and hypothesized 
upon a facile synthetic route. The key step features an organocatalysed [4 + 2] reaction 
based upon work by Magar et al.84 in which the anthraquinone core is furnished with 
connection to the furoxan preprogramed during benzannulation. Water solubility 
would be endowed by sulfonate salt via ‘click’ triazole formation. The retrosynthetic 
analysis is shown in schemes 32 and 33.  
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Scheme 32: Retrosynthetic analysis of compound 84 
 
The desired product 84 could be obtained by click reaction triazole formation from 
anthraquinone 85, which in turn could be synthesised by an organocatalyzed [4 + 2] 
and in situ oxidation reaction between modular building blocks 86 and 87.84 
 
Intermediate 87 could be obtained in 4 steps from 4-bromostyrene and 5-
bromopentene (Scheme 33). A carbon-carbon bond formed via Grignard reaction 
would grant 90, followed by Wieland furoxan synthesis to afford 89. Subsequent 
fluorination and Grubbs metathesis with acrolein leads to the desired compound 87.  
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Scheme 33: Synthesis of organocatalyzed [4 + 2] reaction coupling partners 87 and 86.  
 
Intermediate 86 could be obtained in 4 steps from 2,3-dimethylbutadiene and 1,4-
benzoquinone. Diels Alder reaction grants 94 which can be oxidised to 93. Benzylic 
bromination leads to 92 which can be substituted with amino-azide to form the 
desired intermediate 86. 
  
2.4.1.1 Synthesis of compound 86 
Firstly, a Diels-Alder reaction between commercially available 2,3-dimethylbutadiene 
and 1,4-benzoquinone in the presence of BF3∙OEt2 Lewis acid yielded the adduct in 
high yield following recrystallization in toluene (Scheme 34). 
 
 
Scheme 34: Synthesis of 94 by Diels-Alder reaction.  
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Following successful Diels-Alder adduct formation we next attempted the oxidation of 
94 to naphthoquinone 93 (Table 12). 
 
Table 12: Reagents and conditions used in the oxidation of 94. aIsolated yield by silica 
gel column chromatography.  
 
Entry Reagents Conditions Yield (%)a 
1 Pd/C (5 mol%), acetone (0.25 M) Reflux, 15 h 0 
2 DDQ (3 eq.), dioxane (0.1 M) Reflux, 18 h 28 
3 IBX (3 eq.), DMSO (0.1 M) 80 °C, 18 h 22 
4 MnO2 (10 eq.), toluene (0.1 M) Reflux, 2 h 68 
 
 
Firstly, we attempted dehydrogenation by stirring 94 with Pd/C in refluxing acetone 
overnight, however it resulted in no reaction (Table 12, Entry 1). 
We next attempted oxidation of 94 with DDQ (Table 12, Entry 2). Refluxing 94 with 
DDQ in dioxane overnight granted 93 in 28% yield following purification by column 
chromatography.85 
Stirring 94 and IBX in DMSO overnight yielded 93 in 22% yield (Table 12, Entry 3).86 
We suspected that the starting material and product may be susceptible to side 
reactions, possibly due to over oxidation, so we decided to use the mild oxidising 
agent MnO2. Refluxing 94 and MnO2 in toluene for 2 hours granted 93 in high yield 
(Table 12, Entry 4).87 
The naphthoquinone was then subjected to bromination conditions (Table 13).  
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Table 13: Benzylic bromination of 93 and respective purification attempts. aImpure 
product after chromatography. bProduct obtained following recrystallization with 
minor impurities. cYield obtained following two recrystallization attempts of crude 
material, minor impurities observed.    
 
 
Entry X Time (h) Purification Method Yield (%) 
1 2.3 18 Silica gel chromatography 78a 
2 2.1 16 Silica gel chromatography followed by recrystallisation in 
EtOAc/hexane 
62a/30b 
3 2.1 16 Recrystallization in EtOAc/hexane 52c 
 
 
The reaction proceeded reasonably well but difficulty was encountered with 
purification. Purification by column chromatography alone resulted in coelution of 
byproducts, thought to be mono-brominated or over brominated material (Table 13, 
Entry 1). Attempts at recrystallization helped to reduce the severity of contamination 
but not remove it completely and at the cost of reduced isolated yield (Table 13, Entry 
2). Abstaining from chromatography and utilizing only recrystallization yielded 
reasonably pure material but with successive recrystallization attempts of the 
remaining filtrate the purity diminished and clean product could not be further 
isolated (Table 13, Entry 3).  
 
With recrystallized compound 92 we began screening conditions for the nucleophilic 
substitution of the brominated benzylic positions. Firstly, the amino-azide was 
synthesised from 2-bromoethylamine hydrochloride (Scheme 35), given the volatile 
nature of 98 we used the crude product without further purification.  
 
 
59 
 
 
Scheme 35: Synthesis of azide 98.  
 
Table 14: Conditions investigated in the substitution of benzyl bromide with amine 98. 
aIsolated yield by silica PTLC.  
 
Entry 
Additive 
(0.1 eq.) 
Solvent (2 mM) 
Temp. 
(°C) 
Time. 
(h) 
Yield 86a 
(%) 
Yield 99a 
(%) 
Comment 
1 - MeCN  60 2.5 8 5 - 
2 - MeCN  0 22  14 11 - 
3 - DMSO  r.t. 0.5 - - Decomposition 
4 KI  MeCN  0 18  26 11 - 
5 KI  DCM 0 18  - - No reaction 
   r.t. 68  7 n.d. - 
6 KI  Toluene r.t. 18  - -  No reaction 
   50 20  - - No reaction 
7 KI  THF r.t. 18   12 4 - 
8 KI  MeCN (10 mM) 0 18  14 4 - 
9 KI (0.5 eq.) MeCN  0 18   28 12 - 
10 KI (2 eq.) MeCN  0 18  7 5 - 
 
 
We began our investigation using similar conditions as reported for the nucleophilic 
substitution of (mono) benzylic bromide substituted naphthoquinones with amines 
(Table 14, Entry 1).88 The reaction reached completion in only 2.5 hours turning from 
a bright yellow to a dark red colour. Aqueous workup was required for fear of 
remaining amine species attacking the desired product upon concentration. After 
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PTLC purification we obtained the product as a crystalline orange solid 86 in 8% yield 
along with a more polar oxidised byproduct 99 in 5% yield (Table 14, Entry 1). Lowering 
the reaction temperature to 0 °C increased the yield to 14% and 11% of 86 and 99 
respectively (Table 14, Entry 2). Changing the solvent to more polar DMSO had a 
detrimental effect with almost immediate decomposition into an insoluble black solid 
(Table 14, Entry 3). The addition of catalytic potassium iodide improved the yield 
considerably to 26% and 11% of 86 and 99 respectively (Table 14, Entry 4). Changing 
the solvent to less polar DCM and toluene resulted in no reaction at 0 °C after 18 h 
(Table 14, Entries 5 and 6). Warming the DCM mixture allowed 7% of product to be 
obtained after prolonged reaction time (Table 14, Entry 5). The toluene reaction was 
warmed to 50 °C but no reaction was observed after 20 h, warming to 100 °C led to 
decomposition (Table 14, Entry 6). Changing the solvent to THF at r.t. led to a lower 
yield (Table 14, Entry 7). Increasing the concentration was detrimental to the reaction 
(Table 14, Entry 8). Increasing the equivalents of KI had a negligible effect at 0.5 
equivalents, when increased to stoichiometric levels the yield was low, possibly due 
to attack from the iodide to the electron deficient alkene (Table 14, Entries 9 and 10).  
Our best results gave us a yield of 28% which is reasonable considering the unstable 
nature of the product, which appeared to decompose if kept at room temperature for 
long periods. (Table 14, Entry 9)   
With optimised procedure in hand we decided scale up to 500 mg (Scheme 36).  
 
 
 
Scheme 36: Scale up of nucleophilic substitution reaction to form 86. 
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Stirring overnight granted the desired product in 24% yield and the oxidised product 
in 7% yield. The products were purified by silica chromatography. The slightly lower 
yield compared to table 14, entry 9 can be attributed to decomposition. The instability 
of the compound became immediately apparent as it began to turn brown upon 
standing in air during unavoidable prolonged handling and transfer times.  
 
2.4.1.2 Synthesis of compound 87 
 
The synthesis of the furoxan intermediate 87 began with the Grignard reaction 
between halostyrene and 5-bromopent-1-ene.  
 
We were concerned about polymerization of bromostyrenes so decided to employ 4-
chlorostyrene in the hopes that it was stable to the reaction conditions (Scheme 37). 
We used CuI catalyst with LiCl additive.89 Once the Grignard reagent had been 
prepared from chlorostyrene and magnesium turnings the CuI and LiCl were added 
along with 5-bromopentene. Significant polymerisation occurred but we were able to 
isolate the desired product after column chromatography as the polymer was filtered 
off.  
 
 
Scheme 37: Copper catalysed Grignard reaction to form 90.  
 
In order to improve the yield, we attempted the reaction using Li2CuCl4 as the catalyst 
(Scheme 38). This time we allowed the reaction to reflux gently during Grignard 
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formation. The Grignard solution was added dropwise to a solution of 5-
bromopentene and Li2CuCl4 in THF then stirred at room temperature overnight. 
Following work up and purification on silica the product was obtained in 29% yield, 
once again significant polymerization was observed.  
 
 
Scheme 38: Li2CuCl4 catalysed Grignard reaction. 
 
We found that iron could be a good catalyst for sp2-sp3 Grignard reactions. We first 
tried Fe(acac)3 in THF with NMP additive (Scheme 39).90 After dropwise addition of 
Grignard reagent and overnight stirring the product was obtained in only 8% yield as 
determined by internal standard. The low yield was likely due to the poor reactivity of 
the chlorostyrene as significant unreacted material remained. 
 
 
Scheme 39: Iron catalysed Grignard reaction. 
 
Next, we tried using a different procedure where TMEDA which is used as an additive 
as it is known to improve iron catalysed reactions (Table 15, Entry 1).91 In this 
procedure, no separate formation of Grignard reagent is required as it forms and 
reacts in situ. Following overnight stirring after warming to room temperature only a 
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small quantity of product was formed and once again the low reactivity of 
chlorostyrene was held accountable.  
Changing the 4-chlorostyrene for 4-bromostyrene resulted in a significant increase in 
yield (Table 15, Entry 2). 
Table 15: FeCl3 catalysed Grignard reaction with chloro- or bromo- styrene. 
 
 
Entry X  Time (h) Yield (%) 
1 Cl 22 8 
2 Br 3 44 
 
 
Still unsatisfied with the product yield we used a procedure developed my 
Nakamura.92 In this procedure pre-formed Grignard reagent and TMEDA is added 
dropwise to a solution of bromopentene and FeCl3 catalyst (Scheme 40). To our delight 
the reaction was rapid and high yielding.  
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Scheme 40: Nakamura’s conditions applied to the synthesis of 90. 
 
Applying Weiland conditions to the dialkene granted the desired nitrofuroxan product 
as a mixture of 3- and 4- regioisomers in good yield (Scheme 41). Gratifyingly, only the 
conjugated alkene reacted and the terminal alkene remained untouched.  
 
 
Scheme 41: Synthesis of nitrofuroxan 89 and 101 as a mixture of isomers followed by 
fluorination.  
 
Fluorination of the mixture of nitrofuroxan isomers 89 and 101 with TBAF granted 88 
in high yield (Scheme 41). Compound 101 remained unreacted due to the increased 
electron density on the 3- position and was easily separated from the product by 
column chromatography.  
The final step in the synthesis of the furoxan module was the cross metathesis of 88 
with acrolein. This was firstly attempted with Grubbs-Hoveyda first generation 
catalyst but the reaction was sluggish and the yield was poor, 37% of the starting 
material remained unreacted after 44 hours and crude 1H NMR showed several 
byproducts as part of a complex mixture (Table 16, Entry 1).93  
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Table 16: Hoveyda-Grubbs catalysed cross metathesis of 88 with acrolein. 
 
 
Entry Catalyst Solvent 
Temp. 
(°C) 
Time 
(h) 
Yield 
(%) 
1 Hoveyda-Grubbs 1st generation (10 mol%) DCM (0.35 M) r.t. 44 7 
2 Hoveyda-Grubbs 2nd generation (3 mol%) Toluene (6 mM) 100 28 76 
 
 
Acrolein is rarely reported in cross metathesis reactions as it is notoriously unreactive. 
We did however happen upon a publication which successfully reacted it under high 
dilution and high temperature.94 Using Grubbs-Hoveyda second generation catalyst 
granted us the desired product in 76% yield along with 18% recovered starting 
material (Table 16, Entry 2).  
 
2.4.1.3 Synthesis of compound 85  
 
Finally we combined the recently synthesised naphthoquinone 86 with the furoxan 
aldehyde 87 using organocatalyzed [4 + 2] reaction conditions (Scheme 42).84 After 
stirring for 3 hours 1H NMR of an aliquot suggested little or no reaction had occurred 
so the reaction temperature was increased to 70 °C. After a further 15 hours the 
reaction was complete, purification attempts were partially successful and we 
obtained 85 along with inseparable by-products. The product appeared to precipitate 
out during column chromatography using a variety of solvents (EtOAc/hexane and 
MeOH/DCM). The product also dragged along a PTLC plate and recrystallization 
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attempts were unsuccessful. Furthermore, suspected that the 85 may be slightly 
unstable since each purification attempt resulted in the production of insoluble brown 
material, diminishing the yield further.  
 
 
Scheme 42: Oraganocatalyzed [4 + 2] reaction. aIsolated yield with impurities by silica 
column chromatography. 
 
2.4.1.4 Synthesis of compound 84 
 
We decided to carry the semi-pure 85 forward to the copper catalysed click triazole 
formation with alkenyl sulfonate 102 (Scheme 43).  
 
 
Scheme 43: Attempted triazole formation. 
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After stirring for 5.5 hours 1H NMR suggested that no reaction had occurred so the 
temperature was increased to 50 °C. After a further 2 hours no reaction had occurred 
so the solvent was removed in an attempt to recover the starting material. To our 
surprise most of the material had become an insoluble orange solid. The material was 
insoluble in deuterated solvents (including CDCl3 and D2O) and could not be analysed. 
We suspect that the material had decomposed or if it was the desired product, it was 
too insoluble to purify or obtain structural data.  
 
 2.4.2 Synthesis towards compound 104  
 
The purification and isolation of 84 had proven to be challenging and the azide may 
not be suitable for further reactions, so we decided to investigate an alternative amine 
tethered side chain in the hopes that we could easily purify the products and induce 
water solubility in subsequent steps.  
We envisioned that a pair of quaternary ammonium salts would provide the required 
aqueous solubility. Furthermore, we suspected that an amine tethered Boc group 
would assist with purification. The Boc group could be cleaved using trifluoroacetic 
acid as a final step, providing 104 as a trifluoroacetate salt after removal of solvent 
(Scheme 44). 
 
Scheme 44: Envisioned intermediate 103 and simultaneous deprotection and 
acidification of amines. 
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 2.4.2.1 Synthesis of compound 108 
 
Boc protected amine 107 was obtained in good yield (Scheme 45) 
 
 
Scheme 45: Boc protection of 106. 
 
Amine 107 was then reacted with recrystallized 92, to our delight the Boc tethered 
naphthoquinone 108 was obtained in moderate yield, we also obtained oxidised 
byproduct 109 (Scheme 46).  
 
 
Scheme 46: Synthesis of Boc tethered naphthoquinone 108.  
 
It is of note that as with the azide tethered naphthoquinone, the Boc tethered 
intermediate 108 appears to be inherently unstable and readily oxidises and 
decomposes if left at room temperature. Storing under argon in a freezer prevents 
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excessive decomposition but best results are obtained in the organocatalyzed [4 + 2] 
reaction if 108 is used immediately after synthesis.  
We suspected that we could prevent the oxidative side reaction by degassing the 
MeCN solvent prior to reaction by freeze pump thaw method (Scheme 47).  
 
 
Scheme 47: Synthesis of 108 using degassed MeCN. 
 
The use of degassed solvent led to a significant improvement in the yield of desired 
product 108 and to our surprise we still obtained oxidised byproduct 109 in moderate 
yield. One problem with degassing is that the low concentration of the reaction 
necessitates large volumes of solvent, so the process is somewhat time consuming 
and impractical.  
The purification of dibrominated compound 92 had proven difficult, obtaining partially 
pure product following column chromatography and sequential recrystallization in 
moderate yields. We decided to try a two-step synthesis towards 108 to bypass the 
purification of 92 and hopefully improve the overall yield of the synthesis (Scheme 48).   
 
 
Scheme 48: Two step synthesis towards 108. aImpurities present. 
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Bromination of 93 with NBS granted 89% yield of semi pure 92 following silica 
chromatography. 1H NMR showed the product was impure with mono-brominated 
and multi brominated byproducts present. The intermediate was used in the next 
reaction with Boc tethered amine. Overnight stirring at -10 °C granted 108 in 17% over 
two steps. In previous syntheses of 108 we have used recrystallized 92 which is 
approximately 90% pure and grants 108 in 37% yield if solvent is degassed. The yield 
over the two steps is fairly average yielding but does avoid time consuming 
recrystallization of 92.  
 
2.4.2.2 Synthesis of compound 104  
 
In our first reaction between 87 and 108 (Table 17, Entry 1) we noted that the reagents 
were not fully soluble in toluene which we attributed the low yield to. In the following 
reactions we changed the solvent to MeCN (Table 17, Entry 2) and chloroform (Table 
17, Entry 3) which improved both the solubilities of the reagents and the product 
yields.  
 
Table 17: Organocatalyzed [4 + 2] reaction between 87 and 108. aIsolated by silica gel 
chromatography. 
 
 
Entry Solvent Time (h) Yield (%)a 
1 Toluene 16 26 
2 MeCN 10 36 
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3 CHCl3 15 38 
 
 
As per our design, the presence of the Boc group enabled easy purification of the 
product on silica gel column eluting with 20% EtOAc in hexane. The yields were 
moderate and the product was cleanly isolated. We attribute the moderate yields to 
the instability of compound 108 during the reaction.  
 
The deprotection of 103 was conducted with excess TFA (Scheme 49).  
 
Scheme 49: Deprotection of 103 and salt formation.  
 
Initially we used 15 equivalents of TFA which after 3 hours served only to protonate 
the tertiary amine of 103. After increasing the concentration of TFA to make a 1 : 1 
solvent with DCM, the Boc deprotection proceeded to yield 104. The solvent was 
removed in vacuo and the crude brown insoluble material was filtered and washed 
several times with chloroform. The product was isolated as the double TFA salt 
following sonication in Et2O whereupon it precipitated out as a brown solid. 
Compound 104 was sparingly soluble in water and fully soluble in DMSO, we expected 
that at 100 μM concentration 104 would be soluble in aqueous phosphate buffer 
solution.  
 
2.4.3 NO releasing ability of compound 104  
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The NO releasing ability 104 was analysed by Griess test (Scheme 50). The NO release 
was sluggish with only 13% released after 5 hours of continuous irradiation. The 
release however was switchable as only residual amounts of NO are released under 
the same conditions without irradiation. 
 
 
Scheme 50: NO release of 104 in 50 mM pH 7.4 phosphate buffer.  
 
 2.4.4 Investigation into NO release of compound 104 
  
 We decided to investigate the reason for the slow release and how to resolve it. 
 
2.4.4.1 Synthesis of compound 115  
 
We started by synthesising a disconnected anthraquinone model to test if the 
proximity between the furoxan and anthraquinone had a significant effect (Scheme 
51).  
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Scheme 51: Synthesis towards disconnected sensitizer model. 
 
Diels-Alder reaction between naphthoquinone and 2,3-dimethylbutadiene yielded 
111, which was in turn treated with ethanoic KOH solution whilst air was streamed 
through the solution to oxidise to 112 (Scheme 51).95 Benzylic bromination of 112 gave 
113 along with minor brominated byproducts in 60% yield following column 
chromatography.  
Treatment of 113 with Boc protected primary amine 107 yielded 114 in excellent yield 
(Scheme 52). Clearly the anthraquinone was much more stable to benzylic 
substitution than naphthoquinone.  
 
 
Scheme 52: Formation of 114 and subsequent Boc deprotection and acidification to 
115.  
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Treatment of 114 with TFA in DCM lead to the deprotected salt form following 
filtration and washing with chloroform.  
2.4.4.2 Sensitized isomerization of compound 35 with compound 
  115  
 
With the disconnected anthraquinone synthesised we performed a control 
experiment with fluorofuroxan (Table 18). 
 
Table 18: Irradiation of 155 (30 mM) and 35 (30 mM) in DMSO-d6 with 400–500 nm 
light at rt. Isomerization of 35 and oxidation of 115 was observed. aMeasured by 1H 
NMR using relative peak integration. 
 
 
Time (min) 116 : 115a 35 : 36a 
10 31 : 69 91 : 9 
30 48 : 52 83 : 17 
180 70 : 30 35 : 65 
 
 
75 
 
Irradiation of a 1 : 1 mixture of 115 and 35 in DMSO-d6 lead to partial isomerization of 
the furoxan but the anthraquinone also reacted and became oxidised (Table 18). 
Following oxidation, the solution in the NMR tube became fluorescent red. The rate 
of anthraquinone oxidation (116 : 115) was faster than the rate of furoxan 
isomerization (35 : 36). One explanation for the sluggish release of NO from compound 
104 under irradiation is that in the triplet state, the anthraquinone oxidises rather 
than transfers energy to the furoxan. Once in the oxidised form 117, the molecule 
fluoresces and cannot efficiently transfer energy to the furoxan. This means that 
furoxan isomerization is hindered or even stopped and the NO cannot be released 
(Scheme 53).  
 
 
Scheme 53: Proposed reason for hindered NO release from 104 under irradiation.  
 
2.4.4.3 Synthesis of compound 120 
 
In order to prevent the oxidation of the pyrrolidine type ring we methylated the amine 
of 114 prior to Boc deprotection and treated crude 119 with TFA in DCM to grant 120 
(Scheme 54). 
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Scheme 54: Methylation of 114 and subsequent deprotection and acidification to 120.  
 
2.4.4.4 Sensitization of compound 35 with compound 120 
 
Following the synthesis of 120 we then decided to check the isomerizing ability of 120 
with fluorofuroxan (Table 19) in DMSO-d6.  
 
Table 19: Irradiation of 120 (20 mM) and 35 (20 mM) in DMSO-d6 with 400–500 nm 
light at rt. aMeasured by 1H NMR using relative peak integration. 
 
 
Time (min) 121 : 120a 35 : 36a 
5 0 : 100 100 : 0 
15 0 : 100 100 : 0 
60 0 : 100 100 : 0 
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To our delight the sensitizer no longer oxidised under irradiation but the furoxan no 
longer isomerized either. Previous work with alkoxyfuroxans had suggested that 
observable isomerization is not necessary for reliable NO release. The photostationary 
state may be almost fully towards the non-isomerized configuration but some of the 
isomerized furoxan is present to release NO. We decided to synthesise the N-
methylated anthraquinone-furoxan connected molecule and see if the NO release was 
improved relative to 104. 
 
 2.4.5 Synthesis of compound 122 
 
The methylation of 103 and treatment with acid were performed in one step (Scheme 
55). Simply heating the anthraquinone-furoxan overnight in DCM with MeI methylates 
the amine which can then be diluted with equal portions of TFA to DCM after cooling 
to -10 °C. Compound 122 is isolated by removal of solvent, washing with organic 
solvents and then sonication in Et2O which precipitates out a brown solid.  
 
 
Scheme 55: Methylation and Boc deprotection of 103.  
 
2.4.6 NO releasing ability of compound 122  
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Compound 122 was then tested for NO releasing ability using the Griess method 
(Figure 15).  
 
 
 
 
Figure 15: NO release curve of 122 (100 μM) in 1% DMSO 50 mM phosphate buffer 
containing or omitting 5 mM of ʟ-cysteine under 400–500 nm irradiation at 37 °C. Error 
determined by standard deviation calculations (n=3).  
 
We were delighted to observe NO release from compound 122 under visible light 
irradiation in reasonable quantities. This showed the value of methylation of the 
pyrrole amine which increased total NO release to 39% after 5 hours. The total 
released NO was comparable to 3-toly-4-fluorofuroxan 35 under 300–400 nm 
irradiation, although the rate was slightly slower (Figure 15, blue line).41 Rapid release 
of NO was observed within the first hour of irradiation (up to 20%), however under 
prolonged irradiation the rate of NO-release slowed. This retarded rate of NO release 
is a common trend shared by other NO donors which seem to have intrinsic NO-
release limits. A negative control experiment which omitted irradiation presented only 
background NO-release (up to 2%) in the presence of cysteine after 1 h (not shown).  
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Irradiation in the absence of cysteine led to an unexpected NO release with initial rates 
comparable to that with thiol present (Figure 15, orange line). Reports of furoxans 
that release significant quantities of NO in the absence of thiol are rare and the exact 
reason for NO-release is unknown.37,58,59  
The ability of compound 122 to release NO in the absence of cysteine indicated that 
in addition to the irradiation-independent thiol-mediated NO-release from the 3-
regioisomer, there may be another pathway where the photochemically excited 
fluorofuroxan or secondary transient intermediate can release NO without thiol 
cofactor assistance.  
After demonstrating photoswitchable NO-release, we decided to investigate the level 
of control over release (Figure 16). Compound 122 was irradiated for 1-hour intervals 
with 400−500 nm of light, in between the irradiation periods the sample remained 
under ambient light, aliquots were taken at intervals. As soon as irradiation is ceased, 
the NO-release almost completely stops apart from some minor background release 
(Figure 16). This demonstrates a high level of control over NO-release with compound 
122; therefore, it may be possible to release a specific quantity of NO with selected 
sample concentration and irradiation time. 
 
 
Figure 16: NO-release curve of 122 (100 μM) in 1% DMSO 50 mM phosphate buffer 
containing 5 mM of L-cysteine under 1-h rotations of 400−500 nm irradiation and 
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ambient light at 37 °C. Grey areas indicate periods of non-irradiation in ambient light.  
 
2.4.7 Cellular studies with compound 122 
 
With 122 showing NO release in both the presence and absence of cysteine and to a 
high degree of control we next submitted the sample for studies within a cell culture 
system in the hopes of achieving spatiotemporal NO release (Figure 17). 
HeLa cancer cells were initially incubated with NO550,96 a fluorescent probe for NO 
detection and then treated with 122 for 30 min. After being washed with PBS buffer, 
the cells were irradiated with 400–500 nm light for 1 hour. Disappointingly the cells 
exhibited no significant fluorescence derived from the reaction of NO550 and NO. Due 
to the non-fluorescent nature of 122, it could not be determined whether or not 122 
permeated and entered the cells. The failure in NO-release observation may be due 
to the low cellular uptake of 122, possibly due to the charged nature of the molecule 
and the high molecular weight. 
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Figure 17: Fluorescence imaging of liberated NO in cultured living HeLa cells. (A) HeLa 
cells were incubated with 10 μM NO550 alone (left; exposure time 1 sec) followed by 
the addition of 30 μM NOC7 in the medium (right; exposure time 1 sec). Comparison 
of the images showed that the fluorescent brightness was much greater in the 
presence of NOC7, indicating that NO550 in the cells reacted with liberated NO. (B) 
Fluorescence image of HeLa cells preincubated with NO550 and 5 (left; exposure time 
1 sec), and the image after the exposure of light in the wavelength of 400–500 nm for 
1 hour (right; exposure time 1 sec). Comparison of the images showed no significant 
difference. 
 2.4.8 Synthesis towards compound 126 
 
Recent work within the research group had shown that alkoxyfuroxans exhibited 
switchable PINOD properties and were able to release NO in quantities greater than 
fluorofuroxans under UV irradiation.60 We suspected that an alkoxyfuroxan-tethered 
anthraquinone may release NO via sensitized mechanism in greater quantities than 
122. Prior to cell culture investigations with compound 122 we synthesised an alkoxy 
derivative. 
 
2.4.8.1 Synthesis of compound 124 
 
Firstly, starting from 89 we synthesised the alkoxy derivative 123 under basic 
conditions in high yield (Scheme 56). Compound 123 was then reacted with acrolein 
under Grubbs metathesis catalysis to grant furoxan intermediate 124.94  
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Scheme 56: Synthesis of organocatalyzed [4 + 2] furoxan starting material 124. 
Compound 89 is as an 87:13 mixture with isomer 101 (not shown).  
 
 
 
 
2.4.8.2 Synthesis of compound 126 
 
The union of alkoxy furoxan and anthraquinone was made possible by 
organocatalysed [4 + 2] reaction which granted 125 in 34% after column 
chromatography (Scheme 57) 
 
 
Scheme 57: Organocatalyzed [4 + 2] reaction between 108 and 124.  
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Finally, the pyrrolidine amine was methylated with excess MeI overnight and the Boc 
group deprotected with TBAF to produce an oily residue. The residue was sonicated 
in Et2O for 1 hour which formed a semi-crystalline solid that 1H NMR revealed to be 
126 complexed with an ether molecule (Scheme 58). 
 
 
Scheme 58: Methylation and deprotection of 125.  
 
2.4.9 NO releasing ability of compound 126  
 
The NO releasing ability of 126 was tested under 400–500 nm irradiation using the 
Griess method (Figure 18). 
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Figure 18: NO release curve of 126 (100 μM) in 1% DMSO 50 mM phosphate buffer 
containing 5 mM ʟ-cysteine under 400–500 nm irradiation or ambient conditions at 
37 °C.  
 
Disappointingly, the NO release of 126 was low compared to the fluoro- isomer 122, 
the NO release plateaued at 7% (Figure 18, blue line). The negative control shows only 
marginal NO release which is attributed to background discharge (Figure 18, orange 
line).  
It is likely that the triplet energy level of the methoxyfuroxan is much higher than the 
fluorofuroxan due to the lower relative electronegativity of the oxygen and greater 
electron donation into the ring raising the LUMO. Therefore, successful energy 
transfer from sensitizer to furoxan is perhaps slower due to a misalignment of energy 
levels. It is also possible that rather than isomerizing after sensitized energy transfer, 
the alkoxy furoxan reacts in such a way that NO is not released, potentially reacting 
with the sensitizer itself.  
The exact reason for the poor NO release from 126 is unknown but the fact that 
alkoxyfuroxan can release NO via sensitization was encouraging. The increased 
stability of alkoxyfuroxans relative to fluorofuroxan opened up the synthetic toolbox 
for future designs.  
 
2.4.10 Mechanism of sensitized NO release from furoxan 
 
2.4.10.1 Proposed mechanism of sensitized NO release 
 
Fluorofuroxan shows switchable NO release by isomerizing from 4-fluorofuroxan to 3-
fluorofuroxan. In the isomerized 3-fluorofuroxan state, the molecule is susceptible to 
attack from cysteine whereupon NO is released (Figure 19). The release mechanism 
of furoxans by thiol attack was discussed in the introduction (Scheme 1), here we take 
a closer look at the sensitized release of NO.  
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Scheme 59: Proposed thiol mediated sensitized NO release mechanism. 
 
Since 1H NMR of irradiation experiments showed furoxan isomerization in the 
presence of sensitizer under 400–500 nm irradiation (Table 1) it is logical that the 
same thiol dependant release mechanism occurs (Scheme 59). Energy transfer via 
electron exchange between the excited state anthraquinone and ground state 
fluorofuroxan induces isomerization through an intermediate 127. Once isomerized 
the furoxan is immediately attacked by cysteine and NO is released.  
This thiol dependant mechanism does not explain however, how NO is released in the 
absence of cysteine. It is of note that the experiments conducted in the absence of 
cysteine resulted in lower quantities of NO released (Figure 15). We suspect that the 
water molecules in the phosphate buffer solution may react with the furoxan in the 
transient state between isomerized forms, from here NO may be released. A second 
theory is that once in the excited state a separate sensitization event occurs in which 
the transient furoxan species releases NO. The sensitization of furoxan may not 
directly lead to NO release but instead the formation of intermediates that react with 
solvent and cysteine to release NO. This could explain why experiments conducted 
with cysteine resulted in a greater quantity of NO released, since cysteine may attack 
non-furoxan NO-releasing byproducts. At this point however, we do not have 
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evidence to support or disprove any of the described theories and the exact NO 
release mechanism is unknown. 
 
2.4.10.2 Cyclic voltammetry studies of compound 35 and anthraquinone 
  
Another possible energy transfer mechanism is sensitized electron transfer, we 
decided to test this by measuring the electrochemical properties of anthraquinone 
and fluorofuroxan 35 using cyclic voltammetry (Figure 19). The experiments were 
conducted in degassed MeCN using 0.1 M Bu4NClO4 as a supporting electrolyte and 
revealed the reduction potentials of anthraquinone/ anthraquinone•− and 35•+/35 
couples to be −0.95 V and +2.11 V versus saturated calomel electrode (SCE), 
respectively. The triplet energy of anthraquinone was reported to be 2.73 eV.97 
Following the Rehm−Weller formalism98,99 with the assumption that the work function 
ω is a small contribution,100 the excited-state reduction potential of anthraquinone 
was estimated to be +1.78 V versus SCE, which is not comparable to the reduction 
potential of 35•+/35 couple (+2.11 V versus SCE). Thus, the ΔG0 for the electron 
transfer from 35 to the excited anthraquinone is a large positive value, suggesting that 
this pathway is unlikely.  
 
 
Figure 19: Cyclic voltammograms of 1.0×10-3 M anthraquinone and 4-fluorofuroxan 
35 for the measurement of their reduction and oxidation potentials, respectively. 
Solvent: MeCN, WE: glassy carbon, RE: Ag/Ag+ with 0.1 M TBAClO4 in MeCN, CE: 
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platinum wire, electrolyte: 0.1 M TBAClO4, sweep rate: 50 mV/s. The redox potentials 
corrected to the SCE scale are shown. 
 
2.4.11 Conclusions 
 
By considering the solubility issues of anthraquinone and reactivity of fluorofuroxan 
we were able to devise a convergent synthetic strategy. The organocatalysed [4 + 2] 
reaction with an N-Boc protected naphthoquinone and terminal aldehyde 
fluorofuroxan ensured that the anthraquinone core and carbon linker to the furoxan 
was furnished in one pot under mild conditions. Simple deprotection and 
saponification granted the hybrid PINOD. We were able to show for the first time 
photoswitchable NO release from a furoxan under visible light irradiation which used 
a novel release mechanism. The synthesis was not without its flaws however, and we 
were unable to determine whether the hybrid permeated the cells. This research 
served as a good proof of concept and was the first step towards photoswitchable NO 
release from a furoxan within a cell culture system.  
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Ⅲ: Improvement to visible light PINOD furoxan: 
studies towards aminofluorenone-alkoxyfuroxan  
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3.1 Consideration of compound 122 and required improvements  
 
With a sound prototype in hand we analysed the shortfalls of 122 and considered 
necessary requirements to synthesise an improved molecule. Previously, we were 
unable to determine whether compound 122 was localized within a cell culture system 
and 122 was only sparingly soluble in phosphate buffer solution. Furthermore, the 
synthesis presented restrictions due to the reactive fluorofuroxan requiring mild 
conditions. We also decided that although 400 nm irradiation wavelength is largely 
biologically benign, the absorption wavelength of the sensitizer should be as long as 
possible to assist with tissue penetration.  
This led to new requirements for the synthesis of an improved molecule (Figure 20): 
 The molecule should be fluorescent as well as sensitizing 
 The molecule should have an absorption wavelength >400 nm 
 The molecule should be cell permeable 
 The synthesis should be simplified by finding a more stable furoxan than 
fluorofuroxan. 
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Figure 20: Concept for an improved sensitized furoxan PINOD. 
 
 
 
 
3.2 Investigation into furoxan NO releasing ability 
 
With the knowledge that compound 122 released NO under visible irradiation in the 
absence of thiol cofactor, we decided to test whether furoxan molecules could release 
NO in the absence of thiol under UV irradiation. Previously it had been assumed that 
isomerization was required followed by thiol attack, but it had not been examined 
whether furoxans can release NO under continuous UV irradiation.  
We made the assumption that furoxans that could release significant quantities of NO 
under UV irradiation may also release similar amounts of NO via a sensitized 
mechanism under visible irradiation. To find a suitable furoxan for the next design we 
irradiated furoxans in pH 7.4 50 mM phosphate buffer with 300–400 nm light in the 
absence of cysteine (Table 20). The NO release was determined by Griess test.  
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Table 20: NO release of furoxans (100 μM) in 50 mM pH 7.4 phosphate buffer under 
300–400 nm irradiation. Structures are shown at 50% scale.  
 
Entry 
Structure 
no. 
Furoxan 
%NO release after 2 h continuous 
irradiation 
Comment 
1 37 
 
31 Decrease after 2 h 
2 35 
 
28 Decrease after 2 h 
3 129 
 
10 14% after 5 h 
4 130 
 
- 
41% After 0.5 h then 
decrease 
5 131 
 
12  
6 132 
 
7  
7 133 
 
12  
8 134 
 
17 22% After 5 h 
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9 135 
  
5  10% DMSO in buffer 
10 136 
 
2  
 
 
The first molecule to be tested was 3-tolyl-4 methoxy furoxan 37 (Table 20, Entry 1). 
To our delight the furoxan released a large quantity of NO in the absence of cysteine. 
However, we observed the NO release decreasing with prolonged irradiation (time > 
2 hours) suggesting that NOx species were reacting with furoxan post release 
byproducts. Because of this unusual phenomenon we decided to quantify NO release 
only up to two hours irradiation with subsequent experiments. 
3-Toly-4-fluorofuroxan 35 was included as a control and showed reasonably high 
levels of NO release (Table 20, Entry 2). 3-Tolyl-4-cyanofuroxan 129 released low levels 
of NO at a sluggish rate, this was disappointing since a method for cyanation of 
nitrofuroxan had recently been developed within the group (Table 20, Entry 3).40 To 
our surprise 3-tolyl-4-tetrabutylammonium oxide furoxan 130 released an exceptional 
41% NO within the first 30 minutes of irradiation (Table 20, Entry 4). However, 
compound 130 was hindered by non-selective spontaneous NO release in both 
isomers and so it was not truly a PINOD molecule.101 Increasing the conjugation of the 
furoxan with 3-napthylen-2-yl-4-methoxy furoxan 131 resulted in lower quantities of 
NO release (Table 20, Entry 5). Aliphatic furoxan 3-tolyl-4-hexanfuroxan 132 released 
only 7% (Table 20, Entry 6). Amino furoxans 133 and 134 released low to moderate 
quantities of NO with 12% and 17% respectively (Table 20, Entries 7 and 8). Alkynyl 
135 and trifluoromethyl 136 derivatives released negligible quantities of NO under 
irradiation (Table 20, Entries 9 and 10).  
Compounds 37, 35, 130 and 134 released moderate quantities of NO under irradiation. 
This suggested that electronegative heteroatoms directly bonded to the furoxan ring 
are required to induce significant NO release. The more conjugated naphthylfuroxans 
appeared to release a lower quantity of NO, perhaps a stabilizing effect of conjugation 
reduced the reactivity of the transient excited state intermediates towards NO release 
pathways.  
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Following the screening experiments shown in table 20, methoxyfuroxan 37 was 
selected as the candidate for connection with a fluorescent sensitizer.  
 
3.3 Investigation into potential fluorescent sensitizers of compound 37 
 
With the NO release of furoxans under UV irradiation investigated and a suitable 
furoxan PINOD selected, we explored potential sensitizers which exhibited both 
sensitizing and fluorescent properties. Before beginning the search, we surveyed the 
literature for potential sensitizers of furoxan which held favourable photophysical 
properties. We defined ‘favourable’ properties by first reviewing the successful 
sensitizers for fluorofuroxan (Table 21).72 Note: Following initial sensitizer screening 
at the beginning of the project and after the synthesis of 122, it was found that 9-
fluorenone was also an exceptional photosensitizer of fluorofuroxan 35 inducing 91% 
isomerization in 15 minutes.   
Table 21: Photophysical properties of successful sensitizers of fluorofuroxan. Data 
extracted from ‘The Handbook of Photochemistry’.72 
 
Entry Sensitizer Es/Kj mol-1 Фfl ФT ET/Kj mol-1 τT/µs 
1 Benzil 247 0.0013 0.92 233 5 
2 Anthraquinone 284 - 0.90 261 0.11 
3 9-Fluorenone 266 0.0027 0.48 211 100 
 
 
Compounds 35 and 37 are different molecules and would therefore have different 
HOMO/LUMO energy levels, so these properties were used as a reference rather than 
a definitive range.  
Analysis of the sensitizers in table 21 suggested an acceptable range of triplet energy 
levels between 211 Kj mol-1 and 261 Kj mol-1 to sensitize isomerization in fluorofuroxan 
35. A triplet quantum yield as low as 0.48 was sufficient to induce rapid isomerization 
(90% in 15 minutes with 9-fluorenone) so perhaps even lower values would suffice 
depending on the respective absorption coefficients. As long as the sensitizer absorbs 
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in the visible light range (Es < 300 Kj mol-1) it would be sufficient, although longer 
wavelengths were preferred. Even a short triplet lifetime was acceptable when 
sensitizing 35 (0.11 µs for Anthraquinone) (Table 21, Entry 2).  
Following exhaustive searching we found that the requirements were limiting but a 
few potential sensitizers had been discovered (Table 22).  
 
 
 
 
 
Table 22: Sensitizers showing triplet sensitizing and fluorescent properties suitable for 
sensitization of 35 and perhaps 37.72 Omitted data indicates that it had not been 
recorded in the literature. a0.064 in polar solvent. b0.08 in polar solvent.  
 
Entry Sensitizer Es/Kj 
mol-1 
Фfl ФT ET/Kj mol
-
1 
τT/µs 
1 Proflavin 250 0.40 0.22 205 20 
2 3-Amino-9-fluorenone 262 0.16a 0.26b 193 - 
3 Aminoanthracene 264 0.57 - 184 - 
4 Riboflavin 263 0.12 0.4 - 19 
 
 
Proflavin, aminoanthracene and riboflavin were commercially available and showed 
favourable properties. Proflavin (Table 22, Entry 1) showed attractive fluorescent and 
triplet sensitizing properties and similar photophysical values to the successful 
sensitizers of 35 in table 21. Aminoanthracene did not have a recorded triplet 
quantum yield but did have a recorded triplet energy, albeit a potentially low one 
(Table 22, Entry 3). Riboflavin showed reasonable fluorescence and good triplet 
quantum yield but the triplet energy level was not recorded, since it was commercially 
available we decided to test it anyway. 3-Amino-9-fluorenone had potential, but 
worryingly the favourable fluorescence and triplet sensitizing values decreased in 
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polar solvents (Table 22, Entry 2), nevertheless we decided to synthesise and test the 
sensitizer (Scheme 60).   
 
 
 
 
 
 
 
3.3.1 Synthesis of compound 143  
 
 
Scheme 60: Synthesis of 142. aYield after 2 steps from 139.  
 
The first step in the synthesis towards 142 was the formation of oxime 139 from 4-
nitrobenzaldehyde 137 (Scheme 60). Treatment of 137 with methoxylamine 
hydrochloride formed 139 in 86% yield following purification by column 
chromatography. 
3-Nitro-9-fluorenone was synthesised using a one-pot palladium catalysed Heck and 
C-H insertion reaction.102 Coupling of 139 with iodobenzene 140 formed a mixture of 
oxime intermediate 141 and nitrofluorenone 142. Refluxing the mixture in conc. HCl 
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and DCM helped to form more of the nitrofluorenone but some oxime still remained 
unhydrolyzed. The insoluble product was isolated by pre-binding to silica prior to 
chromatography, the compound eluted with a CHCl3/MeOH mobile phase and was 
obtained in 69% over two steps from compound 139.  
 
 
Scheme 61: Reduction of 142 to grant 3-amino-9-fluorenone. 
 
Compound 142 was reduced with sodium sulphide to grant the sensitizer 143 (Scheme 
61).103  
 
3.3.2 Investigation into sensitized NO release of compound 37 
 
With 143 and the commercially available sensitizers in hand we began screening 
experiments to see if NO was released from 37 under visible light irradiation in the 
presence of a sensitizer (Table 23). All of the sensitizers were soluble in phosphate 
buffer solution at 100 μM concentration, the NO release experiments were conducted 
in the absence of cysteine.  
 
Table 23: Sensitized NO release experiments of 37. Furoxan (100 µM) and sensitizer 
(100 µM) in 1% DMSO 50 mM pH 7.4 phosphate buffer at 37 °C. Irradiated with 400–
500 nm light for 30 minutes. Aliquots treated with Griess reagent and %NO release 
determined spectroscopically. 
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Entry Sensitizer %NO release Comment 
1 Proflavin 0 Photobleached 
2 3-Amino-9-fluorenone 0 Photostable 
3 Aminoanthracene 0 Photobleached 
4 Riboflavin 0 Photobleached 
 
 
Unfortunately, none of the sensitizers induced observable NO release (Table 23). We 
suspected that the lack of NO release was either due to direct photobleaching of the 
sensitizer or that the furoxan and sensitizer were too far apart in solution to interact 
effectively. Proflavin, aminoanthracene and riboflavin all photobleached within 30 
minutes and were not suitable for connection with 37 (Table 23, Entries 1, 3 and 4 
respectively). Interestingly, 3-amino-9-fluorenone was photostable since the UV/vis 
absorption spectrum remained unchanged after an hour of irradiation (Table 23, Entry 
2).  
 
3.3.3 Sensitized isomerization of compound 37 with compound 143 
 
To check whether 143 could sensitize 37 we conducted an isomerization experiment. 
A solution of deaerated deuterated benzene containing a 1 : 1 mixture of 37 and 143 
was irradiated under 400–500 nm and the isomerization ratio between 3- and 4- 
methoxyfuroxan was determined. To our delight the quantity of 3- isomer in the 
sample increased to 10.7% after 45 minutes of irradiation suggesting that 143 could 
indeed sensitize the 37, at least in benzene (Table 24).  
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Table 24: Sensitized isomerization of methoxyfuroxan. 5 mM C6D6 solution containing 
1 : 1 37 and 143. Irradiated with 400–500 nm light. aDetermined relative to dodecane 
internal standard by 1H NMR.  
 
Time (min) Isomerization (%)a Comment 
0 3.5 Residual Isomerization in sample 
15 7.5  
30 9.1  
45 10.7 PS 
60 10.7  
 
3.3.4 Sensitized isomerization of compound 35 with compound 144 
 
A second isomerization experiment was conducted at 100 μM concentration in 
benzene to test whether sensitized isomerization can occur at low concentration. This 
time we used 9-fluoreneone 144 and fluorofuroxan 35 because fluorofuroxan 
indicates isomerization more clearly than alkoxyfuroxan (fluorofuroxan isomerizes up 
to 90% whereas alkoxyfuroxan shows less than 11%) (Table 25).  
 
Table 25: Sensitized isomerization of 35 under 400–500 nm irradiation at 100 μM 
concentrations of sensitizer and furoxan.  
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Time (min) Isomerization% (35 : 36) 
0 Trace 
30 69 
60 88 
 
 
To our delight we observed significant sensitized isomerization of 35 to 36 after one 
hour of irradiation. This is a slower rate of isomerization compared to previous 
experiments which have been conducted at 5 mM concentration but these results 
indicated that the desired photochemical processes occur at 100 μM in benzene.   
 
 
3.4 Synthesis towards compound 145 
 
With the knowledge that 3-amino-9-fluorenone induces isomerization in 
methoxyfuroxan under visible light irradiation, we decided to connect the two 
molecules, the retrosynthetic analysis is shown in scheme 62. 
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Scheme 62: Retrosynthetic analysis of aminofluorenone tethered alkoxyfuroxan 145. 
 
Compound 145 is accessed by nucleophilic aromatic substitution of nitrofuroxan 55 
with 146. Compound 146 is formed from global deprotection of 147 which in turn is 
granted by nucleophilic substitution of silyl ether protected alkyl iodide 149 with Boc 
protected amine 148. A propyl linker was selected over an ethyl linker to discourage 
any intramolecular 5-membered cyclisation between the amine and furoxan. 
Our synthesis began with the Boc protection of 143 (Table 26).  
 
 
 
 
 
 
Table 26: Attempted Boc protection of 143. aIsolated yield.  
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Entry Reagents Conditions Yield (%)a 
1 Boc2O (1.1 eq.), MeOH (0.3 M) 50 °C, 12 h 21 
2 DMAP (1 eq.), Boc2O (1.1 eq.), Et3N (1.1 eq.) THF (0.3 M)  50 °C, 40 h 38 
 
 
The reaction between 143 and Boc2O in MeOH overnight did not reach completion 
(Table 26, Entry 1). 1H NMR suggested only a small portion of product had formed so 
the unreacted starting material was recovered. The low reactivity of 143 was due to 
the amine being conjugated with the aromatic system and electron deficient ketone, 
which had a strong deactivating effect. The next attempt utilized DMAP to activate 
the Boc anhydride to nucleophilic attack from the deactivated amine, once again the 
reaction was slow and after 40 hours significant starting material remained (Table 26, 
Entry 2).   
Given the low reactivity of the amine to Boc protection we suspected that base would 
be necessary to alkylate 148. A solution of compound 148 was pre-treated with NaH 
and then 149 was added dropwise (Scheme 63). Gratifyingly the reactivity was 
enhanced with deprotonation and 147 was isolated in near quantitative yield.  
 
 
Scheme 63: Alkylation of 148. 
Global deprotection of the silyl ether and Boc protecting groups using 4 M HCl in 
dioxane granted 146 (Scheme 64).  
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Scheme 64: Global deprotection of 147.  
 
 
Scheme 65: Nucleophilic aromatic substitution reaction between 146 and 
nitrofuroxan 55.  
 
Finally, reaction of nitrofuroxan with 146 granted 145 (Scheme 65). Initially we tried 
to use a K2CO3 as a mild base but addition of NaOH was necessary to see the reaction 
to completion.  
 
3.5 Absorption and fluorescence of compound 145 
 
To our delight compound 145 showed excellent absorption with a λmax of 456 nm and 
fluorescence with a λmax 545 nm in 50 mM pH 7.4 phosphate buffer solution. However, 
20% DMSO was necessary to keep the molecule from precipitating out of solution 
(Figure 21). 
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Figure 21: Absorption and fluorescence of compound 145 (100 μM) in 20% DMSO pH 
7.4 phosphate buffer at 25 °C. Fluorescence λex 470 nm. 
 
3.6 NO releasing ability of compound 145  
 
Compound 145 exhibited limited solubility in the phosphate buffer so 20% DMSO 
phosphate buffer was used instead. This was not too much of an issue as the molecule 
could be further functionalized with water soluble moieties later. Unfortunately, even 
though the sensitizer and furoxan were connected the molecule did not release NO 
under 400–500 nm irradiation (Scheme 66). The absorption spectrum showed a 
decrease in the fluorenone absorption over time so we suspected that the molecule 
may either react unfavourably under irradiation and photobleach, or simply 
precipitate out of solution (Figure 22). It is of note that the molecule appears to be 
initially soluble in the phosphate buffer, under irradiation the precipitation appeared 
to occur at a faster rate.  
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 Scheme 66: Unsuccessful NO release from compound 145.  
 
 
Figure 22: Absorption of 145 (100 μM) in pH 7.4 phosphate buffer during Griess test. 
Irradiation with 400–500 nm light. 
 
3.7 Synthesis towards compound 150  
 
We suspected that the molecule was reacting unfavourably under irradiation and 
rationalised that the N-H moiety may be responsible for photobleaching, quenching 
or undesired reactivity. We decided to modify the molecule by methylating the amine, 
although this would come at the cost of reduced solubility, we wanted to check if any 
NO could be released and then graft a water-soluble moiety onto the molecule upon 
release confirmation. Since solubility was already an issue and we now knew the 
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amine was fairly unreactive when in resonance with the fluorenone core, we also 
decided to shorten the tether from propyl to ethyl (Scheme 66). 
 
 
Scheme 67: Modification of 145 by alkylating the amine and reducing linker length. 
 
The synthetic route followed the same scheme as 145 but the Boc protected 148 was 
methylated prior to forming the fluorenone-furoxan bridge (Scheme 68). The 
methylation occurred in high yield and Boc deprotection afforded 152.  
 
 
Scheme 68: Methylation of compound 148 and Boc deprotection. 7 
 
In the next step we attempted to synthesize the bridge between furoxan and 
fluorenone. Following deprotonation of 152 with NaH we added dropwise silyl either 
protected ethyl iodide 153. After one hour of reaction we were surprised to observe 
the consumption of 153 but remaining 152. Proton NMR of an aliquot revealed 
complete removal of the silyl protecting group (Scheme 69). For fear of 
oligomerization we did not add further base or silyl ether. We were pleasantly 
surprised that 154 was obtained without oligomers in 66% yield and 34% starting 
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material recovery following chromatography. The basic amide anion is likely able to 
deprotect the sily ether leading to partial deactivation of starting material.  
 
Scheme 69: Alkylation of 152 with unexpected -OTBS deprotection. 
 
We next connected fluorenone and furoxan in high yield (Scheme 70).  
 
 
Scheme 70: Connection of 154 and furoxan 55. 
 
3.8 Absorption and fluorescence of compound 150 
 
Like the non-methylated isomer 145, compound 150 showed a promising albeit less 
intense spectra with absorption λmax of 450 nm and fluorescence λmax of 545 nm in 20% 
DMSO 50 mM pH 7.4 phosphate buffer (Figure 23).  
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Figure 23: Absorption and fluorescence of compound 150 in 20% DMSO pH 7.4 
phosphate buffer at 25 °C. Fluorescence λex of 380 nm. 
 
3.9 NO releasing ability of compound 150  
 
Next the NO releasing ability was analysed by Griess test in 20% DMSO 50 mM pH 7.4 
phosphate buffer under 400–500 nm irradiation (Scheme 71). Unfortunately, despite 
methylation of the amine no discernible NO was released under 400–500 nm 
irradiation and the molecule underwent rapid photobleaching at a rate faster than 
compound 145 (Figure 24).  
 
 
Scheme 71: Unsuccessful NO release from compound 150. 
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Figure 24: Absorption of 150 (100 μM) in pH 7.4 phosphate buffer during Griess test. 
Irradiation with 400–500 nm light.  
 
 3.10 Sensitized isomerization of compounds 145 and 150 
 
With the fluorenone-tethered alkoxyfuroxans being non-NO releasing during Griess 
assays, we decided to check if 145 and 150 truly possessed sensitizing ability by 
irradiating a sample in deuterated benzene and observing any isomerization of the 
furoxan (Table 27). 
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Table 27: Isomerization of 145 and 150 under irradiation in C6D6 (5 mM).  
 
 
 
 
 
The isomerization experiments were conducted on a 5 mM scale in deaerated 
benzene (Table 27). Irradiation with visible light at room temperature for 15-minute 
intervals confirmed that the molecules both possess sensitizing ability. Compound 150 
reached the PS within 15 minutes showing only minor isomerization and compound 
145 showed a greater isomerization ratio reaching PS after 30 minutes.  
This data meant that although the molecules do photochemically interact with 
themselves in non-polar organic solution, they do not photochemically interact in 
aqueous solution.  
One possibility for this is that the aminofluorenone excited state is quenched by the 
solvent cage of polar molecules. Supposedly aminofluorenones can be quenched by 
the solvent rearranging itself around the intramolecular charge transfer excited 
state.104 
Another possibility is that the excited energy levels of the furoxan and sensitizer align 
favourably when in non-polar solvents but are no longer suitably aligned in polar 
solvents. The El-Sayad rule states that the rate of intersystem crossing is relatively 
large if the radiationless transition involves a change of orbital type.105 It is known that 
Compound Time (min) Isomerization% Comment 
150 0 2 Residual isomerization 
 15 7 PS 
 30 7  
 45 7  
    
145 0 0  
 15 13  
 30 21 PS 
 45 21  
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the fluorenone triplet T3 energy level is destabilized in polar solvent relative to the 
singlet S1 excited energy level so intersystem crossing (S1 π-π* to T3 n- π*) becomes 
inefficient and nonradiative relaxation becomes the primary method of 
deactivation,106 this was not however known to us at the time of design. Note that the 
fluorenone T1 and T2 energy levels are of π-π* character so ISC is not easily accessible 
from the S1 state. This theory aligns with the observation of isomerization occurring in 
deuterated benzene but observing no NO release in phosphate buffer solution. This 
does not explain however the observed photobleaching, this may be due to excited 
state quenching by the furoxan or undesired reactivity, another possibility is that the 
molecule simply precipitates out of solution, although we suspect that any 
precipitation is assisted by the irradiation process.  
 
3.11 Conclusions  
 
By considering the shortfalls of our proof of concept anthraquinone-fluorofuroxan 
hybrid we were able to define criteria that an improved molecule would meet. By 
selecting 3-amino-9-fluorenone we acquired theranostic properties and a more 
accessible synthetic route. We were delighted that the 3-amino-9-fluorenone-furoxan 
hybrids worked as intended in benzene but the lack of NO release and difficulty 
encountered when in phosphate buffer solution rendered the design impractical. Of 
course, further modification may have led to a reasonable and functioning molecule 
but modification was tedious and the literature theory behind fluorenones in polar 
protic solvents projected the success of the design unfavourably.  
We decided to continue the search for a fluorescent, triplet sensitizing, water soluble, 
cell permeable and NO releasing molecule by referring once again to literature on the 
topic.   
 
 
Ⅳ: Improvement to visible light PINOD furoxans: 
Naphthalenediimide-alkoxyfuroxan 
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4.1  Naphthalenediimides as fluorescent photosensitizers  
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Naphthalenediimides (NDIs) find application in a variety of fields such as fluorescence 
spectroscopy, electronic devices, supramolecular structures, ion and pH sensors and 
organonucleotide targeting.107 Functionalization with heteroatoms via lateral core 
substitution creates highly tuneable fluorescent NDI analogues depending on the 
nature of functionalization (Figure 25).108  
 
 
 
Figure 25: Core substituted NDI and their respective absorption wavelengths (lower 
number), emission wavelengths (upper number), HOMO (bold) and LUMO (dashed) 
energies. Figure reproduced from Sakai et al.108 
 
Recently Doria et al. reported the synthesis of several water soluble fluorescent NDI 
derivatives which were able to sensitize the formation of singlet oxygen under 
irradiation with visible light via introduction of a bromine atom onto the NDI core 
(Table 28, Entry 1).109 One NDI derivative was particularly remarkable and exhibited 
sensitizing ability without a heavy atom, the tetrasubstituted NDI 156 was later 
applied to cellular studies and reduced cancer cell viability to 40% under visible light 
irradiation (Table 28, Entry 2).110 
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Table 28: Sensitizing and fluorescent NDI derivatives.  aUsing Ru(bpy)3+ as reference 
with a value of 0.028 in aerated water bExcitation at 373 nm. cDetermined from 
phosphorescence of 1O2 at 1270 nm in D2O, under air-equilibrated conditions. All 
solutions are isosbestic at the 532 nm excitation wavelength. dTriplet lifetime in argon-
saturated solution. Excitation at 532 nm. Data adapted from Doria et al.109 
 
NDI λmax (nm) εmax (M-1 cm-1) φFa τf (ns)b φ∆c τT (μs)d 
155 530 7600 0.12 3.33 0.46 22 
156 613 10700 0.17 4.00 0.30 32 
 
 
4.2 Synthesis towards compound 157 
 
Encouraged by the ability of NDIs 155 and 156 to sensitize singlet oxygen through the 
triplet state and the theranostic nature of the molecules, we hypothesized that a 
suitably substituted NDI tethered to a furoxan may induce NO release under 
spatiotemporal control. The hybrid molecule would fluoresce under irradiation 
indicating the cellular uptake and perhaps even localize in DNA as NDIs have been 
known to behave as reversible ligands for G4-quadruplexes often observed in 
telemorase, a key target overexpressed by cancerous cells.110  
One advantage of NO induced cell apoptosis over 1O2 induced cell death is that cell 
death via 1O2 occurs by necrosis and induces an immune response resulting in an 
undesirable and painful inflammatory event, whereas apoptosis does not.63  
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We designed a prototype molecule which utilized the bromo-facilitated spin orbit 
coupling to induce sensitized NO release from alkoxyfuroxan (Scheme 72).  
 
 
Scheme 72: Retrosynthetic analysis of NDI-alkoxyfuroxan hybrid 157. 
 
The desired compound 157 contains two terminal quaternary ammonium salts which 
serve a dual function. Quaternarization is necessary to prevent amine single electron 
transfer from quenching the excited state NDI (at pH 7.4 the amine would not be in a 
continuous protonated state), furthermore the water solubility would be enhanced.  
Compound 157 is accessed by methylation of the terminal amines of 158 which in turn 
is synthesised by nucleophilic aromatic substitution of diimide 159 with pendant 
amino alkoxyfuroxan 160 (Scheme 72). NDI 159 is synthesised by imidization of 
dianhydride 161 with N,N-dimethylaminopropylamine. Compound 161 can be 
constructed by bromination of commercially available anhydride 161 using 
dibromocyanuric acid. Furoxan 160 is synthesized by Boc deprotection of 163 
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previously furnished by nucleophilic aromatic substitution of nitrofuroxan 55 with Boc 
protected 2-aminoethanol 164.  
 
The NDI synthesis up to compound 159 was obtained from previous work by Doria et 
al. in their synthesis towards NDIs that target telomeric G-quadruplex structures 
(Scheme 73).111 
 
Scheme 73: Synthesis of NDI 159. 
 
Starting from commercially available 1,4,5,8-naphthalenetetracarboxylic dianhydride 
162 we brominated the core twice using dibromocyanuric acid 165, the product 161 
is known for being notoriously insoluble and was filtered following precipitation from 
ice water and then washed with hot methanol to afford a crude mixture containing 
161 in quantitative yield. The brominated dianhydride underwent imidization with 
N,N-dimethylaminopropylamine 166 following 1 h reflux in acetic acid, the product 
159 was obtained by silica chromatography in 53% yield.  
 
The furoxan partner 160 was synthesized by Boc protection of 2-aminoethanol 167 
and SNAr reaction onto nitrofuroxan followed by deprotection (Scheme 74).  
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Scheme 74: Synthesis of 160. 
 
Scheme 75: Connection of furoxan and NDI via alkylamino bridge. 
 
Furoxan 160 was connected to NDI 159 by SNAr reaction in dilute DMF. The product 
was highly polar but deactivation of silica gel with triethylamine (5% MeOH, 95% CHCl3, 
0.5% v/v Et3N) enabled the pure red solid to be collected.  
Finally, methylation of the pendant amino groups granted 157 as a purple solid 
following filtration and washing with CHCl3 (Scheme 76). Curiously, the product was 
reasonably soluble in acetonitrile. 
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Scheme 76: Methylation of 158 to afford the desired NDI-furoxan 157.  
 
4.3 Absorption and fluorescence of compound 157 
 
To our delight, even with the furoxan substitution, 157 was water soluble and we were 
able to obtain the absorption and fluorescence spectra in pH 7.4 phosphate buffer 
(Figure 26).  
 
Figure 26: Absorption and fluorescence spectrum of 157 in 50 mM pH 7.4 phosphate 
buffer at 25 °C. Fluorescence λex of 420 nm. 
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Compound 157 showed a broad absorption above 400 nm, the intramolecular charge 
transfer can be seen as an intense peak with a λmax of 533 nm. The fluorescence 
spectrum has a λmax of 581 nm and extends beyond 650 nm which is useful for 
identifying cellular uptake locations. 
 
4.4 NO releasing ability of compound 157 
 
We next investigated the NO releasing ability of 157 under visible irradiation both in 
the presence and absence of excess cysteine.  
In the absence of cysteine compound 157 releases up to 16 μM of NO after 2 hours of 
irradiation with 420–600 nm light (Figure 27). When irradiating with a longer 
wavelength (500–600 nm) the NO release rate is comparatively more gradual, 
reaching 10 μM over 4 hours. Under ambient lighting conditions there is no significant 
NO release observed during 4 hours of irradiation.  
 
 
 
Figure 27: NO release curve of 157 (100 μM) in 50 mM pH 7.4 phosphate buffer under 
420–600 nm, 500–600 nm irradiation or under ambient light at 37 °C. The experiment 
was conducted in the absence of cysteine.  
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When compound 157 was irradiated in phosphate buffer containing 5 mM cysteine 
we were disappointed by the lack of NO release (Figure 28). We suspect that cysteine 
can quench the excited state, possibly by single electron transfer. We have also not 
ruled out the possibility of nucleophilic substitution of the core bromo or amino 
functionalities by the excess thiol.  
 
Figure 28: NO release curve of 157 (100 μM) in 50 mM pH 7.4 phosphate buffer 
containing 5 mM cysteine under 400–500 nm irradiation or under ambient light at 
37 °C.  
 
The lower quantity of NO release in the absence of thiol compared to anthraquinone-
tethered fluorofuroxan 122 can be explained by considering a number of factors; 
compound 157 exhibits theranostic properties so a portion of the absorbed energy 
will be used for fluorescence rather than sensitizing the furoxan. We also suspect that 
alkoxyfuroxan is capable of reacting with the sensitizer inducing side reactivity, 
whereas fluorofuroxan, to the best of our knowledge, does not react with 
anthraquinone. Compound 157 unexpectedly undergoes photobleaching, so only 
partial release of NO can be achieved. 
Compound 157 is almost fully photobleached within 3 hours of continuous irradiation 
(Figure 29a). Furthermore, the fluorescence spectrum undergoes a hypsochromic shift 
from λmax of 581 nm to λmax of 521 nm with a significant increase in fluorescence 
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intensity under prolonged irradiation (Figure 29b). Despite the possibility of limiting 
NO release, this can be a useful property since the molecule behaves as a fluorometric 
indicator to signal when the NO release event has finished. The change in absorption 
of compound 157 with irradiation shows an overall decrease in intensity at both 533 
nm and 371 nm with prolonged irradiation time. The decrease at 371 nm is attributed 
to a perturbation of the NDI core conjugation, perhaps due to decomposition of the 
diimide moieties. The decrease at 533 nm could also be attributed to cleavage of the 
core substituted NDI-amino bond preventing intramolecular charge transfer.  
 
 
Figure 29: (a) Photobleaching of compound 157 under 420–600 nm continuous 
irradiation in 50 mM pH 7.4 phosphate buffer solution at 37 °C. At intervals a 2 mL 
aliquot was taken and the absorption spectra measured at 25 °C (b) Change in 
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fluorescence spectrum of compound 157 under 420–600 nm continuous irradiation in 
50 mM pH 7.4 phosphate buffer solution at 37 °C. At intervals a 2 mL aliquot was taken 
and the fluorescence intensity measured at 25 °C with λex of 420 nm. 
 
The instability of compound 157 in the presence of thiol was unfortunate but it should 
be noted that 5 mM of cysteine is a significant excess compared with cellular levels 
(30–250 µM), however total cellular thiol concentration is much greater.112 It is of note 
that monobrominated core substituted NDIs have been used in cancer cell studies 
previously with no reports of denaturization, so it is likely that the decomposition 
occurs due to the irradiation process rather than any inherent instability. In fact, 
alkylating NDIs showed cytotoxicity towards telemorase positive cells with IC50 values 
in the μM range.111 
 
4.5 Cellular studies with compound 157 
 
We decided to test compound 157 for cell permeability and hoped that despite 
disappointing in vitro experiments, NO may still be released under irradiation from 
within a cell (Figure 30).  
 
 
Figure 30: Fluorescence imaging of 157 taken up into living HeLa cancer cells 
(exposure time 1/3 second). HeLa cells were incubated with 157 (20 μM) for 20 
minutes before washing thrice with PBS buffer solution. Exposure of light in the 
wavelength of 500–600 nm shows successful cellular uptake.  
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Previous research into NDI cellular uptake had shown successful cell permeability 
despite tri- and tetrasubstituted quaternary ammonium moieties, so we were pleased 
to see that even with the dual quaternary ammonium ions and the tethered furoxan 
molecule, the hybrid permeates the cells.110,111 Although the uptake mechanism is not 
fully understood, it has been suggested that similarities between tetracationic 
porphyrins and NDIs indicate endocytosis as a possible pathway.110 Unfortunately, 
when irradiated with 500–600 nm light for 20 minutes there was no indication of NO 
release (not shown). This is probably due to thiol quenching the excited state, the 
same as with the in vitro experiments.  
 
4.6 Conclusions  
 
We consolidated on our previous designs by selecting NDI as a theranostic sensitizer 
core. Furthermore, we were able to successfully connect an alkoxyfuroxan. The 
synthesis of the NDI-furoxan hybrid was much simpler when compared with previous 
sensitizer-furoxan designs. Compound 157 demonstrated photoswitchable 
fluorescent sensitized NO release in phosphate buffer. Unfortunately, when cysteine 
was present the NO release was prevented. In spite of this we were able to observe 
localization within a cell culture system but photoswitchable NO release from within 
the cells was not achieved, likely due to the local thiol concentration. This strategy 
was a further step towards the overall project goal of photoswitchable NO release 
from within a cell culture system.  
 
4.7 Future research 
 
In previous studies tetrasubstituted compound 156 showed photostability and singlet 
oxygen generation after 6 hours of continuous irradiation,109 we hypothesized that 
this is due to increased electron density and the absence of potentially photoreactive 
bromine on the NDI core. We also envisioned that by increasing the conjugation of the 
furoxan partner and introducing electron withdrawing substituents we could lower 
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the orbital energies (HOMO and LUMO) and promote facile sensitization without the 
suspected malign photobleaching interactions between sensitizer and furoxan.  
With the initial results of prototype 157 being promising we designed a furoxan 
tethered tetrasubsituted NDI molecule (Scheme 77).  
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Scheme 77: Retrosynthetic analysis of tetrasubstituted furoxan tethered NDI 168. 
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 Compound 168 can be accessed by exhaustive methylation of the terminal amines of 
intermediate 169. The tetrasubstitution is notoriously difficult from trisubstituted 
NDIs unless microwave irradiation is used, so microwave assisted reaction of 170 with 
a third N,N-dimethylaminopropylamine constructs 169. Connection of furoxan 171 
and NDI 159 is undertaken using the same SNAr approach previously completed. The 
extended conjugation on the furoxan 171 is accessed by SNAr reaction between 
nitrofuroxan 173 and Boc protected tyramine 174. Nitrofuroxan 173 is furnished by 
Wieland procedure on a Stille coupled vinyl naphthalene 175 which is constructed 
from commercially available methyl 6-bromo-2-naphthoate 176.  
We hope that in the future research of this project, NO will be released under 
spatiotemporal control from an NDI-furoxan localized within a cell culture system. 
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Ⅴ: Conclusions       
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In conclusion we have developed a number of photosensitized switchable furoxan NO 
donors with varying degrees of NO donating ability, however so far successful designs 
have been hindered by limited biological application.  
Initial attempts at synthesising an anthraquinone-tethered fluorofuroxan 
encountered regioselectivity issues between the fluoro- and benzylic positions with 
anthraquinone-tethered alkoxy nucleophiles. That being said, the formed product 
may have made an excellent NO donor as it was alkoxy in nature and the remaining 
benzylic position could be functionalized further with water soluble pendant groups.  
However, at the time of conducting the research we were not fully aware of 
alkoxyfuroxans as PINODs and competing research within the group led to the need 
for a different approach which remained focused on fluorofuroxans.  
A second approach utilized a novel Stille coupling reaction between bromo- 
functionalized fluorofuroxans and β-iodostyrenes. The synthesis of a model 
compound was successful following extensive reaction optimisation. However, 
application to anthraquinone β-iodostyrene encountered solubility issues and low 
reactivity due to the extended and unreactive conjugated anthraquinone core. The 
route was also plagued with purification issues due to the insoluble nature of the 
anthraquinone. Despite requiring a redesign, the Stille coupling applied to electron 
deficient and reactive furoxans under mild conditions is a highlight of the research and 
enables expansion of the available reactivity for furoxans. We hope that the furoxan 
Stille coupling reaction conditions will find application within the research group in 
future work, perhaps even expansion of reaction scope.   
To address the difficulty with handling and purification of the anthraquinone we 
designed a combinatorial synthetic route which formed the anthraquinone core at the 
final stages of the synthesis via a proline catalysed [4 + 2] cycloaddition. Initial 
attempts were troublesome once again due to purification issues with the 
anthraquinone. These were addressed by utilizing a Boc protecting group which 
significantly enhanced the solubility of the formed anthraquinone hybrid molecule 
and enabled facile isolation. Simple methylation and acid catalysed deprotection 
granted the product as a water-soluble salt which released NO in a photoswitchable 
manner. To our surprise the molecule did not require cysteine to release NO, however 
cysteine being present did result in greater quantities released. The mechanism of 
release was briefly investigated by electrochemical methods and suggested that 
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electron transfer is unfavourable leading us to propose that the energy transfer is via 
Dexter exchange of electrons. Unfortunately, we could not ascertain whether the 
molecule was cell permeable and therefore could not determine whether NO could 
be released from within a cell culture system. Attempts to improve the NO donating 
ability by utilizing an alkoxy furoxan were lower yielding, possibly due to a higher 
energy level of the (relatively) electron rich alkoxy furoxan.  
Evaluation of the limitations of the anthraquinone tethered fluorofuroxan led us to 
set a series of requirements for a successful furoxan PINOD. The molecule needed to 
be water soluble, cell permeable, fluorescent and triplet sensitizing leading to 
spatiotemporal NO release. We began screening for suitable furoxans and sensitizers 
and found that alkoxy- and fluoro- furoxans release high quantities of NO under 
irradiation, whereas amino furoxans release moderate and alkyl furoxans release 
negligible quantities of NO. This research was especially valuable as it showed that 
almost all furoxans release NO under irradiation in the absence of cysteine, the 
requirement of which is a major limitation for biological application as cellular levels 
vary. We were unsuccessful in finding a wide variety of fluorescent sensitizers with 
only 3-aminofluorenone being photostable under prolonged visible irradiation. The 
aminofluorenone sensitizer showed photosensitizing ability of furoxan in non-polar 
solvents and we synthesized two hybrid molecules. Unfortunately, once submerged 
in phosphate buffer solution the sensitizing ability was quenched. This was possibly 
due to rearrangement of hydrogen bonds around the excited state and difficulty 
accessing the triplet energy level due to destabilization of the triplet energy level 
relative to the excited singlet excited state. The hybrid was also limited by poor 
solubility and possibly underwent furoxan mediated side reaction or photobleaching.  
Finally, we investigated naphthalenediimides as potential fluorescent, water soluble 
and cell permeable photosensitizers of alkoxyfuroxans. Our initial prototype displayed 
favourable properties being able to release moderate quantities of NO under 
irradiation in the absence of cysteine. However, in the presence of cysteine the 
molecule was non-NO releasing and appeared to be quenched, perhaps by thiol single 
electron transfer. The NDI-furoxan hybrid was taken up into HeLa cancer cells and 
could be observed due to fluorescence but NO was not released upon irradiation. This 
limited the biological application so we proposed a further functionalized 
tetrasubstituted NDI which was connected to a highly conjugated and electron 
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deficient furoxan in the hopes that NO release within a cell culture system could be 
achieved in the future. 
As a final comment, the furoxan offers a versatile platform as a photoswitchable NO 
donor being susceptible to photosensitization by a variety of sensitizers and releasing 
NO in moderate quantities. However, when compared to other NO donor platforms 
the furoxan perhaps falls short. S-nitrosothiols, organonitrates and NONOates release 
NO in greater quantities (up to two molar equivalents!). With new photoswitchable 
NO donor platforms being developed and appearing in the literature at an increasing 
frequency, it does make one wonder; is furoxan really competitive enough to match 
or supersede the competition? 
That will be the challenge faced by my successors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ⅵ: Experimental  
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Unless otherwise noted, all reactions were carried out in well cleaned glasswares with 
magnetic stirring. Operations were performed under an atmosphere of dry argon 
using Schlenk and vacuum techniques. All starting materials were obtained from 
commercial sources or were synthesized using standard procedures. Melting points 
were measured on a Yanaco MP-500D and are not corrected. 1H and 13C NMR (400 
and 100 MHz, respectively) were recorded on a Bruker Avance III HD 400 using TMS 
(0 ppm) and CDCl3 (77.0 ppm) as an internal standard. The following abbreviations are 
used in connection with NMR; s = singlet, d = doublet, t = triplet, q = quartet, quin = 
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quintet, sep = septet, and m = multiplet. Mass spectra were measured using a JEOL 
JMS-T100LP (DART method, ambient ionization) or a Thermo Orbitrap Elite (ESI 
method) or Thermo Finnigan LCQ TRACE GC ULTRA (EI method). Preparative column 
chromatography was performed using Kanto Chemical silica gel 60 N (spherical, 
neutral), Fuji Silysia BW- 4:10MH silica gel or YMC_GEL Silica (6 nm I-40−63 μm). Thin 
layer chromatography (TLC) was carried out on Merck 25 TLC silica gel 60 F254 
aluminum sheets. Phosphorescence spectrum was recorded on a spectrofluorometer 
(Jasco FP-6500) using phosphorescence measurement mode. Cyclic voltammetric 
measurements were performed using an ALS CHI606S electrochemical analyzer.  
 
Phosphorescence Measurement of 35 
Phosphorescence of 4-fluorofuroxan 35 was measured for a 1 mM 2-MeTHF solution 
of 35 kept in a quartz ESR tube (Φ 5 mm) at 77 K. The delay time, gate time and 
excitation wavelength were set to be 9 ms, 9 ms and 280 nm, respectively. 
 
Absorption and Fluorescence Spectra 
Photoluminescence spectra were recorded on a spectrofluorometer (Jasco FP-6500) 
with a quartz absorption cuvette (light path: 1 cm). UV–visible spectra were recorded 
on a Shimadzu UV-1800 spectrometer with a quartz absorption cuvette (light path: 1 
cm). 
 
 
Photosensitized isomerization of 4-furoxan regioisomer to 3-furoxan regioisomer 
general procedure 
A solution of 4-furoxan (2.6 µmol) and sensitizer (2.6 µmol) (1 : 1) in deaerated 
deuterated solvent (0.5 mL) was prepared in a Pyrex NMR tube. A small quantity of 
dodecane (approximately 1 μL) was added as an internal standard. Before irradiation 
of the sample, the integration ratio of the 1H NMR peaks corresponding to the 4-
furoxan and dodecane were measured. The solution was irradiated with light (a 300 
W xenon lamp, Asahi Spectra MAX-303 equipped with a 300 to 600 nm 
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ultraviolet−visible module, and a combination of a long-pass and short-pass filters). 
The reaction progress was monitored by 1H NMR analysis. The yield was determined 
from the peak integration relative to dodecane internal standard under the 
assumption that the internal standard was not affected by the experiment or by 
relative peak integration of pre and post irradiated sample. 
 
Redox property experiments 
Cyclic voltammetric measurements were performed at 298 K with solvents being 
deaerated by Ar bubbling for 30 min before each measurement. The supporting 
electrolyte was 0.10 M TBAClO4. A conventional three-electrode cell was used with a 
platinum working electrode and a platinum wire as a counter electrode. The cyclic 
voltammograms were recorded with respect to the Ag/AgNO3 (10 mM) reference 
electrode at a sweep rate of 50 mV/s. The oxidation potential (determined as the peak 
potential) was corrected to the SCE scale by adding 0.31 V, on the basis of the 
measurement of the redox potential (+0.09 V in the cell system used) of the Fc/Fc+ 
couple as the internal standard. 
 
Cellular uptake and NO-release experiment with 122 
HeLa cells (Riken BioResource Center) were cultured in high glucose DME medium 
(Sigma-Aldrich) containing 10 %(v/v) FBS, 1 %(v/v) Penicillin-Streptomycin (P/S) 
(Sigma-Aldrich) at 37 °C in a CO2 incubator (5% CO2). Then, the HeLa cells were seeded 
at a density of 1.5  105 cells/mL in DME medium in a 35 mm glass bottom dish. After 
24 hours of culture, the cells were incubated with 10 μM NO550 for 30 min in a CO2 
incubator (5 % CO2) at 37 °C. After the incubation, the cells were washed thrice with 
PBS buffer and incubated with 30 μM compound 122 or 30 μM NOC7 (DOJINDO) in 
DME medium for 30 min. After 30 min of the incubation, the DME medium was 
removed and the cells were washed thrice with PBS buffer. The cells incubated with 
122 were exposed to the light in the wavelength of 400–500 nm for 1 hour to liberate 
NO and were then washed thrice with PBS buffer. The fluorescence derived from 
NO550 in the cells was then analysed using a fluorescence microscope (BZ-X700; 
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KEYENCE) equipped with BZ-X filter GFP and a 40x objective lens with the exposure 
time of 1 second. 
 
Cellular uptake experiment with 157 
HeLa cells (Riken BioResource Center) were cultured in high glucose DME medium 
(Sigma-Aldrich) containing 10 %(v/v) FBS, 1 %(v/v) Penicillin-Streptomycin (P/S) 
(Sigma-Aldrich) at 37 °C in a CO2 incubator (5% CO2). Then, the HeLa cells were seeded 
at a density of 1  105 cells/mL in DME medium in a 35 mm glass bottom dish. After 
24 hours of culture, the cells were incubated with 20 μM 157 for 20 min in a CO2 
incubator (5 % CO2) at 37 °C. After the incubation, the cells were washed thrice with 
PBS buffer. The fluorescence derived from 157 in the cells was then analysed using a 
fluorescence microscope (BZ-X700; KEYENCE) equipped with BZ-X filter GFP and a 40x 
objective lens with the exposure time of 1/3 second. 
 
Measurement of the NO-releasing ability with light irradiation general procedure 
A 100 μM of NO-release compound was prepared as a 10 mL solution of 50 mM 
phosphate buffer (pH 7.4) containing or omitting 5 mM of cysteine in a pyrex vial. The 
vial was placed into a 37 °C oil bath and then irradiated. At intervals aliquots (0.5 mL) 
were taken and treated with Griess reagent (40 µL). After the samples were stood for 
30 min, the absorbance of the samples at 520 nm was measured. The percent nitrite 
(NO2−) (mol/mol) was determined from a calibration curve prepared in advance by 
using NaNO2 standard solutions (20−100 μM) treated with the Griess reagent. 
The Griess reagent was prepared by diluting a mixture of 1 g of sulfanilamide, 50 mg 
of N-naphthylethylenediamine dihydrochloride, and 2.5 mL of 85% phosphoric acid 
with distilled water to a final volume of 25 mL. 
 
Measurement of the NO-releasing ability without light irradiation general procedure 
A 100 μM solution of NO release compound was prepared as a 10 mL solution of 50 
mM phosphate buffer (pH 7.4) containing or omitting 5 mM of cysteine in a pyrex vial. 
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The vial was placed into a 37 °C oil bath. At intervals aliquots (0.5 mL) were taken and 
treated with Griess reagent (40 µL). After the samples were stood for 30 min, the 
absorbance of the samples at 520 nm was measured. The percent nitrite (NO2−) 
(mol/mol) was determined from a calibration curve prepared in advance by using 
NaNO2 standard solutions (20−100 μM) treated with the Griess reagent. 
 
Measurement of the NO-releasing ability of compound 104  
As per the general NO-releasing procedures but with the following modifications; 50 
mM phosphate buffer solution (pH 7.4) containing 5 mM cysteine was added to a 10 
mM solution of 104 in DMSO. Further DMSO was added to bring the total 
concentration to 100 µM (10% DMSO). The irradiated experiment used wavelength of 
400–500 nm. The non-irradiated control was performed in ambient light. The 
experiments were performed over 5 h. 
   
Measurement of the NO-releasing ability of compound 122 
As per the general NO-releasing procedures but with the following modifications; 50 
mM phosphate buffer solution (pH 7.4) either containing or omitting 5 mM cysteine 
was added to a 10 mM solution of 122 in DMSO to bring the total concentration to 
100 µM (1% DMSO). The irradiated experiment used wavelength of 400–500 nm. The 
non-irradiated control was performed in ambient light. The experiments were 
performed over 7 h. 
 
Measurement of the NO-releasing ability of compound 126 
As per the general NO-releasing procedures but with the following modifications; 50 
mM phosphate buffer solution (pH 7.4) containing 5 mM cysteine was added to a 10 
mM solution of 126 in DMSO to bring the total concentration to 100 µM (1% DMSO). 
The irradiated experiment used wavelength of 400–500 nm. The non-irradiated 
control was performed in ambient light. The experiments were performed over 5 h. 
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Measurement of the NO-releasing ability of compound 145 
As per the general NO-releasing procedures but with the following modifications; 50 
mM phosphate buffer solution (pH 7.4) and DMSO was added to a solution of 145 to 
bring the total concentration to 100 µM (20% DMSO). The irradiated experiment used 
wavelength of 400–500 nm. The non-irradiated control was performed in ambient 
light. The experiments were performed over 45 min. 
 
Measurement of the NO-releasing ability of compound 150 
As per the general NO-releasing procedures but with the following modifications; 50 
mM phosphate buffer solution (pH 7.4) and DMSO was added to a solution of 150 to 
bring the total concentration to 100 µM (20% DMSO). The irradiated experiment used 
wavelength of 400–500 nm. The non-irradiated control was performed in ambient 
light. The experiments were performed over 30 min. 
 
Measurement of the NO-releasing ability of compound 157 
As per the general NO-releasing procedures but with the following modifications; 50 
mM phosphate buffer solution (pH 7.4) containing or omitting 5 mM cysteine was 
added to a solution of 157 to bring the total concentration to 100 µM. At intervals two 
aliquots (0.5 mL) were taken and one treated with Griess reagent (40 µL) and the 
difference in absorption at 520 nm compared. The irradiated experiment used 
wavelength of 420–500 nm or 500–600 nm. The non-irradiated control was performed 
in ambient light. The experiments were performed over 4 h. 
2 Studies towards anthraquinone-fluorofuroxan 
 
2.2 Nucleophilic aromatic substitution towards compound 50 
 
2-[2-[2-[2-[2-[2-(2-
Hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]anthracene-9,10-dione (51)73 
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Compound 51 was synthesized according to the reported method.73 A mixture of 2-
chloroanthraquinone (0.20 g, 0.824 mmol) and K2CO3 (0.20 g, 1.45 mmol) were stirred 
in hexaethyleneglycol (0.75 mL, 3.01 mmol) and heated to 130 °C for 3 h. The reaction 
was cooled and crude mixture purified by silica chromatography (5% MeOH in CH2Cl2) 
to grant 51 as a yellow solid (136 mg, 0.276 mmol, 34%). 1H NMR (400 MHz, CDCl3) 
δH(ppm) 8.32–8.28 (2H, m), 8.27 (1H, apparent d, J = 8.8 Hz), 7.82–7.50 (2H, m), 7.74 
(1H, apparent d, J = 1.4 Hz), 7.31 (1H, dd, J = 12, 2.8 Hz), 4.33 (2H, apparent t, J = 4.8 
Hz), 3.94 (2H, apparent t, J = 4.8 Hz), 3.77–3.60 (20H, m), 2.58 (1H, t, 6.4 Hz); δC (100 
MHz, CDCl3) 183.1, 182.1, 163.6, 135.5, 134.1, 133.7, 133.6, 133.5, 129.7, 127.1, 127.1, 
121.6, 110.6, 72.5, 70.9, 70.6, 70.6, 70.6, 70.6, 70.6, 70.5, 70.3, 69.4, 68.1, 65.8, 61.7; 
IR (neat) 3450, 2883, 1662, 1588, 1578, 1492, 1449, 1345, 1328, 1304, 1237, 1132, 
1101, 1087, 1051, 992, 951, 921, 884, 851, 842, 723, 715; LRMS (DART) m/z [M + H]+ 
Calcd for C26H33O9 489; Found 489; mp 60–62 °C. 
 
3-(4-Methylphenyl)-4-nitrofuroxan (55) 
 
Compound 55 was synthesized according to the reported method.113 To a stirred 
suspension of NaNO2 (105 g, 1.52 mol) in a 0.2 M CH2Cl2 solution of 4-methylstyrene 
(25 mL, 0.19 mol) was added AcOH (86.7 mL, 1.52 mol) over 30 min at rt. After 2 h 
from starting the AcOH addition, a 2 M solution of HCl (570 mL, 1.14 mol) was added. 
The reaction mixture was stirred for 14 h at rt, and then extracted thrice with CH2Cl2. 
The combined organic layer was washed with brine, dried over MgSO4, and filtered. 
The filtrate was concentrated in vacuo. The residue was purified by silica gel 
chromatography (2% EtOAc in hexane), the semi-pure material was then recrystallized 
in EtOAc/hexane to yield yellow needles (11.4 g, 51.5 mmol, 27%). 1H NMR (400 MHz, 
CDCl3) δH(ppm) 7.50 (2H, apparent d, J = 8.4 Hz), 7.37 (2H, apparent d, J = 8.4 Hz), 2.45 
(3H, s); δC (100 MHz, CDCl3) 142.7, 130.0, 128.6, 120.9, 116.3, 109.2, 21.7; IR (neat) 
1606, 1557, 1520, 1488, 1362, 1287, 1272, 1120, 1072, 988, 819, 777, 741; LRMS (EI) 
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m/z [M – CN2O4] Calcd for C8H7N 171; found 171. [M]+ was not observed due to facile 
fragmentation; mp 78–80 °C. 
 
4-Fluoro-3-(4-methylphenyl)furoxan (35) 
 
Compound 35 was synthesized according to the reported method.41 To a solution of 
3-(4-methylphenyl)-4-nitrofuroxan (2.00 g, 9.04 mmol) in THF (18 mL) was added 
dropwise a 1 M solution of TBAF in THF (12.0 mL, 11.8 mmol) at 0 °C. After stirring for 
4 h, the reaction was quenched by the addition of saturated aqueous solution of NH4Cl. 
The mixture was extracted thrice with Et2O. The combined organic layer was dried 
over MgSO4, filtered, and concentrated in vacuo. The residue was purified by silica 
chromatography (3% EtOAc in hexane) to give compound 35 as a white solid (1.51 g, 
7.78 mmol, 86%). 1H NMR (400 MHz, CDCl3) δH(ppm) 7.86 (2H, d, J = 8 Hz), 7.36 (2H, d, 
J = 8 Hz), 2.43 (3H, s); δC (100 MHz, CDCl3) 162.1 (d, JC-F = 258.4 Hz), 142.1, 130.1, 125.8 
(d, J C-F = 3.8 Hz), 117.6 (d, J C-F = 4.2 Hz), 107.6, 21.6; IR (neat) 1663, 1610, 1570, 1520, 
1472, 1404, 1340, 1317, 1155, 1124, 1094, 1046, 978, 834, 815, 730, 581; LRMS (DART) 
m/z [M + H]+ Calcd for C9H8FN2O2 195; Found 195; mp 77–79 °C. 
 
 
 
 
 
3-(4-Bromomethylphenyl)-4-fluorofuroxan (52) 
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4-Fluoro-3-(4-methylphenyl)furoxan (0.20 g, 1.03 mmol) and NBS (0.24 g, 2.06 mmol) 
were stirred in CCl4 at rt. Triethyl borane (62.0 μL of a 1 M solution in THF) was added 
and the mixture stirred for 5.5 h at rt. The reaction mixture was filtered and washed 
with 5% EtOAc in hexane solution. The solvent was removed in vacuo and then diluted 
with water and extracted thrice with Et2O, dried over MgSO4, filtered and 
concentrated. The crude mixture was purified by silica chromatography (5% EtOAc in 
hexane) to yield 52 as a white solid (172 mg, 0.634 mmol, 62%). 1H NMR (400 MHz, 
CDCl3) δH(ppm) 7.97 (2H, d, J = 8 Hz), 7.58 (2H, apparent d, J = 8 Hz), 4.52 (2H, s); δC 
(100 MHz, CDCl3) 161.9 (d, JC-F = 258.6 Hz), 141.2, 130.0, 126.2 (d, JC-F = 3.9 Hz), 120.5 
(d, JC-F = 4.1 Hz), 31.9; IR (neat) 1615, 1570, 1523, 1475, 1411, 1345, 1319, 1228, 1196, 
1155, 1131, 1098, 1090, 990, 835, 812, 741, 730, 637, 601; LRMS (DART) m/z [M + H]+ 
Calcd for C9H7BrFN2O2 273; Found 273; mp 110–113 °C. 
 
 
 (2-Hydroxyethoxy)anthracene-9,10-dione (58)  
 
 
A suspension of 2-chloroanthraquinone (2.00 g, 8.24 mmol) and K2CO3 (1.99 g, 14.4 
mmol) were stirred in 25 mL of ethyleneglycol and heated to 140 °C for 8 h. The 
reaction mixture was diluted with water and extracted thrice with EtOAc, the organics 
were dried over Na2SO4, filtered and solvent removed in vacuo. The crude material 
was pre-bound to silica and purified by silica chromatography (30% EtOAc in hexane–
50% EtOAc in hexane) to yield 58 as a yellow solid (770 mg, 2.85 mmol, 35%). 1H NMR 
(400 MHz, CDCl3) δH(ppm) 8.32–8.28 (2H, m), 8.28 (1H, d, J = 8.8Hz), 7.83–7.75 (2H, 
m), 7.75 (1H, d, 2.8 Hz), 4.29 (2H, apparent t, J = 5.0 Hz), 4.06 (2H, apparent q, 5.0 Hz), 
2.03 (1H, t, J = 6.4 Hz); δC (100 MHz, CDCl3) 183.2, 182.1, 163.4, 135.6, 134.2, 133.8, 
133.6, 133.5, 129.9, 127.4, 127.2, 121.5, 110.6, 69.9, 61.2; IR (neat) 3473, 1667, 1585, 
1493, 1436, 1327, 1243, 1175, 1153, 1103, 1079, 1040, 931, 903, 842, 803, 712, 661; 
LRMS (DART) m/z [M + H]+ Calcd for C16H13O4 269; Found 269; mp 168–171 °C. 
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2-[2-({4-[4-(Bromomethyl)phenyl]furoxan-3-yl}oxy)ethoxy]anthracene-9,10-dione 
(60) 
 
NaH (60% in mineral oil) (16.3 mg, 0.407 mmol) was added to a solution of compound 
58 (0.10 g, 0.37 mmol) in THF (1 mL) at -78 °C and was stirred for 1 h. The deprotonated 
material formed a brown suspension which was added dropwise to a solution of 52 
(100 mg, 0.37 mmol) in THF (1.5 mL). The reaction mixture allowed to warm to rt and 
stirred for 16 h. The mixture was diluted with water and extracted thrice with CH2Cl2. 
The organics were dried over MgSO4, filtered and solvent removed in vacuo. The crude 
mixture was purified by silica chromatography (CHCl3) to yield 60 as a yellow solid (145 
mg, 0.278 mmol, 75%). 1H NMR (400 MHz, CDCl3) δH(ppm) 8.33–8.29 (3H, m), 8.80 (2H, 
apparent d, J = 8.6 Hz), 7.84–7.77 (3H, m), 7.48 (2H, apparent d, 8.6 Hz), 7.34 (1H, dd, 
J = 8, 2.8 Hz), 4.95–4.93 (2H, m), 4.66–4.64 (2H, m), 4.45 (2H, s); δC (100 MHz, DMSO-
d6) 182.3, 181.4, 163.0, 162.0, 140.6, 135.1, 134.7, 134.3, 133.1, 129.8, 129.6, 126.8, 
126.7, 126.5, 121.7, 121.5, 110.9, 107.5, 69.3, 66.4, 33.3; IR (neat) 1665, 1590, 1551, 
1519, 1471, 1408, 1325, 1292, 1240, 1214, 1169, 1150, 1086, 1007, 928, 849, 841, 724, 
590; LRMS (DART) m/z [M + H]+ Calcd for C25H18BrN2O6 521; Found 521; mp 203–
206 °C.  
 
 
 
 
2.3 Palladium catalysis towards compound 61 
 
4-(4-Bromophenyl)-3-nitrofuroxan (65) 
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Compound 65 was synthesized according to the reported method.113 To a stirred 
suspension of NaNO2 (1.51 g, 21.9 mmol) in a 0.2 M CH2Cl2 solution of 4-bromostyrene 
(0.36 mL, 2.73 mmol) was added AcOH (1.25 mL, 21.9 mmol) over 30 min at rt. After 
2 h from starting the AcOH addition, a 2 M solution of HCl (8.2 mL, 16.4 mmol) was 
added. The reaction mixture was stirred for 18 h at rt and then diluted with water and 
extracted thrice with CH2Cl2. The combined organic layer was dried over MgSO4 and 
filtered. The filtrate was concentrated in vacuo and the residue was purified by silica 
chromatography (4% EtOAc in hexane), the semi-pure material was then recrystallized 
in EtOAc/hexane to yield 65 as a yellow oil (0.37 g, 1.18 mmol, 43%). 1H NMR (400 
MHz, CDCl3) δH(ppm) 7.72 (2H, apparent d, J = 8.6 Hz), 7.49 (2H, apparent d, J = 8.6 
Hz); δC (100 MHz, CDCl3) 157.7, 132.7, 130.3, 126.8, 118.3, 108.7; IR (neat) 3104, 1633, 
1586, 1563, 1514, 1486, 1401, 1327, 1330, 1262, 1202, 1182, 1110, 1071, 1009, 967, 
940, 811, 742, 725; LRMS (EI) m/z [M – CN2O4]+ Calcd for C7H4BrN 181; found 181. 
[M]+ was not observed due to facile fragmentation; mp 145–147 °C. 
 
4-(4-Bromophenyl)-3-fluorofuroxan (64) 
 
Compound 64 was synthesized according to the reported method.41 To a solution of 
3-(4-bromophenyl)-4-nitrofuroxan (99.2 mg, 0.348 mmol) in THF (0.2 mL) was added 
dropwise a 1 M solution of tetrabutylammonium fluoride in THF (386 µL, 0.386 mmol) 
at 0 °C. After stirring for 5 h, the reaction was quenched by the addition of saturated 
aqueous solution of NH4Cl. The mixture was extracted thrice with CH2Cl2. The 
combined organic layer was dried over MgSO4, filtered, and concentrated in vacuo. 
The residue was purified by silica chromatography (5% EtOAc in hexane) to give 64 as 
an orange solid (57.2 mg, 0.204 mmol, 58%). 1H NMR (400 MHz, CDCl3) δH(ppm) 7.87 
(2H, apparent d, J = 8.4 Hz), 7.70 (2H, apparent d, J = 8.4 Hz); δC (100 MHz, CDCl3) 161.7 
(d, JC-F = 258.6 Hz), 132.8, 127.1 (d, JC-F = 4.0 Hz), 125.9, 119.5 (d, JC-F = 4.2 Hz), 105.4 
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(d, JC-F = 28.8 Hz); IR (neat) 3102, 1614, 1587, 1569, 1498, 1465, 1396, 1338, 1308, 
1155, 1116, 1073, 1008, 975, 823, 750, 636; LRMS (DART) m/z [M + H]+ Calcd for 
C8H5BrFN2O2 259; Found 259; mp 94–96 °C. 
 
2-Bromoanthracene-9,10-dione (70) 
 
Compound 70 was synthesized according to the reported method.75 To a solution of 
CuBr2 (7.26 g, 32.5 mmol) and tert-butylnitrite (3.35 g, 32.5 mmol) in MeCN (50 mL) 
was added dropwise a suspension of 2-aminoanthraquinone (2.90 g, 13.0 mmol) in 
THF (110 mL) and the reaction was stirred at rt for 20 h. Upon completion the mixture 
was diluted with water and extracted thrice with CHCl3, the organics were washed 
with brine, dried over MgSO4 and filtered. The filtrate was concentrated and purified 
by silica chromatography (1 : 1 CH2Cl2/hexane) to yield 70 as a yellow solid (1.67 g, 
5.83 mmol, 45%). 1H NMR (400 MHz, CDCl3) δH(ppm) 8.45 (1H, s), 8.33–8.31 (2H, m), 
8.19 (1H, apparent d, J = 8.4 Hz), 7.93 (1H, apparent d, J = 8Hz), 7.84–7.82 (2H, m); δC 
(100 MHz, DMSO-d6) 182.3, 181.9, 137.6, 135.3, 135.2, 134.9, 133.4, 133.2, 132.4, 
129.5, 129.5, 129.1, 127.3, 127.3; IR (neat) 3084, 2921, 1676, 1575, 1401, 1317, 1287, 
1257, 1163, 1068, 958, 929, 913, 897, 853, 806, 706, 695, 643; LRMS (DART) m/z [M + 
H]+ Calcd for C14H8BrO2 287; Found 287; mp 207–210 °C. 
 
2-Ethynylanthracene-9,10-dione (68) 
 
Compound 68 was synthesized according to the reported method.114 To a solution of 
2-bromoanthraquinone (1.50 g, 5.22 mmol) and PPh3PdCl2 (36.6 mg, 52.0 μmol) in 1 : 
1 THF/Et3N (17.4 mL) was added CuI (19.8 mg, 0.10 mmol) and stirred at 60 °C for 15 
min. Trimethylsilylacetylene (546 mg, 5.74 mmol) was added dropwise and the 
reaction stirred for 17 h. The reaction mixture was cooled, filtered through Celite and 
washed with 4 : 1 CHCl3/hex. The filtrate was washed with water, 1 M HCl and then 
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dried over MgSO4, filtered and solvent removed in vacuo to yield a crude yellow solid 
(1.74 g). The solid was dissolved in 2 : 1 acetone/ethanol and NaOH (210 mg, 5.22 
mmol) was added, then the reaction mixture stirred at rt for 90 min. The mixture was 
diluted with water and extracted thrice with CHCl3 and organics dried over MgSO4, 
filtered and solvent removed in vacuo. The crude solid was purified by silica 
chromatography (20% hexane in CHCl3) to yield 68 (858 mg, 3.69 mmol, 71%). 1H NMR 
(400 MHz, CDCl3) δH(ppm) 8.42 (1H, d, J = 1.6 Hz), 8.35–8.31 (2H, m), 8.23 (1H, d, J = 
11.2 Hz), 7.88 (1H, dd, J = 8, 1.6 Hz), 7.85–7.80 (2H, m), 3.37 (1H, s); δC (100 MHz, 
CDCl3) 182.4, 182.4, 137.1, 134.4, 134.3, 133.4, 133.4, 133.4, 132.9, 130.9, 128.3, 
127.4, 127.3, 127.3, 82.0, 81.9; IR (neat) 3266, 1673, 1588, 1407, 1329, 1318, 1285, 
1172, 1135, 981, 932, 858, 720, 707, 651; LRMS (DART) m/z [M + H]+ Calcd for C16H9O2 
233; Found 233; mp 200 °C (decomposed).  
 
4-Tributylstannylstyrene (75) 
 
Compound 75 was synthesized according to the reported method.78 To a suspension 
of magnesium turnings (329 mg, 13.7 mmol) in THF (11 mL) was added 
tributyltinchloride (1.49 mL, 5.49 mmol) and 4-bromostyrene (714 μL, 5.49 mmol) and 
the mixture sonicated at rt for 2 hours. The mixture was filtered, diluted with water 
and extracted thrice with CH2Cl2. The organics were washed with brine, dried over 
MgSO4, filtered and solvent removed in vacuo. The crude mixture was purified by silica 
chromatography (hexane) to yield 75 as a colourless oil (1.73 g, 4.38 mmol, 80%). 1H 
NMR (400 MHz, CDCl3) δH(ppm) 7.43 (2H, apparent d, J = 8.0 Hz), 7.36 (2H, apparent 
d, J = 8.0 Hz), 6.70 (1H, dd, J = 17.6, 10.8 Hz), 5.76 (1H, dd, J = 17.6, 0.8 Hz), 5.22 (1H, 
dd, J = 10.8, 0.8 Hz), 1.60–1.50 (6H, m), 1.37–1.22 (6H, m), 1.13–0.96 (6H, m), 0.883 
(9H, t, J = 7.2 Hz); δC (100 MHz, CDCl3) 141.9, 137.2, 137.1, 136.7 (JSn-C = 45.5 Hz), 125.7 
(JSn-C = 20.7 Hz), 113.6, 29.1 (JSn-C = 10.0 Hz), 27.4 (JSn-C = 28.3 Hz), 13.7, 9.6 (JSn-C = 165.4, 
7.4 Hz);  IR (neat) 2955, 2922, 2870, 2851, 1627, 1462, 1455, 1417, 1386, 1376, 1338, 
1290, 1247, 1182, 1149, 1071, 987, 960, 904, 873, 865, 822, 688, 662, 582; LRMS 
(DART) m/z [M + H]+ Calcd for  C20H35Sn 395; Found 395. 
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4-Nitro-3-[4-(tributylstannyl)phenyl]furoxan (74) 
 
Compound 74 was synthesized according to the reported method.113 To a stirred 
suspension of NaNO2 (30.8 g, 0.45 mol) in a 0.2 M CH2Cl2 solution of 4-
tetrabutylstannylstyrene (22.0 g, 55.8 mol) was added AcOH (25.5 mL, 0.45 mol) over 
30 min at rt. Two hours after starting the AcOH addition, a 2 M solution of HCl (100 
mL, 0.34 mol) was added. The reaction mixture was stirred for 18 h at rt, then diluted 
with water and extracted thrice with CH2Cl2. The combined organic layer was dried 
over MgSO4, filtered and concentrated in vacuo. The residue was purified by silica 
chromatography (25% benzene in hexane) to yield 74 as a yellow oil (11.8 g, 23.7 mmol, 
42%). 1H NMR (400 MHz, CDCl3) 7.65 (2H, apparent d, J = 8.2 Hz), 7.51 (2H, apparent 
d, J = 8.2 Hz), 1.65–1.45 (6H, m), 1.34 (6H, sex, J = 7.6 Hz), 1.19–1.02 (6H, m), 0.895 
(9H, apparent t, J = 7.6 Hz); δC (100 MHz, CDCl3) 149.1, 137.1 (JSn-C = 14.8 Hz), 127.3 
(JSn-C = 18.7), 123.1, 118.6, 109.2, 29.0 (JSn-C = 10.2 Hz), 27.4 (JSn-C = 28.8 Hz), 13.7, 9.7 
(JSn-C = 163.6, 7.5 Hz). 
 
 
4-Fluoro-3-[4-(tributylstannyl)phenyl]furoxan (73) 
 
 
Compound 73 was synthesized according to the reported method.41 To a solution of 
3-(4-tributylstanylphenyl)-4-nitrofuroxan (300 mg, 0.60 mmol) in THF (1.2 mL) was 
added dropwise a 1 M solution of TBAF in THF (600 μL, 0.60 mmol) at 0 °C and was 
stirred for 1 h. The reaction was quenched by the addition of saturated aqueous 
solution of NH4Cl and extracted thrice with CH2Cl2. The combined organic layer was 
dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by 
chromatography on silica gel (10% benzene in hexane) to yield 73 as a yellow oil (232 
mg, 0.494 mmol, 82%). 1H NMR (400 MHz, CDCl3) δH(ppm) 7.81 (2H, apparent dd, J = 
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8.4, 1.2 Hz), 7.64 (2H, apparent d, J = 8.4 Hz), 1.634–1.448 (6H, m), 1.34 (6H, sex, J = 
7.4 Hz), 1.19–1.02 (6H, m), 0.89 (9H, apparent t, J = 7.4 Hz); δC (100 MHz, CDCl3) 162.3 
(d, JC-F = 308.6 Hz), 148.3, 137.3 (JC-Sn = 14.7 Hz), 124.6 (d, JC-F = 3.6 Hz, JC-Sn = 28.5 Hz), 
119.8 (d, JC-F = 4.1 Hz), 106.0 (d, JC-F = 26.5 Hz), 29.0 (JC-Sn = 10.3 Hz), 27.3 (JC-Sn = 28.5 
Hz), 11.4, 8.1 (JC-Sn = 7.6 Hz); LRMS (DART) m/z [M – F + H]+ Calcd for C20H32N2O2Sn 452; 
Found 452. [M + H]+ was not observed due to facile fragmentation. 
 
(E)-(2-Iodovinyl)benzene (77) 
 
Compound 77 was synthesized according to the reported method.115 To a stirred 
solution of RuH(CO)Cl(PPh3)3 (267 mg, 0.28 mmol) in toluene (100 mL) was added 
styrene (3.31 mL, 28.8 mmol) and trimethylvinylsilane (4.15 mL, 28.8 mmol) and the 
reaction heated to 100 °C for 6 h. The reaction was cooled to rt and MeCN (400 mL) 
was added followed by N-iodosuccinamide (7.78 g, 34.6 mmol) and the reaction 
stirred at rt for 1 hour. The solvent was removed in vacuo and crude material purified 
by silica column chromatography (hexane) to yield 77 (3.28 g, 14.2 mmol, 49%). 1H 
NMR (400 MHz, CDCl3) δH(ppm) 7.43 (1H, d, J = 14.8 Hz), 7.35–7.26 (5H, m), 6.83 (1H, 
d, J = 14.8 Hz); δC (100 MHz, CDCl3) 145.0, 137.7, 128.7, 128.4, 126.0, 76.7; IR (neat) 
3057, 3045, 3021, 1595, 1568, 1494, 1444, 1299, 1277, 1210, 1169, 1028, 944, 791, 
725, 687, 548; LRMS (DART) m/z [M + H]+ Calcd for C8H8I 231; Found 231. 
 
 
 
 
 
4-Fluoro-3-{4-[(E)-2-phenylethenyl]phenyl}furoxan (78) 
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CuI (189 mg, 0.62 mmol), Pd2(dba)3 (142 mg, 0.16 mmol), LiCl (527 mg, 12.4 mmol) 
and 73 (2.92g, 6.22 mmol) were placed into a flame dried flask which was then 
evacuated and refilled with argon thrice. HMPA (17.2 mL) followed by 77 (1.72 g, 7.06 
mmol) were added and the reaction stirred and heated to 70 °C for 90 min. The 
mixture was cooled, filtered and purified by chromatography (10% w/w K2CO3 silica 
gel) (35% CHCl3 in hexane) to yield 78 as pale-yellow crystals (1.17 g, 4.14 mmol, 67%). 
1H NMR (400 MHz, CDCl3) δH(ppm) 7.98 (2H, d, J = 8.0 Hz), 7.68 (2H, apparent d, J = 8.4 
Hz), 7.68 (2H, apparent d, J = 8.4 Hz), 7.39 (2H, apparent t, J = 7.4 Hz), 7.31 (1H, 
apparent tt, J = 7.4, 1.2 Hz), 7.24 (1H, d, J = 16.0 Hz), 7.13 (1H, d, J = 16.0 Hz); δC (100 
MHz, CDCl3) 162.0 (d, JC-F = 258.5 Hz), 140.4, 136.5, 131.5, 128.8, 128.4, 127.2, 127.0, 
126.8, 126.1, 126.1, 119.1 (d, JC-F = 4.3), 105.9 (d, JC-F = 26.6 Hz); IR (neat) 1611, 1601, 
1522, 1476, 1448, 1411, 1337, 1308, 1154, 1113, 1094, 970, 956, 872, 837, 823, 758, 
722, 692, 633; LRMS (DART) m/z [M + H]+ Calcd for C16H12FN2O2 283; Found 283; mp 
169–172 °C. 
 
1-[4-(4-Fluorofuroxan-3-yl)phenyl]-2-phenylethane-1,2-diol (79) 
 
To a stirred solution of 78 (100 mg, 0.35 mmol) in a mixture of acetone (3.2 mL) and 
water (0.35 mL) was added NMO (62.2 mg, 0.53 mmol) followed by OsO4 (0.04 M in 
tBuOH, 0.44 mL, 17.7 μmol) and stirred at 28 °C for 15 h. The mixture was quenched 
with aqueous Na2SO3 and extracted thrice with EtOAc. The organics were washed with 
brine, dried over MgSO4, filtered and solvent removed in vacuo. The crude solid was 
purified by silica chromatography (5% MeOH in CHCl3) to yield 79 as a white solid (94.6 
mg, 0.30 mmol, 86%). 1H NMR (400 MHz, CDCl3) δH(ppm) 7.84 (2H, apparent d, J = 8.0 
Hz), 7.30–7.25 (5H, m), 7.14–7.11 (2H, m), 4.81 (1H, dd, J = 7.8, 2.2 Hz), 4.68 (1H, dd, 
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J = 7.8, 3.0 Hz).  3.09 (1H, d, J = 2.2 Hz), 2.71 (1H, d, J = 3.0 Hz); δC (100 MHz, DMSO-
d6) 161.8 (d, JC-F = 256.3 Hz), 145.6, 141.4, 127.4, 126.7, 126.5, 126.2, 124.5 (d, JC-F = 
3.1 Hz), 118.0 (d, JC-F = 27.3 Hz), 106.2 (d, JC-F = 27.3 Hz), 76.5, 76.3; IR (neat) 3407, 
3212, 1668, 1615, 1574, 1521, 1474, 1449, 1410, 1383, 1342, 1300, 1248, 1225, 1197, 
1155, 1087, 1068, 1042, 1029, 835, 820, 776, 709, 695; LRMS (DART) m/z [M − OH + 
H]+ Calcd for C16H13N2FN2O3 300; Found 300. [M + H]+ was not observed due to facile 
fragmentation; mp 156–158 °C. 
 
2-Iodoanthracene-9,10-dione (82) 
 
Compound 82 was synthesized according to the reported method.75 To a stirred 
solution of 2-aminoanthraquinone in concentrated HCl (10 mL) was added a solution 
of NaI (4.94 g, 33.0 mmol) in water (40 mL) dropwise at 0 °C and allowed to warm to 
rt over 2 h. The reaction was then heated to 50 °C for 15 h. Upon completion the 
mixture was diluted with aqueous NH4Cl and extracted thrice with CH2Cl2. The organics 
were dried over MgSO4, filtered and solvent removed in vacuo. The crude solid was 
purified by silica chromatography (CH2Cl2/hexane 1 : 1) to yield 82 as a yellow solid 
(1.48 g, 4.43 mmol, 57%). 1H NMR (400 MHz, CDCl3) δH(ppm) 8.66 (1H, d, J = 1.6 Hz), 
8.34–8.28 (2 H, m), 8.16 (1H, dd, J = 8.6, 1.8 Hz), 8.01 (1H, d, J = 8.6 Hz), 7.85–7.806 
(2H, m); δC (100 MHz, DMSO-d6) 181.5, 180.8, 142.4, 134.4, 134.1, 134.0, 133.1, 132.3, 
132.0, 131.5, 127.8, 126.2, 126.1, 102.7; IR (neat) 3080, 1672, 1567, 1397, 1325, 1315, 
1280, 1163, 1096, 1062, 952, 927, 915, 848, 801, 706, 689, 705, 689, 650, 639, 630; 
LRMS (DART) m/z [M + H]+ Calcd for C14H8IO2 335; Found 335; mp 178–181 °C.  
 
 
 
 
(E)-2-(2-(Trimethylsilyl)vinyl)anthracene-9,10-dione (80) 
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Compound 80 was synthesized according to the reported method.116 2-
Iodoanthraquinone (400 mg, 1.20 mmol), tetrabutylammonium acetate (721 mg, 2.39 
mmol), Pd(OAc)2 (13.4 mg, 60.0 µmol) were added to the reaction vessel which was 
then evacuated and refilled with argon thrice. DMF (3 mL) was added followed by 
vinyltrimethylsilane (208 μL, 1.44 mmol) and the reaction stirred at rt for 16 h. The 
reaction mixture was diluted with CHCl3 and washed with 10% aqueous NH4Cl thrice, 
organics were dried over MgSO4, filtered and solvent removed in vacuo. The crude 
was purified by silica chromatography (20% hexane in CH2Cl2) to yield 80 as a yellow 
solid with minor inseparable impurities present (327 mg, 1.07 mmol, 89%); 1H NMR 
(400 MHz, CDCl3) δH(ppm) 8.34–8.30 (3H, m), 8.27 (1H, d, J = 8.0 Hz), 7.83–7.87 (3H, 
m), 7.01 (1H, d, J = 19.2 Hz), 6.83 (1H, d, J = 19.2 Hz), 0.21 (9H, s); δC (100 MHz, CDCl3) 
183.4, 182.9, 144.0, 141.7, 136.0, 134.3, 134.1, 133.9, 133.8, 132.6, 131.6, 128.0, 
127.4, 127.3, 125.0, -1.3; IR (neat) 2954, 2894, 1675, 1588, 1326, 1289, 1245, 1205, 
1174, 982, 933, 834, 744, 729, 704; LRMS (DART) m/z [M + H]+ Calcd for C19H19O2Si 
307; Found 307; mp 90–93 °C. 
 
 
2-[(E)-2-Iodoethenyl]anthracene-9,10-dione (81) 
 
To a suspension of 80 (100 mg, 0.33 mmol) in MeCN (3 mL) was added iodine 
monochloride (19.7 μL, 0.39 mmol) dropwise at 0 °C. To the mixture was added CH2Cl2 
(3 mL) and allowed to warm to rt over 2 h. The reaction was quenched by aqueous 
Na2SO3, diluted with water and extracted thrice with CH2Cl2. The organics were dried 
over MgSO4, filtered and solvent removed in vacuo. The crude was bound to silica and 
purified by silica chromatography (CH2Cl2/hexane 1 : 1) to yield 81 as yellow solid (103 
mg, 0.286 mmol, 87%). 1H NMR (400 MHz, CDCl3) δH(ppm) 8.35–8.30 (2H, m), 8.28 (1H, 
d, J = 8.4 Hz), 8.23 (1H, apparent d, J = 1.6 Hz), 7.84–7.79 (2H, m), 7.70 (1H, dd, J = 8.4, 
1.6 Hz), 7.59 (1H, d, J = 15.0 Hz), 7.30 (1H, d, J = 15.0 Hz); δC (100 MHz,DMSO-d6) 181.7, 
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181.3, 142.2, 142.1, 134.0, 133.9, 132.9, 132.5, 131.5, 130.6, 126.7, 126.2, 126.1, 
123.7, 86.1; IR (neat) 3063, 3051, 1670, 1587, 1421, 1326, 1288, 1209, 1175, 1159, 
1142, 990, 977, 944, 932, 905, 855, 796, 771, 705, 657, 635; LRMS (DART) m/z [M + 
H]+ Calcd for C16H10IO2 361; Found 361; mp 222-225 °C 
 
2-{(E)-2-[4-(4-Fluorofuroxan-3-yl)phenyl]ethenyl}anthracene-9,10-dione (62) 
 
Compound 81 (50.0 mg, 0.138 mmol), Pd2(dba)3 (3.16 mg, 3.45 μmol) and LiCl (10.7 
mg, 0.26 mmol) were added to the reaction vessel which was then evacuated and 
filled with argon thrice. Compound 73 (59.3 mg, 0.13 mmol) was added followed by 
HMPA (1.4 mL) and the reaction heated to 70 °C for 90 min. The crude mixture was 
filtered through a plug of 10% K2CO3 w/w silica with EtOAc. The filtrate was washed 
with 1 : 1 brine/water thrice and organics dried over MgSO4, filtered and solvent 
removed in vacuo. The crude was purified by silica PTLC (CH2Cl2) to yield 62 as a yellow 
solid (6.20 mg, 15.0 μmol, 12%) which contained inseparable impurities. 1H NMR (400 
MHz, CDCl3) δH(ppm) 8.48 (1H, apparent d, J = 1.2 Hz), 8.36–8.33 (3H, m), 8.04 (2H, d, 
J = 8.4 Hz), 7.93 (1H, dd, J = 8, 2 Hz), 7.85–7.81 (2, m), 7.76 (2H, d, J = 8.4 Hz), 7.39 (2H, 
d, J = 12.4 Hz); IR (neat) 2962, 1670, 1609, 1587, 1520, 1475, 1410, 1328, 1303, 1294, 
1260, 1233, 1178, 1157, 1092, 1047, 1018, 980, 963, 932, 848, 709, 658, 642; LRMS 
(DART) m/z [M + H]+ Calcd for C24H14FN2O4 413; Found 413; mp 283 °C (decomposed). 
 
2-{2-[4-(4-fluorofuroxan-3-yl)phenyl]-1,2-dihydroxyethyl}anthracene-9,10-dione (61) 
 
Compound 62 (10.0 mg, 24.0 μmol), NMO (7.50 μL, 36.0 μmol) and OsO4 (0.04 M in 
tBuOH, 60.0 μL, 2.40 μmol) were added to the reaction vessel followed by tBuOH (0.6 
mL), CH2Cl2 (1.2 mL) and H2O and the reaction stirred at 35 °C for 36 h. The reaction 
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was quenched with aq. Na2SO3, diluted with water and extracted thrice with CH2Cl2. 
The organics were dried over MgSO4, filtered and solvent removed in vacuo. The crude 
material was purified by silica PTLC (5% MeOH, 1% Et3N in CHCl3) to yield an insoluble 
white solid (1.90 mg, 4.25 μmol, 18%). Due to the insoluble nature of the compound, 
the obtainable data is tentatively assigned as a mixture of 3- and 4-fluorofuroxan 
isomers. Discernible major 4-fluorofuroxan isomer peaks are reported. 1H NMR (400 
MHz, CDCl3) δH(ppm) 8.32–8.28 (2H, m), 8.22–8.18 (1H, m), 8.11 (1H, apparent d, J = 
1.6 Hz), 7.88 (2H, d, J = 8.2 Hz), 7.83–7.79 (2H, m), 7.54 (1H, dd, J = 8 Hz, 1.6 Hz), 7.35 
(2H, d, J = 8.2 Hz), 4.92 (1H, d, J = 7.0 Hz), 4.87 (1H, d, J = 7.0 Hz); 19F -117.4, -162.1. 
 
 
2.4 Organocatalyzed [4 + 2] reaction towards compounds 104, 122 and 126 and 
 evaluation of NO releasing abilities 
 
6,7-Dimethyl-4a,5,8,8a-tetrahydronaphthalene-1,4-dione (94). 
 
To a stirred solution of 1,4-benzoquinone (10.0 g, 92.5 mmol) and BF3· OEt2 (1.14 mL, 
9.25 mmol) in toluene was added 2,3-dimethyl-1,3- butadiene (12.6 mL, 111 mmol) 
dropwise at −16 °C over 10 min. After addition completion the reaction was allowed 
to warm to rt over 80 min. Upon completion the mixture was washed twice with brine 
and the organics dried over Na2SO4, filtered and solvent condensed under vacuum. 
The product was recrystallized from toluene to yield 94 as yellow crystals (13.3 g, 70.0 
mmol, 76%). 1H NMR (400 MHz, CDCl3) δH(ppm) 6.65 (2H, s), 3.22−3.17 (2H, m), 2.40 
(2H, apparent d, J = 16.9 Hz), 2.08 (2H, apparent d, J = 16.9 Hz), 1.63 (6H, s); δC (100 
MHz, CDCl3) 200.3, 139.3, 123.3, 47.1, 30.3, 18.9; IR (neat) 2919, 2876, 2828, 1679, 
1602, 1441, 1427, 1373, 1354, 1262, 1196, 1095, 887, 864, 848, 805, 749, 682 cm−1; 
HRMS (DART) m/z [M + H]+ Calcd for C12H15O2 191.1067; Found 191.1072; mp 
119−121 °C. 
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6,7-Dimethylnaphthalene-1,4-dione (93) 
 
Naphthoquinone 93 was synthesized according to the reported method.87 To a stirred 
solution of 94 (3.54 g, 18.6 mmol) in toluene (140 mL) was added portion wise 
activated MnO2 (17.4 g, 200 mmol) and refluxed for 2 h. The reaction mixture was 
cooled and filtered through Celite by washing with EtOH. The solvent was condensed 
and crude material purified by column chromatography to yield 93 as a yellow solid 
(2.42 g, 12.7 mmol, 68%). Rf = 0.30 (5% EtOAc in hexane); 1H NMR (400 MHz, CDCl3) 
δH(ppm) 7.83 (2H, s), 6.90 (2H, s), 2.41 (6H, s); δC (100 MHz, CDCl3) 185.3, 143.8, 138.5, 
129.9, 127.4, 20.2; IR (neat) 2948, 2920, 1664, 1595, 1447, 1392, 1341, 1326, 1307, 
1221, 1144, 1057, 1017, 994, 972, 835, 769, 712, 626 cm−1; HRMS (DART) m/z [M + 
H]+ Calcd for C12H11O2 187.0754; Found 187.0759; mp 121−123 °C. 
 
6,7-bis(bromomethyl)naphthalene-1,4-dione (92) 
 
 
A stirred solution of 93 (4.50 g, 24.2 mmol), NBS (10.8 g, 60.5 mmol) and benzoyl 
peroxide (293 mg, 1.21 mmol) in benzene (242 mL) was heated to reflux for 22 h. Upon 
reaction completion the mixture was washed twice with distilled water, the organic 
layer was dried over MgSO4, filtered and solvent condensed in vacuo. The crude 
residue was recrystallized from a minimum of hot benzene twice to yield 92 as a semi-
crystalline yellow solid (4.33 g, 12.6 mmol, 52%). Minor impurities were observed. 1H 
NMR (400 MHz, CDCl3) δH(ppm) 8.08 (2H, s), 7.01 (2H, s), 4.71 (4H, s); δC (100 MHz, 
CDCl3) 183.9, 142.7, 138.8, 132.0, 129.1, 28.0; IR (neat) 3035, 1659, 1599, 1456, 1333, 
1309, 1221, 1209, 1171, 1144, 1051, 945, 849, 769, 711, 644, 628, 605; LRMS (DART) 
m/z [M + H]+ Calcd for C12H979Br81BrO2 345; Found 345; mp 173–176 °C. 
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2-Azidoethanamine (98) 
 
2-Chloroethylamine hydrochloride (5.00 g, 43.1 mmol) and NaN3 (8.41 g, 129 mmol) 
were stirred in water (48 mL) at 80 °C for 15 h. The reaction mixture was basified with 
KOH and extracted with Et2O 5 times. The organics were washed with brine, dried over 
MgSO4, filtered and solvent removed in vacuo to yield a colourless oil (2.95 g, 34.2 
mmol, 79%). Compound 98 was used without further purification. 1H NMR (400 MHz, 
CDCl3) δH(ppm) 3.37 (2H, t, J = 5.6 Hz), 2.88 (2H, t, J = 5.6 Hz); δC (100 MHz, CDCl3) 54.6, 
41.3; IR (neat) 3368, 2936, 2865, 2092, 1595, 1446, 1344, 1285, 1094, 1038, 904, 855, 
801, 628. 
 
2-(2-azidoethyl)-2,3-dihydro-1H-benzo[f]isoindole-5,8-dione (86) 
 
Compound 92 (50.0 mg, 0.145 mmol), K2CO3 (91.0 mg, 0.66 mmol) and KI (11.0 mg, 
66.0 μmol) were stirred in MeCN (60 mL) and sparged with argon for 15 min. The 
reaction mixture was then cooled to 0 °C, compound 98 (20.2 μL, 0.132 mmol) was 
added and the mixture stirred for 18 h. Upon reaction completion the reaction mixture 
was concentrated, diluted with water and extracted thrice with CH2Cl2. The combined 
organics were dried over MgSO4, filtered and solvent removed in vacuo. The crude 
material was purified by silica PTLC (EtOAc/hexane 1 : 1) to yield 86 as an orange solid 
(9.90 mg, 36.9 μmol, 25%). Compound 86 should be used immediately in the next step 
as it is unstable and prone to spontaneous oxidation.  1H NMR (400 MHz, CDCl3) 
δH(ppm) 7.92 (2H, s), 6.96 (2H, s), 4.13 (4H, s), 3.51 (2H, t, J = 6.0 Hz), 3.02 (2H, t, J = 
6.0 Hz); δC (100 MHz, CDCl3) 185.0, 146.4, 138.6, 131.6, 120.4, 58.9, 54.4, 50.0; IR 
(neat) 2926, 2887, 2807, 2104, 1660, 1607, 1451, 1327, 1303, 1268, 1191, 1154, 1130, 
1047, 972, 933, 840, 644; LRMS (DART) m/z [M + H]+ Calcd for C14H13N4O2 269; Found 
269; mp 87 °C (decomposed).  
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2-(2-azidoethyl)-6-{2-[4-(4-fluorofuroxan-3-yl)phenyl]ethyl}-2,3-dihydro-1H-
naphtho[2,3-f]isoindole-5,10-dione  (85)  
 
Compound 85 was synthesized according to the reported method.84 A mixture of 86 
(90.0 mg, 0.335 mmol), 87 (148 mg, 0.537 mmol), L- proline (7.70 mg, 67.0 μmol) and 
benzoic acid (3.81 mg, 34.0 μmol) in toluene (1.7 mL) was stirred at 50 °C for 3 h and 
then 70 °C for a further 15 h. After reaction completion the mixture was diluted with 
water and extracted thrice with CH2Cl2. The organics were dried over MgSO4, filtered 
and solvent removed in vacuo. The residue purified by silica chromatography (3% 
EtOAc in CHCl3) to afford 85 as an orange solid (68.3 mg, 0.13 mmol, 39%). Minor 
impurities observed. 1H NMR (400 MHz, CDCl3) δH(ppm) 8.30 (1H, dd, J = 8.0, 1.6 Hz), 
8.13 (1H, s), 8.11 (1H, s), 7.92 (2H, d, J = 8.0 Hz), 7.65 (1H, t, J = 7.6 Hz), 7.53 (2H, 
apparent d, J = 8.0 Hz), 7.48 (1H, dd, J = 7.6, 1.2 Hz), 4.16 (4H, s), 3.58–3.51 (4H, m), 
3.07–3.03 (4H, m). 
 
1-Ethenyl-4-(pent-4-en-1-yl)benzene (90) 
 
Compound 90 was synthesized according to the reported method.92 To a mixture of 
5-bromopent-1-ene (11.3 mL, 95.6 mmol), FeCl3 (47.8 mL of a 0.1 M THF solution, 4.78 
mmol) was added at 0 °C a mixture of 4-ethenylphenylmagnesium bromide (115 mL 
of a 1M THF solution, 115 mmol) and TMEDA (17.2 mL, 115 mmol) dropwise over 2.5 
h at a rate that keeps the reaction mixture yellow (4-ethenylphenylmagnesium 
bromide was prepared by dropwise addition of a 1 M solution of 4-ethenylphenyl 
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bromide in THF to Mg turnings at a rate which maintained gentle reflux, following 
addition the mixture was stirred for a further 30 min). Once addition was completed 
the reaction was stirred for a further 20 min. Saturated aqueous NH4Cl was added 
followed by 1 M HCl and water, the reaction mixture was extracted thrice with EtOAc 
and the organics washed with brine, dried over MgSO4 and filtered. Solvent was 
removed in vacuo and the residue purified by silica column chromatography (hexane) 
to yield 90 as a colourless oil (11.8 g, 68.6 mmol, 72%). Rf = 0.47 (hexane); 1H NMR 
(400 MHz, CDCl3) δH(ppm) 7.33 (2H, d, J = 8.0 Hz), 7.15 (2H, d, J = 8.0 Hz), 6.70 (1H, dd, 
J = 17.6, 11.0 Hz), 5.84 (1H, ddt, J = 17.2, 10.2, 6.8 Hz), 5.71 (1H, dd, J = 17.6, 1.0 Hz), 
5.20 (1H, dd, J = 11.0, 1.0 Hz), 5.03 (1H, dq, J = 17.2, 2.0 Hz), 4.98 (ddt, J = 10.2 Hz, 3.2 
Hz, 1.2 Hz), 2.62 (2H, t, J = 7.6 Hz), 2.01 (2H, q, J = 6.8 Hz), 1.72 (2H, quin, J = 7.6 Hz); 
δC (100 MHz, CDCl3) 142.3, 138.6, 136.7, 135.2, 128.7, 126.2, 114.8, 112.9, 35.1, 33.3, 
30.6; IR (neat) 3081, 3000, 2973, 2927, 2853, 1641, 1620, 1511, 1438, 1406, 988, 902, 
836, 817 cm−1. HRMS (DART) m/z [M + H]+ Calcd for C13H17 173.1325; Found 173.1330. 
 
4-Nitro-3-[4-(pent-4-en-1-yl)phenyl]furoxan (89) 
 
Nitrofuroxans 89 and 101 were synthesized according to a reported method.113 To a 
stirred suspension of NaNO2 (961 mg, 13.9 mmol) in a 0.2M CH2Cl2 solution of 90 (300 
mg, 1.74 mmol) was added AcOH (796 μL, 13.9 mmol) over 30 min at room 
temperature. Two hours after starting the AcOH addition, a 2 M solution of HCl (5.2 
mL, 10.5 mmol) was added. The reaction mixture was stirred for 14 h at rt, and then 
extracted three times with CH2Cl2. The combined organic layer was washed with brine, 
dried over MgSO4, and filtered. The filtrate was concentrated in vacuo. The residue 
was purified by silica chromatography (30% CH2Cl2 in hexane) to yield 89 and 101 (181 
mg, 0.66 mmol, 38%) as an 87:13 (87:13) mixture. The reaction can be conducted on 
a larger scale at the cost of diminished yield as byproduct formation increases. Data 
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reported is for the major isomer. Rf = 0.25 (30% CH2Cl2 in hexane); 1H NMR (400 MHz, 
CDCl3) δH(ppm) 7.52 (2H, apparent dt, J = 8.6, 2.0 Hz), 7.37 (2H, apparent d, J = 8.6 Hz), 
5.83 (1H, ddt, J = 17.0, 10.4, 6.4 Hz), 5.04 (1H, dq, J = 17.0, 2.0 Hz), 5.01 (1H, ddt, J = 
10.4, 2.0, 1.2 Hz), 2.71 (2H, t, J = 8.0 Hz), 2.11 (2H, q, J = 6.4 Hz), 1.76 (2H, quin, J = 7.2 
Hz); δC (100 MHz, CDCl3) Major isomer 87; 158.2, 147.1, 138.1, 129.4, 128.6, 116.5, 
115.2, 109.2, 35.3, 33.2, 30.2; distinguishable minor isomer 101; 147.4, 138.1, 129.2, 
128.6; IR (neat) 3075, 2924, 2856, 1612, 1560, 1519, 1492, 1357, 1270, 1115, 1069, 
983, 909, 839, Article 812, 785, 755 cm−1. HRMS (DART) m/z [M + H]+ Calcd for 
C13H14N3O4 276.0979; Found 276.0984. 
 
4-Fluoro-3-[4-(pent-4-en-1-yl)phenyl]furoxan (88) 
 
Fluorofuroxan 88 was synthesized according to the reported method.41 To a solution 
containing the mixed isomers of 89 and 101 (1.00 g, 3.63 mmol) in THF (7.3 mL) was 
added dropwise a 1 M solution of tetrabutylammonium fluoride (TBAF) in THF (3.63 
mL, 3.63 mmol) at 0 °C. After 1 h the reaction was diluted with water and extracted 
thrice with CH2Cl2. The organics were dried over MgSO4, filtered and solvent removed 
in vacuo. The residue was purified by silica chromatography (30% CH2Cl2 in hexane) to 
yield 88 as a colourless oil (652 mg, 2.63 mmol, 72%). Rf = 0.36 (30% DCM in hexane); 
1H NMR (400 MHz, CDCl3) δH(ppm) 7.89 (2H, d, J = 8.6 Hz), 7.37 (2H, d, J = 8.6 Hz), 5.83 
(1H, ddt, J = 17.2, 10.4, 6.4 Hz), 5.06−4.98 (2H, m), 2.70 (2H, t, J = 8.0 Hz), 2.10 (2H, q, 
J = 7.6 Hz), 1.75 (2H, quin, J = 8.0 Hz); δC (100 MHz, CDCl3) 161.0 (d, JC−F = 258.4 Hz), 
145.5, 137.1, 128.5, 124.8 (d, JC−F = 3.8 Hz), 116.9, 114.1, 104.9 (d, JC−F = 26.4 Hz), 34.2, 
32.1, 29.1; IR (neat) 3072, 2975, 2924, 2856, 1612, 1568, 1522, 1476, 1411, 1338, 1321, 
1154, 1124, 1093, 977, 909, 825, 800, 733, 634, 608, 590 cm−1. HRMS (DART) m/z [M 
+ H]+ Calcd for C13H14FN2O2 249.1034; Found 249.1039. 
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(2E)-6-[4-(4-Fluoro-furoxan-3-yl)phenyl]hex-2-enal (87) 
 
Furoxan 87 was synthesised according to the reported method.94 To a stirred solution 
of 88 (300 mg, 1.21 mmol) and Hoveyda-Grubbs second generation catalyst (22.7 mg, 
36.3 μmol) was added acrolein monomer and the mixture heated to 100 °C for 28 h. 
Upon reaction completion the solvent was removed in vacuo and crude material 
purified by column chromatography on silica gel (35% EtOAc in hexane) to give 87 (252 
mg, 0.913 mmol, 76%) as a pale yellow crystalline solid. Rf = 0.44 (35% EtOAc in 
hexane); 1H NMR (400 MHz, CDCl3) δH(ppm) 9.52 (1H, d, J = 7.8 Hz), 7.91 (2H, d, J = 8.4 
Hz), 7.37 (2H, d, J = 8.4 Hz), 6.85 (1H, dt, J = 15.6, 6.8 Hz), 6.14 (1H, ddt, J = 15.6, 7.8, 
1.2 Hz), 2.75 (2H, t, J = 8.0 Hz), 2.39 (2H, qd, J = 8.0, 1.6 Hz), 1.89 (2H, quin, J = 7.6 Hz); 
δC (100 MHz, CDCl3) 193.8, 162.0 (d, JC−F = 258.4 Hz), 157.4, 145.4, 133.4, 129.4, 126.0 
(d, JC−F = 3.7 Hz), 118.3, 105.8 (d, JC−F = 26.5 Hz), 35.2, 32.0, 29.0; IR (neat) 2951, 2935, 
2870, 2829, 2739, 1679, 1612, 1568, 1522, 1473, 1408, 1340, 1326, 1305, 1292, 1150, 
1120, 1091, 974, 831, 814, 725, 598 cm−1. HRMS (DART) m/z [M + H]+ Calcd for 
C14H14FN2O3 277.0983; Found 277.0989; mp 53−56 °C. 
 
tert-butyl-N-(2-aminoethyl)carbamate (107) 
 
To a solution of 1,2-diaminoethane (12.0 mL, 180 mmol) in 1,4-dioxane (60 mL) was 
added dropwise a solution of Boc2O (5.24 g, 24.0 mmol) in 1,4-dioxane (60 mL) over 1 
h at rt. Following addition, the reaction was stirred for a further 2h. Upon completion 
the reaction mixture was filtered, solvent removed in vacuo and then diluted with 
brine and extracted thrice with CH2Cl2. The organics were dried over MgSO4, filtered 
and solvent removed in vacuo to yield 107 as a colourless oil (3.21 g, 20.1 mmol, 84%) 
156 
 
without further purification. 1H NMR (400 MHz, CDCl3) δH(ppm) 4.85 (1H, br s), 3.17 
(2H, apparent q, J = 6.0 Hz), 2.80 (2H, t, J = 6.0 Hz), 1.45 (9H, s); δC (100 MHz, CDCl3) 
156.3, 79.1, 43.2, 41.7, 28.4; IR (neat) 3360, 2975, 2932, 2867, 1683, 1593, 1529, 1455, 
1391, 1365, 1270, 1250, 1167, 1039, 954, 870, 781, 629; LRMS (DART) m/z [M + H]+ 
Calcd for C7H17N2O2 161; Found 161. 
 
tert-Butyl [2-(5,8-dioxo-1,3,5,8-tetrahydro-2H-benzo[f ]isoindol- 2-
yl)ethyl]carbamate (108) 
 
Compound 92 (500 mg, 1.45 mmol) was stirred in a mixture containing K2CO3 (729 mg, 
5.28 mmol) and KI (110 mg, 0.66 mmol) in MeCN (750 mL). To the mixture was added 
107 (212 mg, 1.32 mmol) at −10 °C and stirred for 16 h. Upon reaction completion the 
reaction mixture was concentrated and the crude material was purified by silica 
chromatography (35% EtOAc in CH2Cl2) to yield 108 as an orange solid (107 mg, 0.313 
mmol, 24%). Compound 108 should be used immediately in the next step as it is 
unstable and prone to spontaneous oxidation. Rf = 0.31 (40% EtOAc in hexane); 1H 
NMR (400 MHz, CDCl3) δH(ppm) 7.91 (2H, s), 6.96 (2H, s), 5.01 (1H, broad s), 4.06 (4H, 
s), 3.37–3.32 (2H, m), 2.90 (2H, t, J = 6.0 Hz), 1.45 (9H, s); δC (100 MHz, CDCl3) 185.0, 
156.0, 149.7, 146.6, 138.5, 131.5, 120.4, 58.6, 54.7, 39.0, 28.4; IR (neat) 3368, 3048, 
3013, 2980, 2980, 2930, 281, 2761, 1688, 1663, 1608, 1524, 1435, 1385, 1362, 1327, 
1305, 1273, 1240, 1153, 1129, 1040, 964, 838 cm−1; HRMS (DART) m/z [M + H]+ Calcd 
for C19H23N2O4 343.1652; Found 343.1658; mp 110 °C (decomposed). 
 
 
 
tert-Butyl [2-(6-{2-[4-(4-fluorofuroxan-3-yl)phenyl]ethyl}-5,10-dioxo-1,3,5,10-
tetrahy- dro-2H-naphtho[2,3-f ]isoindol-2-yl)ethyl]carbamate (103) 
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Compound 103 was synthesized according to the reported method.84 A mixture of 108 
(100 mg, 0.292 mmol), 87 (129 mg, 0.468 mmol), L- proline (6.70 mg, 58.0 μmol) and 
benzoic acid (3.40 mg, 30.0 μmol) in CHCl3 (1.5 mL) was stirred at 50 °C for 15 h. After 
reaction completion the solvent was condensed in vacuo and the residue purified by 
silica chromatography (20% EtOAc in hexane) to afford 103 (67.1 mg, 0.11 mmol, 38%) 
as an orange solid. Rf = 0.35 (20% EtOAc in hexane); 1H NMR (400 MHz, CDCl3) δH(ppm) 
8.31 (1H, dd, J = 7.8, 1.2 Hz), 8.12 (1H, s), 8.10 (1H, s), 7.92 (2H, d, J = 8.0 Hz), 7.65 (1H, 
t, J = 7.8 Hz), 7.52 (2H, d, J = 8.0 Hz), 7.48 (1H, dd, J = 8.0, 1.2 Hz), 5.05 (1H, br s), 4.10 
(4H, s), 3.56 (2H, t, J = 7.8 Hz), 3.40−3.33 (2H, m), 3.05 (2H, t, J = 7.8 Hz), 2.93 (2H, 
apparent t, J = 6.4 Hz), 1.46 (9H, s); δC (100 MHz, CDCl3) 184.9, 183.4, 162.1 (d, JC−F = 
258.3 Hz), 156.0, 147.0, 146.4, 145.9, 144.6, 137.8, 135.5, 134.5, 133.3, 132.3, 131.0, 
129.8, 126.8, 125.9 (d, JC−F = 3.7 Hz), 121.2, 120.5, 118.1 (d, JC−F = 4.2 Hz), 105.9 (d, JC−F 
= 26.6 Hz), 79.4, 58.7, 58.6, 54.8, 39.1, 37.6, 37.2 28.4; IR (neat) 2958, 2927, 2846, 
1712, 1666, 1606, 1584, 1522, 1471, 1321, 1298 1252, 1168, 1153, 1115, 981, 726 
cm−1; HRMS (DART) m/z [M + H]+ Calcd for C33H32FN4O6 599.2300; Found 599.2306; 
mp 209 °C (decomposed). 
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2-(2-azaniumylethyl)-6-{2-[4-(4-fluorofuroxan-3-yl)phenyl]ethyl}-5,10-dioxo-
2,3,5,10-tetrahydro-1H-naphtho[2,3-f]isoindol-2-ium bis(trifluoroacetate)  (104) 
 
 
To a stirred solution of compound 103 (50.0 mg, 83.5 µmol) in CH2Cl2 (2 mL) at -10 °C 
was added TFA (2 mL) and the reaction was allowed to warm to rt over 1 h. Upon 
reaction completion the solvent was removed in vacuo to grant a brown oil. The oil 
was sonicated in Et2O for 1 h whereupon it solidified and was filtered and washed with 
CHCl3 to afford 104 as a brown solid (45.6 mg, 62.8 µmol, 75%). 1H NMR (400 MHz, 
DMSO-d6) δH(ppm) 8.13–8.08 (3H, m), 7.80 (2H, d, J = 8.2 Hz), 7.74 (1H, t, J = 8.0 Hz), 
7.68 (1H, apparent d, 6.8 Hz), 7.54 (2H, d, J = 8.2 Hz), 4.55 (4H, br s), 3.46 (2H, apparent 
t, J = 7.6 Hz), 3.31 (2H, br s), 3.10 (2H, br s),  2.93 (2H, apparent t, J = 7.6 Hz); δC (100 
MHz, DMSO-d6) 184.7, 183.0, 145.5 (JC-F = 111.1 Hz), 138.5, 135.2, 135.0, 134.2, 132.7, 
130.9, 129.9, 126.7, 126.7, 126.6, 121.8, 121.0, 118.5 (JC-F = 4.0 Hz), 115.5, 107.3 (JC-F 
= 27.4 Hz), 79.8, 79.4, 58.6, 58.5, 51.9, 37.0, 36.8, 36.6; IR (neat) 3016, 2561, 2673, 
1609, 1524, 1476, 1435, 1416, 1327, 1294, 1177, 1128, 1046, 1009, 980, 890, 836, 794, 
717; ); mp 145 °C (decomposed). 
 
2,3-Dimethylanthracene-9,10-dione (112) 
 
Furoxan 112 was synthesised according to the reported method.95 To a stirred solution 
of 1,4-naphthaquinone (1.00 g, 6.32 mmol) in EtOH (4.14 mL) was added 2,3-
dimethylbutadiene (1.43 mL, 12.7 mmol) and the mixture heated to 80 °C for 5 h. 
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Upon completion the reaction was cooled, filtered and washed with cold ethanol to 
grant white crystals (1.29 g, 5.36 mmol, 85%). The crude intermediate (1.00 g, 4.17 
mmol) was stirred in a 5% KOH ethanolic solution (13.8 mL) and air bubbled through 
the solution for 2 h at rt. The reaction mixture was filtered and washed with cold EtOH, 
water and finally Et2O before drying to grant 112 as a yellow solid (913 mg, 3.86 mmol, 
92%).  1H NMR (400 MHz, CDCl3) δH(ppm) 8.31–8.27 (2H, m), 8.06 (2H, s), 7.80–7.76 
(2H, m), 2.44 (6H, s); δC (100 MHz, CDCl3) 183.3, 144.1, 133.8, 133.6, 131.4, 128.1, 
127.0, 20.3; IR (neat) 3062, 2921, 2852, 1668, 1588, 1446, 1327, 1294, 1260, 1222, 
1101, 1024, 955, 903, 799, 788, 710, 614; LRMS (DART) m/z [M + H]+ Calcd for C16H13O2 
237; Found 237; mp 215–217 °C.  
 
2,3-bis(Bromomethyl)anthracene-9,10-dione (113) 
 
A stirred solution of 112 (600 mg, 2.54 mmol), NBS (1.04 g, 5.83 mmol) and benzoyl 
peroxide (30.0 mg, 0.127 mmol) in benzene (25.4 mL) was heated to reflux for 15 h. 
Upon reaction completion the mixture was washed twice with distilled water, the 
organic layer was dried over MgSO4, filtered and solvent condensed in vacuo. The 
crude residue was purified by silica chromatography to yield 113 as a yellow solid (593 
mg, 1.51 mmol, 60%). Minor impurities were observed. 1H NMR (400 MHz, CDCl3) 
δH(ppm) 8.34–8.31 (2H, m), 8.30 (2H, s), 7.86–7.81 (2H, m), 4.76 (4H, s); IR (neat) 3037, 
1676, 1588, 1329, 1296, 1227, 1189, 967, 932, 797, 712, 617; LRMS (DART) m/z [M + 
H]+ Calcd for C16H1181Br2O2 397; Found 397; mp 228 °C (decomposed).  
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tert-butyl [2-(5,10-dioxo-1,3,5,10-tetrahydro-2H-naphtho[2,3-f]isoindol-2-
yl)ethyl]carbamate (114) 
 
Compound 113 (500 mg, 1.28 mmol) was stirred in a mixture containing K2CO3 (704 
mg, 5.10 mmol) and KI (106 mg, 0.638 mmol) in MeCN (638 mL). To the mixture was 
added 107 (204 mg, 1.28 mmol) at −10 °C and stirred for 16 h. The reaction was not 
complete and so was allowed to warm to rt for 3 h and finally heated to 70 °C for 2 h. 
Upon reaction completion the reaction mixture was concentrated. The crude material 
was diluted with water and extracted thrice with CHCl3. The organics were dried over 
MgSO4, filtered and solvent removed in vacuo. The crude solid was purified by silica 
chromatography (1 : 1 EtOAc/CH2Cl2) to yield 114 as an orange solid (300 mg, 0.77 
mmol, 60%). 1H NMR (400 MHz, CDCl3) δH(ppm) 8.33–8.30 (2H, m), 8.14 (2H, s), 7.81–
7.79 (2H, m), 5.04 (1H, br s), 4.10 (4H, s), 3.38–3.40 (2H, m), 2.92 (2H, t, J = 6.0 Hz), 
1.45 (9H, s); δC (100 MHz, CDCl3) 183.0, 156.0, 146.8, 134.1, 133.4, 133.1, 127.2, 121.0, 
79.3, 58.6, 54.8, 39.0, 28.4; IR (neat) 2975, 2932, 1705, 1672, 1589, 1493, 1454, 1365, 
1326, 1300, 1249, 1213, 1160, 1082, 1003, 954, 861, 794, 709; LRMS (DART) m/z [M + 
H]+ Calcd for C23H25N2O2 393; Found 393; mp 139 °C (decomposed). 
 
2-(2-ammonioethyl)-5,10-dioxo-2,3,5,10-tetrahydro-1H-naphtho[2,3-f]isoindol-2-
ium 2,2,2-trifluoroacetate (115) 
 
To a solution of compound 114 (100 mg, 0.255 mmol) in CH2Cl2 (1.3 mL) was added 
TFA (1.3 mL) and the reaction stirred for 2 h at rt. Upon reaction completion the 
solvent was removed in vacuo to grant a brown oil. The oil was sonicated in Et2O for 1 
h whereupon it solidified and was filtered and washed with CHCl3 to afford 115 as a 
brown solid (86.8 mg, 0.166 mmol, 65%). 1H NMR (400 MHz, DMSO-d6) δH(ppm) 8.25–
8.23 (2H, m), 8.17 (2H, s), 7.97–7.95 (2H, m), 4.39–4.24 (4H, m), 3.18–3.04 (4H, m); δC 
(100 MHz, DMSO-d6) 181.6, 157.8 (JC-F = 33.2 Hz), 134.1, 132.6, 132.3, 126.2, 120.5, 
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57.5, 50.8, 35.3; IR (neat) 3012, 2568, 1672, 1615, 1590, 1435, 1326, 1311, 1295, 1197, 
1176, 1122, 957, 836, 795, 710; LRMS (DART) m/z [M − 2CF3CO2 - H]+ Calcd for 
C18H18N2O2 293; Found 293. [M + H]+ was not observed due to facile fragmentation; 
mp 185 °C (decomposed).  
 
2-(2-((tert-butoxycarbonyl)amino)ethyl)-2-methyl-5,10-dioxo-2,3,5,10-tetrahydro-
1H-naphtho[2,3-f]isoindol-2-ium iodide (119) 
 
To a solution of 114 (100 mg, 0.255 mmol) in MeCN (1.3 mL) was added MeI (31.7 μL, 
0.51 mmol) and the reaction stirred at 50 °C for 16 h. Upon reaction completion the 
solvent was removed in vacuo and the crude residue filtered, washed with CH2Cl2 and 
dried to grant 119 as a brown solid (74.2 mg, 0.134 mmol, 53%).  1H NMR (400 MHz, 
CDCl3) δH(ppm) 8.37–8.31 (4H, m), 7.88–7.84 (2H, m), 5.83 (1H, t, J = 6.6 Hz), 5.57 (2H, 
d, J = 15.2 Hz), 5.18 (2H, d, J = 15.2 Hz), 4.43 (2H, apparent t, J = 6.0 Hz), 3.87 (2H, 
apparent q, J = 6.0 Hz), 3.57 (3H, s), 1.47 (9H, s); IR (neat) 2959, 2922, 2853, 1699, 
1674, 1622, 1589, 1507, 1456, 1367, 1328, 1302, 1254, 1163, 1096, 1021, 958, 927, 
801, 712; mp 185 °C (decomposed). 
 
2-(2-ammonioethyl)-2-methyl-5,10-dioxo-2,3,5,10-tetrahydro-1H-naphtho[2,3-
f]isoindol-2-ium 2,2,2-trifluoroacetate (120) 
 
To a stirred solution of 119 (50.0 mg, 94.0 μmol) in CH2Cl2 was added TFA (0.75 mL) at 
-10 °C. After 1 h the solvent was removed in vacuo and the crude solid filtered and 
washed with CHCl3 and Et2O to yield a black solid (48.6 mg, 91.0 μmol, 97%). 1H NMR 
(400 MHz, D2O) δH(ppm) 8.24 (2H, s), 8.22–8.18 (2H, m), 7.88–7.84 (2H, m), 5.18 (2H, 
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apparent d, J = 15.2 Hz), 5.12 (2H, apparent d, J = 15.2 Hz), 4.04–4.00 (2H, m), 3.59–
3.55 (2H, m), 3.33 (3H, s); δC (100 MHz, DMSO-d6) 181.4, 157.7 (JC-F = 33.9 Hz), 139.1, 
134.3, 133.2, 132.3, 126.4, 121.7, 68.3, 59.0, 49.3, 32.6; IR (neat) 3203, 1673, 1591, 
1429, 1328, 1302, 1199, 1128, 957, 835, 799, 711; LRMS (DART) m/z 
[M−2CF3CO2−C2H4NH2]+ Calcd for C17H14NO2 264; Found 264. [M + H]+ was not 
observed due to facile fragmentation. 
 
2-(2-Aminoethyl)-6-[4[(4-fluorofuroxan-3-yl)phenyl]ethyl]-2-methyl-5,10-dioxo-
2,3,5,10-tetrahydro-1H-naphtho[2,3-f ]isoindol-2-ium bistrifluoroacetate (122) 
 
Compound 103 (60.0 mg, 0.10 mmol) was stirred in CH2Cl2 (1 mL) and MeI (32.0 μL, 
0.50 mmol) was added and the reaction warmed to 40 °C for 20 h. The solvent and 
excess MeI were removed under vacuum. To the crude material was added CH2Cl2 (0.5 
mL) and cooled to −10 °C, TFA (0.5 mL) was added the mixture stirred for 1 h. The 
solvent and excess TFA were removed in vacuo and the brown oil sonicated in Et2O 
for 1 h whereupon it solidified and was filtered to afford 122 (58.9 mg, 80.0 μmol, 
80%) as a brown solid. 1H NMR (400 MHz, D2O) δH(ppm) 8.14 (1H, s), 8.09 (1H, dd, J = 
7.6, 1.2 Hz), 8.03 (1H, s), 7.68−7.64 (3H, m), 7.56 (1H, t, J = 7.6 Hz), 7.23 (2H, d, J = 8.0 
Hz), 5.17−5.06 (4H, m), 4.05−4.01 (2H, m), 3.62−3.58 (2H, m), 3.51–3.46 (2H, m), 3.33 
(3H, s), 2.94 (2H, t, J = 7.2 Hz); δC (100 MHz, DMSO-d6) 183.9, 182.4, 162.5 (d, JC−F = 
256.3 Hz), 158.2 (q, JC−F = 32.5 Hz), 145.5, 144.6, 139.8, 139.2, 138.2, 135.2, 134.6, 
134.0, 133.0, 130.4, 129.4, 126.3 (d, JC−F = 3.1 Hz), 122.6, 121.8, 118.2, 106.9 (d, JC−F = 
27.4 Hz), 68.9, 59.6, 49.9, 36.6, 36.3, 33.3; IR (neat) 3006, 2929, 2860, 1667, 1614, 
1523, 1473, 1415, 1327, 1298, 1197, 1173, 1125, 976, 836, 796, 719 cm−1. HRMS 
(DART) m/z [M−2CF3CO2−C2H4NH2]+ Calcd for C27H21FN3O4 470.1511; Found 470.1516. 
[M + H]+ was not observed due to facile fragmentation 
4-Methoxy-3-[4-(pent-4-en-1-yl)phenyl]furoxan (123) 
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To a solution of compound 89 (0.70 g, 2.54 mmol) and MeOH (616 μL, 75.3 mmol) in 
THF (12.7 mL) was added dropwise NaOH 50% wt. aqueous solution (460 μL) and the 
reaction stirred at rt for 10 min. Upon reaction completion the mixture was diluted 
with water and extracted thrice with CH2Cl2, organics dried over MgSO4, filtered and 
solvent removed in vacuo. The crude oil was purified by silica chromatography (1 : 1 
benzene/hexane) to yield 123 as a colourless oil (526 mg, 2.02 mmol, 80%). 1H NMR 
(400 MHz, CDCl3) δH(ppm) 8.04 (2H, apparent d, J = 8.6 Hz), 7.31 (2H, d, 8.6 Hz), 5.82 
(1H, ddt, J = 17.2, 10.4, 6.4 Hz), 5.06–4.97 (2H, m), 4.21 (3H, s), 2.68 (2H, t, J = 7.6 Hz), 
2.10 (2H, q, J = 7.6 Hz), 1.74 (2H, quint, J = 7.6 Hz); δC (100 MHz, CDCl3) 162.9, 145.4, 
138.3, 129.0, 126.2, 119.8, 115.0, 107.8, 57.5, 35.2, 33.2, 30.3; IR (neat) 3075, 2934, 
2858, 1602, 1568, 1554, 1520, 1475, 1455, 1405, 1340, 1295, 1199, 1163, 1122, 1088, 
995, 953, 911, 840, 810, 740, 701, 616; LRMS (DART) m/z [M + H]+ Calcd for C14H17N2O3 
261; Found 261. 
 
(2E)-6-[4-(4-Methoxy-furoxan-3-yl)phenyl]hex-2-enal (124) 
 
Furoxan 124 was synthesised according to the reported method.94 To a stirred solution 
of 123 (350 mg, 1.35 mmol) and Hoveyda-Grubbs second generation catalyst (33.7 mg, 
54.0 µmol) was added acrolein monomer (359 μL, 5.38 mmol) and the mixture heated 
to 100 °C for 29 h. Upon reaction completion the solvent was removed in vacuo and 
crude material purified by column chromatography on silica gel (35% EtOAc in hexane) 
to give 124 (323 mg, 1.12 mmol, 83%) as an orange oil. 1H NMR (400 MHz, CDCl3) 
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δH(ppm) 9.52 (1H, d, J = 7.6 Hz), 8.06 (2H, apparent d, J = 8.4 Hz), 7.31 (2H, d, J = 8.4 
Hz), 6.84 (1H, dt, J = 15.8, 6.8 Hz), 6.14 (1H, ddt, J = 15.8, 7.6, 1.2 Hz), 4.22 (3H, s), 2.73 
(2H, t, J = 7.6 Hz), 2.38 (2H, apparent q, J = 7.6 Hz), 1.88 (2H, quint, J = 7.6 Hz); δC (100 
MHz, CDCl3) 193.9, 162.9, 157.7, 144.2, 133.4, 128.9, 126.4, 120.2, 107.7, 57.5, 35.1, 
32.0, 29.1; IR (neat) 2941, 2859, 2826, 2743, 1682, 1634, 1598, 1568, 1556, 1519, 1472, 
1455, 1403, 1340, 1325, 1296, 1200, 1160, 1125, 1112, 1088, 995, 972, 952, 841, 818, 
741, 699, 599; LRMS (DART) m/z [M + H]+ Calcd for C15H17N2O4 289; Found 289. 
 
tert-Butyl [2-(6-{2-[4-(4-methoxyfuroxan-3-yl)phenyl]ethyl}-5,10-dioxo-1,3,5,10-
tetrahy-dro-2H-naphtho[2,3-f ]isoindol-2-yl)ethyl]carbamate (125) 
 
Compound 125 was synthesized according to the reported method.84 A mixture of 108 
(80.0 mg, 0.234 mmol), 124 (108 mg, 0.374 mmol), L- proline (5.40 mg, 47.0 µmol) and 
benzoic acid (9.17 mg, 0.82 mmol) in CHCl3 (1.2 mL) was stirred at 50 °C for 3 h. After 
reaction completion the solvent was condensed in vacuo and the residue purified by 
silica chromatography (25% EtOAc in CH2Cl2) to afford 125 (48.2 mg, 79.0 µmol, 34%) 
as an orange solid. 1H NMR (400 MHz, CDCl3) δH(ppm) 8.29 (1H, dd, J = 8.0, 1.6 Hz), 
8.11 (1H, s), 8.09 (1H, s), 8.07 (2H, d, J = 8.4 Hz), 7.64 (1H, t, J = 7.6 Hz), 7.49–7.44 (3H, 
m), 5.05 (1H, br s), 4.22 (3H, s), 4.09 (4H, s), 3.56 (2H, apparent t, J = 8.0 Hz), 3.38–3.34 
(2H, m), 3.03 (2H, apparent t, J = 7.8 Hz), 2.92 (2H, apparent t, J = 6.0 Hz), 1.45 (9H, s); 
δC (100 MHz, CDCl3) 184.8, 183.4, 162.9, 156.1, 146.9, 146.2, 144.8, 144.8, 137.8, 
135.3, 134.5, 133.3, 143.3, 131.0, 129.2, 126.7, 126.2, 121.2, 120.5, 120.0, 107.8, 79.3, 
58.7, 58.6, 57.5, 54.8, 39.0, 37.6, 37.1, 28.4; IR (neat) 2969, 2930, 1712, 1666, 1598, 
1568, 1556, 1520, 1471, 1407, 1365, 1321, 1298, 1251, 1205, 1163, 1117, 1087, 1045, 
995, 981, 860, 844, 820, 799, 726, 714; LRMS (DART) m/z [M - CH2N(H)CO2C(CH3)3 - 
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CNO2OCH3 + H]+ Calcd for C26H20N2O2 392; Found 392. [M + H]+ was not observed due 
to facile fragmentation. mp 148 °C (decomposed).  
        
2-(2-Aminoethyl)-6-[4[(4-methoxyfuroxan-3-yl)phenyl]ethyl]-2-methyl-5,10-dioxo-
2,3,5,10-tetrahydro-1H-naphtho[2,3-f ]isoindol-2-ium bistrifluoroacetate (126) 
 
Compound 125 (35.0 mg, 57.0 µmol) was stirred in CH2Cl2 (0.6 mL) and MeI (10.7 μL, 
0.172 mmol) was added and the reaction warmed to 40 °C for 16 h. The solvent and 
excess MeI were removed under vacuum. To the crude material was added CH2Cl2 (0.6 
mL) and cooled to −10 °C, TFA (0.6 mL) was added the mixture stirred for 1 h. The 
solvent and excess TFA were removed in vacuo and the brown oil sonicated in Et2O 
for 1 h whereupon it solidified and was filtered to afford 126 (38.0 mg, 45.0 µmol, 
79%) as a brown solid. The product appeared to precipitate out as a complex with one 
equivalent of Et2O. Discernible peaks are reported. 1H NMR (400 MHz, DMSO-d6) 
δH(ppm) 8.34 (1H, s), 8.29 (1H, s), 8.21 (1H, dd, J = 7.6, 1.6 Hz), 7.99 (2H, d, J = 8.4 Hz), 
7.84 (1H, t, J = 7.6 Hz), 7.77 (1H, apparent dd, J = 7.6, 1.2 Hz), 7.57 (2H, d, J = 8.4 Hz), 
5.19 (1H, apparent d, J = 15.4 Hz), 5.14 (1H, apparent d, J = 15.4 Hz), 4.18 (3H, s), 3.88–
3.84 (2H, m), 3.51 (4H , br s overlapping), 3.38 (6H, q, J = 7.0 Hz), 3.30 (3H, s), 2.99 (2H, 
apparent t, J = 8.0 Hz), 1.09 (4H, t, J = 7.0 Hz); δC (100 MHz, DMSO-d6) 183.3, 181.8, 
162.3, 157.6 (JC-F = 32.0 Hz), 144.2, 144.1, 139.1, 138.5, 137.6, 134.6, 134.0, 133.4, 
132.3, 129.7, 128.5, 125.7, 122.0, 121.2, 119.0, 107.0, 68.3, 64.3, 58.9, 57.3, 49.3, 36.0, 
35.7, 32.7, 26.5, 14.6; IR (neat) 2929, 1668, 1600, 1567, 1557, 1520, 1472, 1455, 1406, 
1327, 1298, 1198, 1127, 991, 924, 838, 798, 719; LRMS (DART) m/z [M – 2CF3CO2 - 
NH2CH2 - CH3 - CNO2OCH3 + H]+ Calcd for C26H20N2O2 392; Found 392. [M + H]+ was 
not observed due to facile fragmentation. mp 119 °C (decomposed).  
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3. Improvements to visible light photoinduced nitric oxide donor furoxans: 
 studies  towards aminofluorenone-alkoxyfuroxan 
 
4-Nitrobenzaldehyde-O-methyl oxime (139) 
 
To a solution of methoxylamine hydrochloride (1.42 g, 17.0 mmol) and sodium acetate 
(1.23 g, 15.0 mmol) in 3 : 1 water/THF was added p-nitrobenzaldehyde (1.51 g, 10.0 
mmol) and the reaction stirred for 2 h at rt. Upon reaction completion the mixture 
was diluted with water and extracted thrice with EtOAc. The organics were dried over 
MgSO4, filtered and solvent removed in vacuo. The crude was purified by silica 
chromatography (3% EtOAc in hexane) to yield a white solid (1.55 g, 8.60 mmol, 86%). 
1H NMR (400 MHz, CDCl3) δH(ppm) 8.23 (2H, apparent d, J = 9.0 Hz), 8.10 (1H,s), 7.75 
(2H, apparent d, 9.0 Hz), 4.04 (3H, s); δC (100 MHz, CDCl3) 148.3, 146.3, 138.4, 127.6, 
124.0, 62.7; IR (neat) 3110, 3089, 3012, 2989, 2948, 2906, 2826, 1613, 1596, 1585, 
1513, 1464, 1442, 1409, 1385, 1344, 1312, 1296, 1217, 1182, 1172, 1107, 1046, 1009, 
931, 868, 850, 829, 748, 689, 630; LRMS (DART) m/z [M + H]+ Calcd for C8H9N2O3 181; 
Found 181; mp 107–108 °C. 
 
3-Nitro-9H-fluoren-9-one (141) 
 
Compound 141 was synthesized according to the reported method.102 Trifluoroacetic 
acid (13.2 mL), 139 (1.20 g, 6.66 mmol) and iodobenzene (4.48 mL, 40.0 mmol) were 
added to Pd(OAc)2 (22.4 mg, 0.10 mmol) and silver(I) oxide (232 mg, 1.00 mmol) and 
the mixture stirred at 120 °C for 36 h. The mixture was cooled and filtered through a 
pad of Celite and washed with CH2Cl2. The filtrate was condensed to 5 mL and 12 M 
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HCl was added (2.0 mL) and the reaction heated to 95 °C for 8 h. The reaction mixture 
was cooled, diluted with water and extracted thrice with EtOAc. The organics were 
dried over MgSO4, filtered and concentrated. The crude was purified by silica 
chromatography (5% EtOAc in hexane) to yield 141 as a yellow solid (1.04 g, 4.61 mmol, 
69%). 1H NMR (400 MHz, CDCl3) δH(ppm) 8.35 (1H, d, J = 1.6 Hz), 8.21 (1H, dd, J = 8.0, 
2.0 Hz), 7.82 (1H, d, J = 8.4 Hz), 7.76 (1H, apparent d, 7.2 Hz), 7.67 (1H, apparent d, J = 
7.6 Hz), 7.62 (1H, td, J = 7.4, 1.2 Hz), 7.43 (1H, td, J = 7.4, 1.2 Hz); δC (100 MHz, CDCl3) 
191.5, 152.2, 145.7, 142.5, 138.4, 135.7, 134.1, 130.5, 125.0, 124.8, 124.7, 121.2, 
115.3; IR (neat) 3091, 1711, 1605, 1527, 1444, 1347, 1300, 1260, 1192, 1152, 1104, 
925, 912, 872, 785, 763, 727, 672, 656; LRMS (DART) m/z [M + H]+ Calcd for C13H8NO3 
226; Found 226; mp 229–232 °C.  
 
3-Amino-9H-fluoren-9-one (143) 
 
Compound 143 was synthesized according to the reported method.103 A solution of 
compound 141 (900 mg, 3.97 mmol), NaOH (1.60 g, 40.0 mmol) and sodium sulphite 
nonohydrate (2.21 g, 9.20 mmol) in EtOH (40 mL) and water (40 mL) was stirred at 
80 °C for 1 h. Upon reaction completion the reaction was cooled, concentrated in 
vacuo and extracted with EtOAc thrice. The organics were dried over MgSO4, filtered 
and solvent removed in vacuo. The crude material was prebound to silica and purified 
by silica chromatography (2.5% EtOAc in CHCl3) to yield 143 as a red solid (564 mg, 
2.89 mmol, 73%). 1H NMR (400 MHz, CDCl3) δH(ppm) 7.61 (1H, apparent d, J = 8.4 Hz), 
7.51 (1H, d, J = 8.0 Hz), 7.46–7.41 (2H, m), 7.31–7.27 (1H, m), 6.77 (1H, d, J = 2.0 Hz), 
6.46 (1H, dd, J = 8.0, 2.0 Hz), 4.26 (2H, br s); δC (100 MHz, CDCl3) 192.3, 152.9, 147.4, 
143.2, 136.0, 133.6, 129.1, 126.8, 124.6, 123.5, 119.8, 113.3, 106.3; IR (neat) 3485, 
3388, 3211, 2921, 2855, 1687, 1608, 1584, 1495, 1489, 1449, 1376, 1292, 1249, 1205, 
1155, 916, 867, 827, 771, 761, 743, 675; LRMS (DART) m/z [M + H]+ Calcd for C13H10NO 
196; Found 196; mp 148–151 °C.  
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tert-butyl (9-oxo-9H-fluoren-3-yl)carbamate (148) 
 
To a solution of compound 141 (150 mg, 0.256 mmol), DMAP (31.3 mg, 0.256 mmol) 
and Et3N (39.3 µL, 0.282 mmol) in THF (0.85 mL) was added Boc2O (61.6 mg, 0.282 
mmol) and the reaction heated to 50 °C for 40 h. The reaction mixture was diluted 
with water and extracted thrice with EtOAc, the organics were dried over MgSO4, 
filtered and solvent removed in vacuo. The crude was purified by silica 
chromatography (5% EtOAc in CHCl3) to yield 148 as a yellow solid (28.9 mg, 97.9 mol, 
38%). 1H NMR (400 MHz, CDCl3) δH(ppm) 7.85 (1H, apparent d, J = 1.6 Hz), 7.63 (1H, d, 
J  = 7.2 Hz), 7.59 (1H, d, J = 8.0 Hz), 7.53 (1H, d, J = 7.2 Hz), 7.47 (1H, td, J = 7.2, 1.2 Hz), 
7.30 (1H, td, J = 7.4, 0.8 Hz), 7.03 (1H, dd, J = 8.2, 1.6 Hz), 1.55 (9H, s); δC (100 MHz, 
CDCl3) 192.8, 152.1, 146.5, 144.6, 143.6, 135.1, 134.3, 129.3, 128.7, 125.5, 123.9, 
120.4, 117.4, 109.9, 81.5, 28.3; IR (neat) 3296, 3249, 3192, 3122, 3058, 2976, 1723, 
1690, 1593, 1537, 1490, 1490, 1474, 1451, 1428, 1391, 1365, 1297, 1281, 1233, 1149, 
1110, 1052, 1027, 908, 888, 858, 835, 764, 731, 670, 647; LRMS (DART) m/z [M + H]+ 
Calcd for C18H18NO3 296; Found 296; mp 177–179 °C.  
 
1-Bromo-3-(tert-butyldimethylsiloxy)propane (149) 
 
To a stirred solution of 3-bromopropanol (649 μL, 7.19 mmol) and imidazole (951 μL, 
14.4 mmol) in CH2Cl2 (18 mL) was added TBSCl (1.08 g, 7.19 mmol) at 0 °C and allowed 
to warm to rt after 1 h. After a further 5 h the reaction was diluted with water and 
extracted thrice with CH2Cl2, the organics were washed with NaHCO3, brine and then 
dried over MgSO4, filtered and solvent removed in vacuo. The crude material was 
purified by silica chromatography (hexane) to yield 149 as a colourless oil (1.36 g, 5.40 
mmol, 75%). 1H NMR (400 MHz, CDCl3) δH(ppm) 3.67 (2H, t, J = 5.8 Hz), 3.45 (2H, t, J = 
6.6 Hz), 2.00–1.94 (2H, m), 0.90 (9H, s), 0.07 (6H, s); δC (100 MHz, CDCl3) 60.4, 35.6, 
30.6, 25.9, 18.3, -5.4; IR (neat) 2954, 2928, 2857, 1471, 1462, 1385, 1361, 1254, 1211, 
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1147, 1099, 1061, 1030, 951, 939, 832, 774, 717, 662; LRMS (DART) m/z [M + H]+ Calcd 
for C9H22BrOSi 253; Found 253. 
 
tert-butyl (3-((tert-butyldimethylsilyl)oxy)propyl)(9-oxo-9H-fluoren-3-yl)carbamate 
(147) 
 
To a solution of NaH (60% in mineral oil) (32.0 mg, 0.80 mmol) in DMF (3 mL) was 
added 148 (200 mg, 0.68 mmol) and stirred for 30 min at rt. A solution of 149 (101 mg, 
40.0 mmol) in DMF (3 mL) was added dropwise and the reaction heated to 70 °C for 1 
h. The reaction was quenched with aq. NH4Cl and diluted with CH2Cl2 and H2O. The 
organics were washed with water thrice and dried over MgSO4, filtered and solvent 
removed in vacuo. The crude oil was purified by silica chromatography (10% EtOAc in 
hexane) to yield 147 as an orange oil (186 mg, 0.38 mmol, 99%). 1H NMR (400 MHz, 
CDCl3) δH(ppm) 7.64 (1H, d, J = 7.2 Hz), 7.61 (1H, d, J = 8.0 Hz), 7.50–7.43 (3H, m), 7.31–
7.27 (1H, m), 7.14 (1H, dd, J = 8.0, 2.0 Hz), 3.79 (2H, t, J = 7.2 Hz), 3.65 (2H, t, J = 6.0 
Hz), 1.88–1.83 (2H, m), 1.48 (9H, m), 0.84 (6H, m); δC (100 MHz, CDCl3) 192.9, 154.0, 
149.0, 145.3, 143.8, 134.7, 134.5, 130.9, 129.2, 126.0, 124.8, 124.2, 120.3, 118.3, 81.0, 
60.5, 47.2, 32.0, 28.4, 25.9, 18.3, -5.4; IR (neat) 2953, 2927, 2852, 1702, 1610, 1471, 
1448, 1387, 1365, 1297, 1248, 1161, 1141, 1100, 996, 916, 832, 764, 737, 682; LRMS 
(DART) m/z [M + H]+ Calcd for C27H38NO4Si 468; Found 468. 
 
 
3-[(3-hydroxypropyl)amino]-9H-fluoren-9-one (146) 
 
To a stirred solution of 147 (145 mg, 0.31 mmol) in CH2Cl2 (3 mL) was added 4 M HCl 
in dioxane (320 μL, 1.28 mmol) and stirred at rt for 18 h. Upon reaction completion 
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the mixture was diluted with EtOAc and washed with 1 M NaOH. Water was added to 
the organics and extracted thrice with EtOAc. The organics were dried over MgSO4, 
filtered and solvent removed in vacuo. The crude material was purified by silica 
chromatography (40% EtOAc in CHCl3) to yield 146 as an orange solid (59.9 mg, 0.24 
mmol, 77%). 1H NMR (400 MHz, CDCl3) δH(ppm) 7.60 (1H, apparent d, J = 7.2 Hz), 7.53 
(1H, d, J = 8.4 Hz), 7.45–7.39 (2H, m), 7.29–7.27 (1H, m), 6.71 (1H, d, J = 2.0 Hz), 6.38 
(1H, dd, J = 8.0, 2.0 Hz), 4.79 (1H, br s), 3.89–3.85 (2H, m), 3.45–3.41 (2H, m), 1.95 (2H, 
apparent quin, J = 6.2 Hz), 1.50 (1H, t, J = 4.8 Hz);  δC (100 MHz, CDCl3) 192.1, 154.1, 
147.3, 143.3, 136.3, 133.3, 129.0, 126.8, 123.3, 123.2, 119.6, 110.9, 104.1, 61.3, 41.4, 
31.4; IR (neat) 3293, 1676, 1612, 1584, 1551, 1475, 1452, 1428, 1384, 1361, 1312, 
1297, 1242, 1210, 1196, 1156, 1122, 1100, 1066, 1021, 1007, 919, 867, 767, 734, 676, 
651; LRMS (DART) m/z [M + H]+ Calcd for C16H16NO2 254; Found 254; mp 146–149 °C.  
 
4-(3-((9-oxo-9H-fluoren-3-yl)amino)propoxy)-3-(p-tolyl)-1,2,5-oxadiazole 2-oxide  
(145) 
 
Compound 55 (24.0 mg, 109 µmol), 146 (25.0 mg, 98.9 µmol) and K2CO3 (16.4 mg, 0.12 
mmol) were stirred in THF (1.0 mL) at 50 °C for 21 h. NaOH (2.40 mg, 60.0 µmol) was 
added and the reaction stirred for a further 1 hour. Upon reaction completion the 
mixture was diluted with water and extracted thrice with CHCl3. The organics were 
washed with brine, dried over MgSO4, filtered and solvent removed in vacuo. The 
crude mixture was purified by silica chromatography (5% EtOAc in CHCl3) to yield 145 
an orange solid (33.6 mg, 78.6 μmol, 80%). 1H NMR (400 MHz, CDCl3) δH(ppm) 7.99 
(2H, apparent d, J = 8.4 Hz), 7.60 (1H, d, J = 7.2 Hz), 7.51 (1H, d, J = 8.0 Hz), 7.40 (1H, 
dt, J = 7.4, 1.2 Hz), 7.34 (1H, apparent d, J = 7.2 Hz), 7.32–7.29 (2H, m), 7.26 (1H, dd, J 
= 7.2, 0.8 Hz), 6.66 (1H, d, J = 2.0 Hz), 6.36 (1H, dd, J = 8.0, 2.0 Hz), 4.66 (2H, t, J = 6.2 
Hz), 4.61–4.58 (1H, m), 3.55–3.50 (2H, m), 2.40 (3H, s), 2.30 (2H, quin, J = 6.2 Hz); δC 
(100 MHz, CDCl3) 192.1, 162.2, 153.4, 147.3, 143.1, 141.1, 136.2, 133.4, 129.7, 129.1, 
126.8, 126.0, 123.8, 123.5, 119.7, 119.4, 110.8, 107.6, 104.2, 68.6, 40.4, 28.5, 21.6; IR 
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(neat) 3432, 3358, 2964, 2925, 1682, 1588, 1551, 1512, 1473, 1454, 1367, 1335, 1312, 
1300, 1262, 1202, 1165, 1122, 1099, 1025, 1007, 973, 911, 851, 818, 791, 766, 732, 
676; LRMS (DART) m/z [M + H]+ Calcd for C25H22N3O4 428; Found 428; mp 175–178 °C. 
    
3-(Boc-methylamino)-9H-fluoren-9-one (151) 
 
To a solution of compound 148 (50.0 mg, 0.169 mmol) in THF was added NaH (60% 
wt. in mineral oil) (136 mg, 0.339 mmol) and stirred at rt for 30 min. Iodomethane 
(42.6 µL, 0.339 mmol) was added dropwise and after 5 min the mixture was diluted 
with water and extracted thrice with EtOAc. The organics were washed with brine, 
dried over MgSO4, filtered and solvent removed in vacuo. The crude was purified by 
silica chromatography (15% EtOAc in hexane) to yield 151 as yellow oil (50.5 mg, 0.163 
mmol, 97%). 1H NMR (400 MHz, CDCl3) δH(ppm) 7.65 (1H, d, J = 7.6 Hz), 7.62 (1H, d, J 
= 8.0 Hz), 7.52–7.46 (3H, m), 7.30 (1H, dt, J = 7.2, 1.6 Hz), 7.14 (1H, dd, J = 8.0, 2.0 Hz), 
3.34 (3H, s), 1.51 (9H, s); δC (100 MHz, CDCl3) 192.9, 154.1, 149.8, 145.1, 143.8, 134.7, 
134.5, 130.4, 129.2, 124.7, 124.4, 124.2, 120.3, 117.1, 81.3, 37.0, 28.3; LRMS (DART) 
m/z [M + H]+ Calcd for C19H20NO3 310; Found 310. 
 
3-(Methylamino)-9H-fluoren-9-one (152) 
 
To a solution of compound 151 (50.0 mg, 0.162 mmol) in CH2Cl2 (0.8 mL) was added 
TFA (0.8 mL) and the mixture stirred at rt for 1 h. The reaction mixture was diluted 
with 1 M NaOH and extracted thrice with CHCl3, the organics were dried over MgSO4, 
filtered and solvent removed in vacuo. The crude residue was purified by silica 
chromatography (2.5% EtOAc in hexane) to yield 152 as an orange solid (24.0 mg, 
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0.115 mmol, 71%). 1H NMR (400 MHz, CDCl3) δH(ppm) 7.60 (1H, d, J = 7.2 Hz), 7.53 (1H, 
d, J = 8.0 Hz), 7.46–7.40 (2H, m), 7.28 (1H, dd, J = 7.2, 1.6 Hz), 6.69 (1H, d, J = 2.0 Hz), 
6.37 (1H, dd, J = 8.0, 2.0 Hz), 4.21 (1H, br s), 2.98 (3H, d, J = 5.2 Hz); δC (100 MHz, CDCl3) 
192.2, 154.9, 147.2, 143.2, 136.3, 133.3, 129.0, 126.7, 123.3, 123.2, 119.7, 110.6, 
103.8, 30.3; IR (neat) 3299, 1675, 1609, 1581, 1463, 1453, 1417, 1370, 1299, 1244, 
1207, 1151, 1097, 1057, 1023, 1005, 917, 857, 817, 764, 733, 674; LRMS (DART) m/z 
[M + H]+ Calcd for C14H12NO 210; Found 210; mp 116–119 °C. 
 
1-Iodo-2-(tert-butyldimethylsilyloxy)ethane (153) 
 
To a stirred solution of 2-iodoethanol (454 μL, 5.81 mmol) and imidazole (769 μL, 5.81 
mmol) in CH2Cl2 (14.5 mL) was added TBSCl (876 mg, 11.6 mmol) at 0 °C and allowed 
to warm to rt. After 1 h the reaction was diluted with water and extracted thrice with 
CH2Cl2. The organics were washed with NaHCO3, brine and then dried over MgSO4, 
filtered and solvent removed in vacuo to yield 153 a colourless oil (727 mg, 2.54 mmol, 
44%). 1H NMR (400 MHz, CDCl3) δH(ppm) 3.84 (2H, t, J = 7.2 Hz), 3.20 (2H, t, J = 7.2 Hz), 
0.91 (9H, s), 0.09 (6H, s); δC (100 MHz, CDCl3) 64.3, 25.9, 18.3, 7.0, -5.2; IR (neat) 2954, 
2928, 2885, 2856, 1471, 1463, 1276, 1254, 1189, 1166, 1120, 1081, 997, 939, 833, 775, 
708, 667; LRMS (DART) m/z [M + H]+ Calcd for C8H20IOSi 287; Found 287. 
 
3-[(2-hydroxyethyl)(methyl)amino]-9H-fluoren-9-one (154) 
 
To a solution of compound 152 (22.4 mg, 107 µmol) in DMF (1.0 mL) was added NaH 
(60% wt. in mineral oil) (8.6 mg, 214 µmol) and stirred at rt for 30 min. To the mixture 
was added dropwise 153 (33.7 mg, 118 µmol) and the reaction heated to 70 °C for 1 
h. The mixture was cooled, diluted with CHCl3 and washed with water 5 times. The 
organics were dried over MgSO4, filtered and solvent removed in vacuo. The crude 
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was purified by silica chromatography (25% EtOAc in CHCl3) to yield 154 as a red solid 
(17.8 mg, 70.3 µmol, 66%). 1H NMR (400 MHz, CDCl3) δH(ppm) 7.60 (1H, d, J = 7.2 Hz), 
7.54 (1H, d, J = 8.4 Hz), 7.47 (1H, apparent d, J = 7.2 Hz), 7.42 (1H, td, J = 7.2, 1.2 Hz), 
7.28 (1H, apparent dd, J = 7.2, 1.2 Hz), 6.86 (1H, s), 6.53 (1H, dd, J = 8.4 Hz, 2.4 Hz), 
3.92 (2H, q, J = 5.6 Hz), 3.67 (2H, t, J = 5.6 Hz), 3.17 (3H, s); δC (100 MHz, CDCl3) 192.3, 
154.7, 147.1, 143.4, 136.4, 133.3, 128.9, 126.5, 123.2, 122.2, 119.6, 110.4, 103.4, 60.3, 
54.7, 39.5; IR (neat) 3393, 2924, 2872, 1673, 1608, 1586, 1507, 1454, 1377, 1308, 1298, 
1259, 1209, 1188, 1156, 1106, 1049, 1025, 1006, 917, 838, 810, 785, 764, 732, 674; 
LRMS (DART) m/z [M + H]+ Calcd for C16H16NO2 254; Found 254; mp 125–128 °C. 
 
4-(2-(methyl(9-oxo-9H-fluoren-3-yl)amino)ethoxy)-3-(p-tolyl)-1,2,5-oxadiazole 2-
oxide  (150) 
 
To a solution of compound 154 (16.8 mg, 66.3 µmol) and 55 (16.2 mg, 73.2 µmol) in 
THF (0.7 mL) was added NaOH (2.92 mg, 73.0 µmol) and the reaction stirred at rt for 
4 h. The mixture was diluted with water and extracted thrice with CHCl3. The organics 
dried over MgSO4, filtered and solvent removed in vacuo. The crude was purified by 
silica chromatography (2% EtOAc in CHCl3) to yield 150 as a yellow solid (22.9 mg, 53.6 
µmol, 81%). 1H NMR (400 MHz, CDCl3) δH(ppm) 7.84 (2H, apparent d, J = 8.2 Hz), 7.61 
(1H, d, J = 7.6 Hz), 7.56 (1H, d, J = 8.4 Hz), 7.44–7.39 (2H, m), 7.31–7.26 (1H, m), 7.24 
(2H, d, J = 8.2 Hz), 6.91 (1H, d, J = 2.4 Hz), 6.56 (1H, dd, J = 8.0, 1.2 Hz), 4.74 (2H, t, J = 
5.4 Hz), 4.03 (2H, t, J = 5.4 Hz), 3.21 (3H, s), 2.29 (3H, s); δC (100 MHz, CDCl3) 192.1, 
162.1, 154.0, 147.1, 143.3, 141.0, 136.2, 133.4, 129.5, 129.1, 126.5, 126.0, 123.4, 
123.0, 119.7, 118.9, 110.6, 107.6, 103.6, 67.4, 50.6, 39.0, 21.5; IR (neat) 1688, 1608, 
1590, 1547, 1506, 1474, 1451, 1375, 1334, 1314, 1267, 1243, 1212, 1165, 1108, 1026, 
994, 917, 843, 816, 766, 734, 676; LRMS (DART) m/z [M + H]+ Calcd for C25H22N3O4 
428; Found 428; mp 155–158 °C.  
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 4. Improvement to visible light photoinduced nitric oxide donor furoxans: studies 
 towards naphthalenediimide-talkoxyfuroxan 
 
N-Boc-ethanolamine (164) 
  
To a stirred solution of 2-aminoethanol (1.02 mL, 16.4 mmol) in CH2Cl2 was added di-
tert-butyl dicarbonate (3.57 g, 16.4 mL) and stirred for 16 h at rt. The reaction mixture 
was diluted with water and extracted thrice with CH2Cl2. The organics were dried over 
MgSO4, filtered and solvent removed in vacuo to yield 164 as a colourless oil (2.28 g, 
14.1 mmol, 86%). The product was used without further purification. 1H NMR (400 
MHz, CDCl3) δH(ppm) 4.94 (1H, br s), 3.71 (2H, q, J = 5.2 Hz), 3.29 (2H, q, J = 5.2 Hz), 
2.39 (1H, br s); δC (100 MHz, CDCl3) 156.9, 79.6, 43.1, 28.4, 8.61; IR (neat) 3341, 2977, 
2929, 2874, 1681, 1514, 1454, 1389, 1366, 1279, 1247, 1167, 1064, 862 cm-1; LRMS 
(DART) m/z [M + H]+ Calcd for C7H16NO3 162; Found 162. 
 
tert-Butyl-2-((3-(4-methylphenyl))-4-furoxany-4-yl)oxy)ethylcarbamate (163)  
 
To a solution of 55 (250 mg, 1.13 mmol) and K2CO3 (468 mg, 3.39 mmol) in THF was 
added 164 (218 mg, 1.36 mmol) and stirred at 45 °C for 18 h. Upon reaction 
completion the mixture was diluted with water and extracted thrice with CHCl3. The 
organics were dried over MgSO4, filtered and solvent removed in vacuo. The crude 
was purified by silica chromatography (CHCl3) to yield 163 as an off white solid (290 
mg, 0.87 mmol, 77%). 1H NMR (400 MHz, CDCl3) δH(ppm) 8.01 (2H, d, J = 8.0 Hz), 7.32 
(2H, d, J = 8.0 Hz), 4.84 (1H, br s), 4.55 (2H, t, J = 5.2 Hz), 3.67 (2H, apparent q, J = 5.2 
Hz), 2.42 (3H, s), 1.44 (9H, s); δC (100 MHz, CDCl3); 162.2, 155.7, 141.0, 129.6, 126.1, 
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119.4, 107.7, 80.0, 70.0, 39.5, 28.4, 21.6; IR (neat) 3349, 2983, 2927, 1681, 1604, 1556, 
1537, 1519, 1481, 1442, 1383, 1359, 1332, 1314, 1287, 1274, 1253, 1163, 1115, 1046, 
1030, 998, 966, 860, 839, 822, 631 cm-1; HRMS (DART) m/z [M + H]+ Calcd for 
C16H22N3O5 336.1566; Found 336.1560; mp 157–159 °C. 
 
 
4-(2-Aminoethyloxy)-3-(4-methylphenyl)furoxan (160) 
 
 
To a solution of 163 (270 mg, 0.805 mmol) in CH2Cl2 (4 mL) was added TFA (4 mL) and 
the reaction stirred at rt for 1 h. The mixture was diluted with K2CO3 basified water 
(pH 8) and extracted thrice with CH2Cl2. The organics were dried over MgSO4, filtered 
and solvent removed in vacuo to yield an orange solid (98.4 mg, 0.42 mmol, 56%). The 
product was used without further purification. 1H NMR (400 MHz, CDCl3) δH(ppm) 8.01 
(2H, d, J = 8.4 Hz), 7.32 (2H, d, J = 8.4 Hz), 4.53 (2H, t, J = 5.2 Hz), 3.23 (2H, t, J = 5.2 Hz), 
2.41 (3H, s); δC (100 MHz, CDCl3) 162.4, 141.0, 129.6, 126.1, 119.4, 107.7, 72.8, 40.8, 
21.6; IR (neat) 3386, 2954, 2922, 2862, 1691, 1597, 1550, 1516, 1441, 1396, 1310, 
1159, 1123, 990, 857, 818, 797, 732 cm-1; HRMS (DART) m/z [M + H]+ Calcd for 
C11H14N3O3 236.1034; Found 236.1035; mp 97–99 °C. 
 
 
2,6-Dibromonaphtalene-1,4,5,8-tetracarboxylic dianhydride (161) 
 
Compound 161 was synthesized according to the reported method.117 To a solution of 
dibromocyaburic acid (9.56 g, 33.3 mmol) in concentrated H2SO4 (0.3 M) was added 
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portionwise 1,4,5,8-naphthalenetetracarboxylic dianhydride (4.47 g, 16.7 mmol) at 
room temperature, following complete addition the reaction was heated to 130 °C for 
18 h. Upon completion the reaction was cooled, poured into ice water and stirred until 
yellow precipitate formed. The precipitate was filtered and washed with water and 
hot MeOH then dried to yield a yellow crude mixture containing 161 (7.37 g, 17.3 
mmol, 104%). Due to the insoluble nature of 161, the mixture is used without further 
purification.1H NMR (400 MHz, DMSO-d6) δH(ppm) 8.79 (2H, s) proton data is in 
agreement with the literature117 ; IR (neat) 3203, 3081, 2832, 1782, 1744, 1692, 1460, 
1400, 1262, 1189, 1137, 1069, 977, 776, 698 cm-1; LRMS (DART) m/z [M + H]+ Calcd 
for C28H2Br2O6 426; Found 426. 
 
N,N’-Bis((dimethylamino)propylamino)-2,6-dibromonaphthalene-1,4,5,8- tetra-
carboxylic acid bisimide (159) 
 
Compound 159 was synthesized according to the reported method.118 To a solution of 
compound 161 (1.00 g, 2.34 mmol) in acetic acid (40 mL) was added dropwise 3-
(dimethylamino)-1-propylamine (736 µL, 5.85 mmol) and the reaction heated to 
130 °C for 30 minutes. Upon reaction completion the mixture was poured into ice 
water, basified with K2CO3 (pH 8) and extracted 6 times with CHCl3. The organics were 
dried over Na2SO4, filtered and solvent removed in vacuo. The crude solid was purified 
by silica chromatography (5% MeOH, 0.5% Et3N in CHCl3) to yield 159 as an orange 
solid (734 mg, 1.24 mmol, 53%). 1H NMR (400 MHz, CDCl3) δH(ppm) 9.00 (2H, s), 4.27 
(4H, t, J = 7.2 Hz), 2.45 (4H, t, J = 7.2 Hz), 2.24 (12H, s), 1.93 (4H, quin, J = 7.2 Hz); δC 
(100 MHz, CDCl3) 160.8, 160.7, 139.0, 128.3, 127.7, 125.3, 124.1, 57.1, 45.4, 40.0, 25.6; 
IR (neat) 3057, 2943, 2815, 2762, 1707, 1651, 1561, 1434, 1420, 1364, 1309, 1216, 
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1178, 1040, 857, 785, 759, 714 cm-1; mp 210 °C (decomposed) data is in agreement 
with the literature.118 
 
Synthesis of alkoxyfuroxan tethered NDI 6 (Scheme 5). N,N ’ -Bis(3-
(dimethylamino)propylamino)-2-bromo-6-(2-{[3-(4-methylphenyl)furoxan-4-
yl]oxy}ethylamino)-1,4,5,8-naphthalenetetracarboxylic bisimide (158) 
 
Compound 158 was synthesized according to the reported method.111 NDI 159 (1.00 
g, 1.68 mmol) and furoxan 160 (515 mg, 2.19 mmol) were stirred in DMF (0.02 M) at 
60 °C 14 h. The reaction mixture was cooled and poured into Na2CO3 (pH 8) basified 
water, diluted with EtOAc and washed gently 5 times with an excess of aq. Na2CO3. 
The organics were dried over Na2SO4, filtered and solvent removed in vacuo. The 
crude was purified by silica chromatography (5% MeOH, 1% Et3N, 94% CHCl3) to yield 
158 as a red solid (1.04 g, 1.39 mmol, 83%). 1H NMR (400 MHz, CDCl3) δH(ppm) 10.44 
(1H, t, J = 7.2 Hz), 8.84 (1H, s), 8.28 (1H, s), 7.89 (2H, d, J = 8.4 Hz), 7.15 (2H, d, J = 8.4 
Hz), 4.86 (2H, t, J = 5.2 Hz), 4.24–4.14 (6H, m), 2.46 (4H, q, J = 6.8 Hz), 2.33 (3H, s), 2.27 
(6H, s), 2.26 (6H, s), 1.95–1.86 (4H, m); δC (100 MHz, CDCl3) 166.0, 161.9, 161.7, 161.7, 
161.2, 151.7, 141.0, 138.5, 129.5, 128.4, 127.5, 126.0, 123.6, 123.4, 121.6, 121.1, 
119.6, 119.1, 107.6, 101.1, 68.7, 57.1, 45.3, 45.2, 41.5, 39.8, 38.9, 25.8, 25.6, 21.6; IR 
(neat) 2937, 2812, 2759, 1707, 1686, 1662, 1633, 1604, 1580, 1439, 1312, 1256, 1256, 
1218, 1178, 1162, 1016, 817, 791 cm-1; HRMS (ESI) m/z [M + H]+ Calcd for C35H39BrN7O7 
750.2068; Found 750.2076;  mp 163 °C (decomposed).  
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N,N ’ -Bis(3-(trimethylamino)propylamino)-2-bromo-6-(2-{[3-(4-
methylphenyl)furoxan-4-yl]oxy}ethylamino)-1,4,5,8-naphthalenetetracarboxylic 
bisimide diiodide (159) 
 
To a solution of compound 158 (20.0 mg, 26.7 µmol) in MeCN (2.60 mL) was added 
MeI (3.65 µL, 58.8 µmol) and the reaction heated to 35 °C for 6 h. Upon completion 
the solvent was removed in vacuo and the crude solid diluted with CHCl3, filtered and 
washed with hexane and CHCl3 to yield a purple solid (22.5 mg, 21.5 µmol, 95%). 1H 
NMR (400 MHz, acetonitrile-d3) δH(ppm) 10.27 (1H, apparent t, J = 7.6 Hz), 8.73 (1H, 
s), 8.28 (1H, s), 7.70 (2H, d, J = 8.4 Hz), 7.01 (2H, d, J = 8.4 Hz), 4.85 (2H, t, J = 5.2 Hz), 
4.24–4.20 (4H, m), 4.11 (2H, t, J = 6.8 Hz), 3.45–3.38 (4H, m), 3.04 (9H, s), 3.00 (9H, s); 
δC (100 MHz, acetonitrile-d3) 166.9, 16.2, 162.9, 162.7, 162.2, 153.4, 141.9, 138.1, 
130.1, 129.5, 128.2, 126.7, 124.6, 124.4, 122.6, 121.4, 120.4, 108.7, 101.5, 70.7, 65.2, 
65.0, 53.9, 42.0, 38.7, 37.9, 22.8, 22.5, 21.4; IR (neat) 3435, 2954, 2917, 2847, 1709, 
1670, 1637, 1584, 1517, 1475, 1444, 1311, 1267, 1241, 1191, 1163, 1124, 960, 785, 
738, 720 cm-1; HRMS (ESI) m/z [M – 2I]2+ Calcd for C37H44BrN7O7 389.6227; Found 
389.6232;   mp 188 °C (decomposed).  
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